



Strategies to enhance rational use of antibiotics in hospital: a guideline by the German Society for Infectious Diseases

K. de With¹ · F. Allerberger² · S. Amann³ · P. Apfalter⁴ · H.-R. Brodt⁵ · T. Eckmanns⁶ · M. Fellhauer⁷ · H. K. Geiss⁸ · O. Janata⁹ · R. Krause¹⁰ · S. Lemmen¹¹ · E. Meyer¹² · H. Mittermayer⁴ · U. Porsche¹³ · E. Presterl¹⁴ · S. Reuter¹⁵ · B. Sinha¹⁶ · R. Strauß¹⁷ · A. Wechsler-Fördös¹⁸ · C. Wenisch¹⁹ · W. V. Kern²⁰

Published online: 11 April 2016

© The Author(s) 2016. This article is published with open access at Springerlink.com

Abstract

Introduction In the time of increasing resistance and paucity of new drug development there is a growing need for strategies to enhance rational use of antibiotics in German and Austrian hospitals. An evidence-based guideline on recommendations for implementation of antibiotic stewardship (ABS) programmes was developed by the German Society for Infectious Diseases in association with the following societies, associations and institutions: German Society of Hospital Pharmacists, German Society for

Hygiene and Microbiology, Paul Ehrlich Society for Chemotherapy, The Austrian Association of Hospital Pharmacists, Austrian Society for Infectious Diseases and Tropical Medicine, Austrian Society for Antimicrobial Chemotherapy, Robert Koch Institute.

Materials and methods A structured literature research was performed in the databases EMBASE, BIOSIS, MEDLINE and *The Cochrane Library* from January 2006 to November 2010 with an update to April 2012 (MEDLINE and *The Cochrane Library*). The grading of recommendations in relation to their evidence is according to the AWMF Guidance Manual and Rules for Guideline Development.

Conclusion The guideline provides the grounds for rational use of antibiotics in hospital to counteract antimicrobial resistance and to improve the quality of care of patients with infections by maximising clinical outcomes while minimising toxicity. Requirements for a successful implementation of ABS programmes as well as core and supplemental ABS strategies are outlined. The German version of the guideline was published by the German Association of the Scientific Medical Societies (AWMF) in December 2013.

AWMF (Association of the Scientific Medical Societies in Germany) Registry No. 092/001.
S3-Guideline of the German Society for Infectious diseases Reg.Soc. (Deutsche Gesellschaft für Infektiologie e.V., DGI) in association with the following professional societies/associations/institutions:
German Society of Hospital Pharmacists (ADKA).
German Society for Hygiene and Microbiology (DGHM).
Paul Ehrlich Society for Chemotherapy (PEG).
The Austrian Association of Hospital Pharmacists (AAHP).
Austrian Society for Infectious Diseases and Tropical Medicine (ÖGIT).
Austrian Society for Antimicrobial Chemotherapy (ÖGACH).
Robert Koch Institute (RKI), Berlin.
External reviewer: Prof. Dr. Stephan Harbarth, Genf.
Patient representative: Viktoria Mühlbauer, Düsseldorf.
Editor of the English version: Sina Helbig, Dresden.

H. Mittermayer: Deceased.

✉ K. de With
Katja.deWith@uniklinikum-dresden.de

¹ Division of Infectious Diseases, University Hospital Carl Gustav Carus at the TU Dresden, Fetscherstr. 74, 01307 Dresden, Germany

² Division Public Health, Austrian Agency for Health and Food Safety (AGES), Vienna, Austria

Keywords Antibiotic stewardship · ABS · Guideline · Antimicrobial resistance · Quality of care · Rational use

³ Hospital Pharmacy, Munich Municipal Hospital, Munich, Germany

⁴ Institute for Hygiene, Microbiology and Tropical Medicine (IHMT), National Reference Centre for Nosocomial Infections and Antimicrobial Resistance, Elisabethinen Hospital Linz, Linz, Austria

⁵ Department of Infectious Disease Medical Clinic II, Goethe-University Frankfurt, Frankfurt, Germany

Table of Contents

I Introduction and aims of the guideline	III Recommendations of the guideline
II Summary of recommendations	1 Requirements
1 Requirements	1.1 Availability of a team of ABS experts
1.1 Availability of a team of ABS experts	1.2 Availability of surveillance data on pathogens, resistance, and antimicrobial consumption
1.2 Availability of surveillance data on pathogens, resistance, and antimicrobial consumption	1.2.1 Pathogens and resistance
1.2.1 Pathogens and resistance	1.2.2 Antimicrobial consumption
1.2.2 Antimicrobial consumption	2 ABS core strategies
2 ABS core strategies	2.1 Application of local treatment guidelines/pathways, hospital antiinfective formulary, formulary restrictions and approval requirements
2.1 Application of local treatment guidelines/pathways, hospital antiinfective formulary, formulary restrictions and approval requirements	2.2 Design and implementation of education, training and information
2.2 Design and implementation of education, training and information	2.3 Conducting proactive audits of antiinfective use
2.3 Conducting proactive audits of antiinfective use	2.4 Quality indicators
2.4 Quality indicators	3 Supplemental ABS strategies
3 Supplemental ABS strategies	3.1 Special programmes for treatment optimisation
3.1 Special programmes for treatment optimisation	3.1.1 De-escalation
3.1.1 De-escalation	3.1.2 Duration of treatment
3.1.2 Duration of treatment	3.1.3 Parenteral-to-oral conversion
3.1.3 Parenteral-to-oral conversion	3.1.4 Dose optimisation
3.1.4 Dose optimisation	3.1.5 Scheduled switch of antimicrobials
3.1.5 Scheduled switch of antimicrobials	3.2 Special rules for communication of microbiology results
3.2 Special rules for communication of microbiology results	3.3 Special rules for management of patients with multidrug-resistant microorganisms and <i>C. difficile</i>
3.3 Special rules for management of patients with multidrug-resistant microorganisms and <i>C. difficile</i>	3.4 Computerised information technology
3.4 Computerised information technology	
	Appendix

⁶ Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany

⁷ Hospital Pharmacy, Schwarzwald-Baar Hospital, Villingen-Schwenningen, Germany

⁸ Department of Hospital Epidemiology and Infectiology, Sana Kliniken AG, Ismaning, Germany

⁹ Department for Hygiene and Infection Control, Danube Hospital, Vienna, Austria

¹⁰ Section of Infectious Diseases and Tropical Medicine, Medical University of Graz, Graz, Austria

¹¹ Division of Infection Control and Infectious Diseases, University Hospital RWTH Aachen, Aachen, Germany

¹² Institute of Hygiene and Environmental Medicine, Charité, University Medicine Berlin, Berlin, Germany

¹³ Department for Clinical Pharmacy and Drug Information, Landesapotheker, Landeskliniken Salzburg (SALK), Salzburg, Austria

¹⁴ Department of Infection Control and Hospital Epidemiology, Medical University of Vienna, Vienna, Austria

¹⁵ Clinic for General Internal Medicine, Infectious Diseases, Pneumology and Osteology, Klinikum Leverkusen, Leverkusen, Germany

¹⁶ Department of Medical Microbiology and Infection Prevention, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

¹⁷ Department of Medicine I, Gastroenterology, Pneumology and Endocrinology, University Hospital Erlangen, Erlangen, Germany

¹⁸ Department of Antibiotics and Infection Control, Krankenhaus Rudolfstiftung, Vienna, Austria

¹⁹ Medical Department of Infection and Tropical Medicine, Kaiser Franz Josef Hospital, Vienna, Austria

²⁰ Division of Infectious Diseases, Department of Medicine, Freiburg University Medical Center, Freiburg, Germany

I Introduction and aims of the guideline

The dramatic increase in antibiotic resistance seen in many areas and regions combined with the paucity of new drug development more than ever calls for prudent, controlled, and appropriate use of anti-infectives in all areas of medicine. This affects almost all disciplines and medical specialties. The density of anti-infective treatment—with all its implications for cost, toxicity, the emergence of resistance and recommendations on diagnosis and follow-up, as well as recommendations on further therapy in the outpatient setting—is so high, in particular in the hospital sector, that safety and quality assurance processes will no longer succeed without a panel of experts and strategic discussions. Following a first position paper of the European Commission in 2001, in a second report on “Prudent use of antimicrobial agents in human medicine” published in 2010, EU Member States were recommended to establish or enhance surveillance systems for antibiotic resistance and antibiotic consumption. Particular importance gains this recommendation in Germany in light of the amendment of the Infection Protection Act [Infektionsschutzgesetz (IfSG), especially §4 and §23] in July 2011. The Act not only stipulates collection of data on antibiotic consumption, pathogenic microorganisms and resistance, it also requires that data on antibiotic consumption be assessed taking into account the local resistance situation, and that appropriate conclusions be drawn regarding the use of antibiotics. Furthermore, that the necessary adjustments to antibiotic consumption be communicated to staff and implemented (IfSG § 23 paragraph 4). Antibiotic stewardship (ABS) programmes should and can assume this responsibility in combination with policies and programmes for infection prevention. The aim of ABS programmes in hospital is to continuously improve the quality of anti-infective prescribing with regard to agent selection, dosing, administration and duration of treatment in order to maximise clinical outcomes while minimising toxicity to the patient as well as the emergence of resistance and costs.

Many reviews published since 2005 [1–12] on antibiotic stewardship describe the requirements and elements needed to institutionalise this type of programme in hospitals. More recent publications also detail use of these programmes in intensive care units [13–15], paediatrics [16–18] or small community hospitals [19–21]. A relatively new systematic review on ABS activities in critical care medicine, assesses 24 studies between 1996 and 2010, among them six methodologically ambitious investigations [15]. These were projects limiting cephalosporin use to minimise the emergence of resistance, studies on the implementation of computerised decision support systems and infectious diseases consultation services, as well as introduction of new guidelines for therapy and prophylaxis. The review provides good insight into the effects of various ABS strategies on consumption, costs and resistance, as demonstrated in recent years by a number of

other original papers. Most studies show a 10–40 % reduction in anti-infective drug use, shorter treatment duration and cost reduction. Programmes that were active for longer than 6 months were also associated with an improvement in resistance rates depending on the drug–pathogen combination [15]. A recent Cochrane review of 2013 (89 studies up to 2007) reached a similar conclusion. The review shows that the effect of interventions (e.g. antimicrobial restriction) is usually delayed (6 months) in respect of microbiological endpoints (e.g. antibiotic resistance); however, a prompt effect (frequently as soon as 1 month) is noted with regard to prescribing endpoints. According to the meta-analysis of methodologically robust studies (including randomised and controlled before-after studies with interrupted time-series analyses), professional interventions to reduce excessive anti-infective prescribing are successful in minimising the emergence of resistance and reducing hospital-acquired infections, as well as in improving individual treatment outcomes [22].

The two most recent reviews mentioned demonstrate the importance of ABS programmes and rational prescribing strategies in terms of minimising resistance. Instituting ABS programmes to save costs is not any more the driving factor, although this aspect is still important. An analysis published in 2012 on the cost-effectiveness of an ABS programme initiated at a University Hospital in Maryland, USA, showed interesting results. Over a period of 3 years, gross savings of roughly USD 3 million were realised, i.e. approximately USD 1 million/year. This was opposed by expenses of roughly USD 200,000/year to finance the programme (personnel costs). Although yearly cost savings dropped to approximately USD 400,000 p.a. over the full 7-year term of the ABS programme, it nevertheless remained cost-effective and delivered net savings with only one full-time personnel per 500 beds (infectious diseases physician, pharmacist, IT specialist). When the programme was discontinued after 7 years, anti-infective costs rapidly rose by around USD 2 million during the subsequent 2 years [23]. Cost-benefit analyses performed in other more recent pharmaco-economic investigations of ABS programmes are no longer limited to the potential “savings” achieved in drug and material costs; rather they show that adequate anti-infective therapy is associated with lower mortality, shorter length of hospital stay and duration of treatment, and that it can reduce the overall cost of treatment and improve patient safety [24].

This guideline recommends and outlines the requirements and main elements of ABS programmes with which the above objectives can be achieved. The recommendations are based on a systematic evaluation of many new observational and interventional studies with clinical and microbiological endpoints, as well as the endpoints anti-infective prescribing and costs, which were mainly conducted in adult patients in acute-care hospitals. The available literature was compiled based on the guideline published by two

American societies (IDSA, SHEA) focusing on the development of facility-specific ABS programmes (“Guidelines for Developing an Institutional Program to Enhance Antimicrobial Stewardship”) as well as on a Cochrane Review by Davey et al. from 2005 on “Interventions to improve antibiotic prescribing practices for hospital inpatients (Review)”, taking into account its update (2013) [2, 6, 22, 25]. Further literature was systematically searched until 15 April 2012 and evaluated. For details see the methodology report published online (<http://www.awmf.org>). Although some of the recommendations are not new in content, they altogether draw on much better study evidence and a greater number of examples for successful programmes. The recommendations were derived by consensus by the guideline development group based on review of the literature, taking into account relevance, evidence, applicability and practicability in German and Austrian acute-care hospitals. Key challenges are the current trends in multidrug-resistant pathogens (VRE, multidrug-resistant Gram-negative bacteria) and *Clostridium difficile* in Germany and Austria, the lack of skilled personnel—especially infectious diseases physicians—and limited experience with well-functioning infectious disease consultation services established elsewhere, increasing cost pressure in hospitals and outsourcing of microbiological diagnostics.

For the purpose of safety and quality assurance, it is recommended to use a selection of indicators from a catalogue developed and agreed upon by members of the guideline development group and users in Germany. Further experience with validation especially of process indicators as well as international experience gained in particularly France, England and Scotland on use of such indicators for internal and external quality assurance should be taken into account.

II Summary of recommendations

1 Requirements

1.1 Availability of a team of ABS experts

For effective implementation of ABS programmes, it is essential that a multidisciplinary team should be instructed by the hospital administration and allocated with adequate resources to draw up guidelines derived by consensus with the users for the treatment of infectious diseases and to ensure their implementation through ABS strategies (A).

The team should consist of at least one infectious diseases physician (or clinician with infectious diseases training) and an experienced clinical pharmacist/hospital pharmacist, as well as a specialist in microbiology, virology and infection epidemiology being responsible for laboratory diagnostic and microbiological consultation; furthermore, the physician

locally responsible for infection control. The team members should either have appropriate training in antibiotic stewardship or already be sufficiently experienced (A).

The team will receive the support and collaboration of the hospital administration, and activities within the ABS programme should be compensated with a minimum of one full-time equivalent (FTE) of 0.5 per 250 beds (A). There should be good collaboration between the Therapeutics and Drugs Committee, Hospital Infection Control Committee, pharmacy and representatives of clinical divisions/departments (ABS representatives), for which purpose the team should issue its own Rules of Procedure (A).

Significance in practice:

- ABS programmes should be instituted facility-wide which necessitates a multidisciplinary team with the competence for interdisciplinary cooperation.
- Infectious diseases specialists serving as consultants improve the clinical outcome of patients with infections, and ensure the quality of drug prescribing.
- Clinical pharmacists improve the quality of drug prescribing (e.g. dosing and drug application, avoidance of adverse drug events).
- Microbiologists facilitate high-grade infection medicine by ensuring the quality of microbiological diagnostics and preanalytics, and by expertly evaluating and conveying microbial culture results.
- Various ABS programmes describe an FTE of 0.5 per 250 beds as being the minimum staff resources necessary to cost-effectively conduct an ABS programme.

1.2 Availability of surveillance data on pathogens, resistance, and antimicrobial consumption

1.2.1 Pathogens and resistance Antimicrobial susceptibility data on major pathogens should be available and accessible at least yearly on a hospital-wide level and separately for general and intensive care units, or department-specific, as the case may be. Data on primary isolates should be shown by pathogen and type of specimen, e.g. blood, urine, miscellaneous samples. Culture results from screening tests should be shown separately. Susceptibility rates should indicate the number of isolates tested. Infection rates should relate consistently to a single denominator (e.g. patient-days/number of cases). Participation in an established surveillance system is recommended (A).

Significance in practice:

- Conducting an additional material analysis (e.g. number of blood culture sets per patient or 1000 patient-days, number of urine cultures per patient, number of catheter-associated urine cultures, etc.) also with regard to

material quality and positivity/contamination rates (e.g. blood cultures) can be useful.

- Whether the susceptibility rates of pathogens should be limited to agents listed on the hospital formulary should be discussed within the team.
- The amendment of the Infection Protection Act (Infektionsschutzgesetz, IfSG) (reporting, documentation) is mandatory.

1.2.2 Antimicrobial consumption Data on antimicrobial consumption, expressed as use density (daily doses per 100 patient-days) should be collected at least annually or preferably quarterly and are generally reported by the pharmacist. Data are reported institution-wide, at the ward level as well as for individual (speciality) departments. On demand, data should be broken down to the agent level and should be provided to the ABS team. Participation in an established surveillance system is recommended (A).

Point prevalence surveys should be conducted for systematic quantitative and qualitative assessment of antiinfective use, and, if required should be reevaluated short-term (A). Antiinfective use data are collected at the patient level which allows to assess prescribing quality based on indication and type of infection, and to recognise the need for targeted ABS strategies. Access to patient-level data ought to be guaranteed.

Significance in practice:

- Use density should be presented by antibiotic class and not only by individual agent.
- Reporting consumption data and antiinfective costs ranked by individual agent or class (e.g. top 5 or 10) is also reasonable.
- Point prevalence surveys are a simple tool to examine process quality.
- The amendment of the Infection Protection Act (Infektionsschutzgesetz, IfSG) (reporting, documentation) must be observed.

2 ABS core strategies

2.1 Application of local treatment guidelines/pathways, hospital antiinfective formulary, formulary restrictions and approval requirements

Developing and updating local treatment guidelines, clinical pathways, and an antiinfective formulary is one of the ABS team's chief responsibilities. The antiinfective formulary should be based on national and international guidelines as well as on the local/regional pathogen and

resistance patterns, and possibly drug costs. Drugs on the antiinfective formulary should be categorised according to recommended versus reserve or special compounds. In addition, these should be tagged with special prescription status and be subject to approval and preauthorisation requirements. The antiinfective formulary is updated at least yearly based on therapy guidelines and whenever necessary and approved by the Therapeutics and Drugs Committee (A).

Adherence to guidelines regarding substance selection, dosing, route and duration of treatment may improve clinical outcome in terms of mortality, as well as treatment duration and length of hospital stay. To ensure adherence, users should be involved in developing the guidelines and be educated through audits of antiinfective use or antiinfective point-of-care chart reviews (A).

Individualising antiinfective prescriptions with or without special approval requirements improves targeted therapy and reduces inappropriate treatment. Various possibilities for implementation have been described and should be used, from simple antimicrobial order forms to highly differentiated antiinfective request forms that may be subject to specific time limits or limited to certain hospital areas (A). Guideline-based antiinfective drug use or use of individual defined substances can be controlled by this means, thus minimising consumption, costs and adverse drug events.

Restricting whole substance classes can—by shifting to an alternative substance—prove to be an effective strategy for controlling nosocomial infections and the development of critical resistance levels; accordingly, antiinfective restriction ought to be targeted (B). At the same time, routine surveillance of antibiotic consumption and locally prevalent pathogens and their susceptibility patterns should be performed to detect possible adverse effects of the strategy in time (A).

Significance in practice:

- Local guidelines serve quality assurance and are a core strategy of every ABS programme.
- The antiinfective formulary is a useful ABS tool especially in small and medium-sized hospitals.
- Clinical pathways are rarely employed, can, however, be very helpful in the emergency room.
- Special order forms are highly effective ABS tools. Efforts should be undertaken to foster acceptance by prescribers.
- Restrictions on use to control resistance and nosocomial infections are frequently only temporarily effective. They should be time-restricted by the ABS team and reconsidered depending on the effects.

2.2 Design and implementation of education, training and information

Targeted education, training and information are essential elements of any ABS programme. They provide the foundation of knowledge needed to promote more rational use of antibiotics and reasonable microbiological diagnostic, and to improve acceptance of ABS programmes. They have the objective of optimising the therapeutic and diagnostic management of patients with infection through greater adherence to recommendations. They should preferably take place as an active training measure rather than in the form of passive communication of information (A).

Education, training and information in different formats and on various topics should be offered repeatedly as they are not sustainable as a one-off measure. They should be organised in agreement and integration with local ABS programmes (A).

Education, training and information should be independent of commercial interests, whereby the hospital administration is responsible for implementing and financing the measures (A).

Significance in practice:

- The target group for local training and educational sessions should be clearly defined.
- The handling of conflicts of interest should be laid down in writing (Rules of Procedure) by the ABS team.
- Informative meetings and educational/training sessions should give special attention to a critical evaluation of published study results.

2.3 Conducting proactive audits of antiinfective use

Proactive on-site audits of antiinfective use in the context of antiinfective point-of-care chart reviews are important elements of ABS programmes and should be performed routinely by the ABS team (A). They enhance compliance with guidelines or clinical pathways, improve outcome in patients with infection and improve the quality of prescribing with regard to indication, choice of agent, dosing, dosing interval, administration route and treatment duration.

Depending on the problem and treatment target, besides point prevalence studies, agent-, indication- and/or diagnosis-related audits of antiinfective use should be conducted within the scope of regular antiinfective point-of-care chart reviews hospital-wide or at the unit level, whereby quality indicators should preferably be applied (A).

Results should be fed back in direct interaction with the prescribing physicians and discussed with them (A).

Significance in practice:

- Performing proactive audit of antiinfective use with review and feedback is time-consuming; it does, however, promote interdisciplinary collaboration.
- Antiinfective point-of-care chart reviews can increase the number of treatments complying with guidelines and thus substantially improve process quality.

2.4 Quality indicators

ABS programmes should be integrated within the hospital's quality management. Content overlaps with the Therapeutics and Drugs Committee (drug safety) and Hospital Infection Control Committee (prevention of nosocomial infection) is useful and desired. Appropriate quality indicators to measure prescription practice (process measure), emergence of resistance or trend in consumption (outcome measure) and structure ought to be set and applied in every ABS programme (B). At least three indicators measuring structural quality and at least three indicators measuring process quality should be set regularly (A).

Significance in practice:

- Quality indicators are used to evaluate the progress of an ABS programme.
- Quality indicators help to recognise hospital areas which will benefit from the implementation of targeted and intensive ABS measures.

3 Supplemental ABS strategies

3.1 Special programmes for treatment optimisation

3.1.1 De-escalation A key aspect of supplemental measures is to streamline treatment after initial empirical broad-spectrum therapy and conversion from empirical to targeted therapy. This ought to be done based on clinical criteria as well as microbiology results or other diagnostic findings. De-escalation measures ought to preferably be performed at the patient level in the context of antiinfective point-of-care chart reviews and proactive audits of antiinfective drug use (B). Programmes promoting antiinfective de-escalation are expected to, by reducing antibiotic load, impact beneficially on the emergence of resistance, the prevention of secondary infections, cost levels and adverse drug reactions (B).

Significance in practice:

- De-escalation includes conversion from an empirical combination therapy to targeted monotherapy based on knowledge of the microorganism isolated, susceptibility and infectious disease.

- De-escalation should be initiated early on (after 48–72 h), which also includes discontinuation of initial therapy if diagnosis is not secured. Observational studies show that this strategy is not adopted in 20–60 % of cases.
- De-escalation programmes should point out that depending on the exact diagnosis in some cases instead of de-escalation, escalation may in fact be necessary.

3.1.2 Duration of treatment It is possible to shorten the duration of antiinfective treatment for many indications (e.g. perioperative antibiotic prophylaxis) and this is recommended wherever backed by good studies and evidence. The ABS team should utilise local guidelines and antiinfective point-of-care chart reviews to draw attention to the excessive duration of treatment frequently encountered in practice. The ABS team should define the duration of treatment recommended as a rule, since this is expected to impact substantially on antiinfective drug use, side effects and costs (A). Use of biomarkers such as Procalcitonin may be useful for controlling the duration of treatment in cases where there is clinical uncertainty. As a result, the number of days of antibiotic therapy can be reduced and under certain circumstances costs can be cut (C).

Significance in practice:

- Shortening the duration of treatment appropriately reduces the density of antiinfective use without compromising clinical outcome or costs, it also minimises the emergence of resistance by decreasing selection pressure.
- The duration of treatment is well established for a number of indications, e.g. pneumonia, endocarditis, perioperative antibiotic prophylaxis. Therapy, thus, only needs to be individualised and extended in certain cases.

3.1.3 Parenteral-to-oral conversion If sufficient bioavailability is assured, and if the patient's condition allows, therapy should be switched from parenteral to oral antibiotic application (A). This measure reduces the length of hospital stay and the risk of line-related adverse events. Furthermore, it leads to a reduction in the total cost of treatment. Implementation of programmes allowing parenteral-to-oral conversion of antimicrobial agents at the institutional level ought to be facilitated by developing clinical criteria and through explicit designation in institutional guidelines or clinical pathways (B).

Significance in practice:

- Switch to oral therapy should be assessed on day 3–4 of parenteral antiinfective therapy.
- Switching to oral therapy not only results in direct cost savings (antiinfective agents, supplies, nursing time)

and lowers risk of line infections, it also increases the patient's mobility.

3.1.4 Dose optimisation Adequate adjustment and optimisation of the dose and dosing interval is essential for effective, safe and responsible administration of antiinfective therapy, and an important part of ABS programmes. Besides individual patient factors, optimal dosing of antiinfectives should take into account the nature and severity of illness, the causative microorganism, concomitant medications, as well as the pharmacokinetics and pharmacodynamics of the agents prescribed. Strategies to optimise dosing in ABS programmes should include assessment of organ function for drug dose adjustment in order to avoid adverse drug events and unwanted drug interactions (A).

Furthermore, optimising the dosing interval and duration of infusion is recommended in particular in critically ill patients, best by employing a therapeutic drug monitoring (TDM) scheme; appropriate consented local institutional guidelines should be available and up to date (B).

Significance in practice:

- Prolonged infusion of beta-lactams (taking into account physico-chemical stability) is reasonable and recommended particularly in critically ill patients.
- TDM can avoid under-/over-dosing and minimise organ toxicity.
- Programmes for doses optimisation are cost-effective.

3.1.5 Scheduled switch of antimicrobials So-called "Cycling" programmes, which involve periodically removing a specific antimicrobial drug or an antimicrobial drug class as the standard recommended therapy and later reintroducing it (periodic scheduled rotation), are not suitable as a strategy to reverse critical emergence of resistance or to control nosocomial outbreaks with multiple resistant pathogens and, as such, should not be used as a strategy to do so (A).

Strategic rotation of specific antimicrobial drugs or antimicrobial drug classes ought to be undertaken to limit the selective pressures and to achieve a reduction of infectious microorganisms or microorganisms displaying specific resistance properties for a certain time (B). There is evidence to suggest that a balanced use of different antimicrobial drugs or antimicrobial drug classes (so-called "mixing") can minimise the emergence of resistance. In both cases, routine surveillance of antimicrobial drug use and resistance should be performed (A).

Significance in practice:

- Strategic rotation of specific antimicrobials or antimicrobial classes should be planned by the ABS team in consultation with the facility's infection control team

and the microbiology department. Continuous surveillance of pathogens, resistance patterns and consumption is imperative.

- Guidelines and anti-infective formularies that recommend predominant use of fluoroquinolones or third-generation cephalosporins should be considered as critical.

3.2 Special rules for communication of microbiology results

The quality of microbiology diagnostics depends crucially on compliance with guidelines on procedures in the pre-analytical phase. Expert consensus recommends that deviations from protocol ought to be reported and the reasons for rejecting the samples stated (**B**).

Technical progress and up-to-date molecular diagnostic methods for rapid pathogen detection should be used if they improve the quality of care and/or substantially improve identification and epidemiologic investigation of local outbreaks (**A**).

Positive blood culture findings, interim microscopic findings, results of rapid testing results and rapid susceptibility testing should be communicated promptly to the physician (**A**).

Antibiograms ought to adhere to local guidelines with respect to antimicrobial use and diagnostic findings, be presented selectively in agreement with the ABS team, and, if need be, include relevant interpretative comments. This procedure aids selection of a targeted, guideline-based antibiotic regimen (**B**).

The microbiology laboratory is responsible for the timely identification of critical trends in antimicrobial resistance and prompt communication of observations to the ABS team and the physicians responsible for infection control (**A**). This way, the clinical and epidemiological significance of the observations can be defined at an early stage.

Significance in practice:

- Molecular diagnostic methods can expedite pathogen specification.
- Selective reporting of susceptibility results with respect to choice and number of antimicrobial agents, and comments on daily treatment costs, route of administration, hospital formulary drug, resistance mechanisms supports adherence to local guidelines.

3.3 Special rules for management of patients with multidrug-resistant microorganisms and *C. difficile*

ABS strategies should be used to prevent infection with *C. difficile* (**A**). Restricting use of certain antimicrobial drugs

or substitution of antimicrobial drug classes (e.g. penicillin for cephalosporins or fluoroquinolones) can considerably reduce the incidence of *C. difficile* infection. Infection prevention and control strategies are frequently also applied at the same time; however, they have less impact on the *C. difficile* incidence than in the epidemiology of MRSA or VRE.

Targeted ABS strategies are to varying degrees also effective in reducing multidrug resistant Gram-negative bacteria, particularly ESBL-producing microorganisms, MRSA and VRE, and ought to be specifically applied here too (**B**). In case of high prevalence of multidrug-resistant microorganisms, recommendations on diagnostic tests, evaluation of findings and treatment, as well as infection control management should be coordinated immediately and disseminated locally (**A**).

Routine surveillance of antimicrobial consumption and antimicrobial susceptibility data should be performed (**A**) to avoid indiscriminate compensatory use of other antimicrobial drug classes, since this can promote the unintentional and uncontrolled emergence of resistance.

Significance in practice:

- Reducing consumption of cephalosporins and/or fluoroquinolones or substituting them for penicillin may reduce the frequency of *C. difficile* infection and possibly also have a beneficial effect on the incidence of infections caused by multidrug-resistant pathogens.

3.4 Computerised information technology

The ABS team should be supported by novel information and communication technology in the implementation of ABS programmes. Local treatment guidelines, the anti-infective formulary, and other ABS documents should be available electronically (**A**).

Electronic prescribing tools with and without linkage to electronic preauthorisation solutions, to ABS documents or to active communication of information using computerised reminders to the prescriber should be used to improve the use of anti-infectives in the interest of patient safety (**A**). They ought to be used to reduce consumption and/or costs (**B**).

Computerised decision support systems that are integrated into the hospital's internal information system can, by utilising electronic medical records, help to evaluate and optimise the indication for anti-infective therapy, drug selection and dosing (**C**).

To implement computerised ABS measures, the ABS team must have hospital-wide access rights to electronic medical records (with due respect to data protection).

Significance in practice:

- The local treatment guideline and the anti-infective formulary should be readily electronically accessible from every clinical computer workstation.
- For ABS activities or for surveillance and analysis of antimicrobial usage, computer physician order entry (CPOE) systems should be designed in such a way as to allow automated generation of exact lists of the anti-infectives used.
- Surgical software should be utilisable in such a manner as to ensure that antibiotic prophylaxis is compliant with guidelines.
- Computer-based expert systems cannot replace a physician's clinical judgement.

III Recommendations of the guideline

1 Requirements

1.1 Availability of a team of ABS experts

The guideline development group recommends:

For effective implementation of ABS programmes, it is essential that a multidisciplinary team should be instructed by the hospital administration and allocated with adequate resources to draw up guidelines derived by consensus with the users for the treatment of infectious diseases and to ensure their implementation through ABS strategies (A).

The team should consist of at least one infectious diseases physician (or clinician with infectious diseases training) and an experienced clinical pharmacist/hospital pharmacist, as well as a specialist in microbiology, virology and infection epidemiology being responsible for laboratory diagnostic and microbiological consultation; furthermore, the physician locally responsible for infection control. The team members should either have appropriate training in antibiotic stewardship or already be sufficiently experienced (A).

The team will receive the support and collaboration of the hospital administration, and activities within the ABS programme should be compensated with a minimum of one full-time equivalent (FTE) of 0.5 per 250 beds (A). There should be good collaboration between the Therapeutics and Drugs Committee, Hospital Infection Control Committee, pharmacy and representatives of clinical divisions/departments (ABS representatives), for which purpose the team should issue its own Rules of Procedure (A).

In the community hospital setting, ABS programmes should be available hospital-wide, i.e. involving physicians across all operative and non-operative medical fields. A multidisciplinary team (so-called ABS team) of ABS-trained members (so-called ABS experts) is considered essential to the success of this type of programme. It should have the support of hospital administration, and collaboration of the infection control team and Therapeutics and Drugs committee, the pharmacy and of the responsible physicians (so-called ABS representatives) in the corresponding departments [2, 6]. The advantage of a multidisciplinary team is justified by the necessary diversity of ABS programmes which have different objectives of interventions depending on hospital, type of ward and speciality discipline [26]. At least one randomised controlled [27, 28] and several prospective before-and-after studies [29–35] on the implementation of a trained ABS team, led to a decrease in mortality, a reduction in nosocomial infections and significantly shorter length of hospital stay. In addition, it resulted in an improved quality of prescribing, which in turn, led to fewer drug-related adverse events. The studies show that to achieve different objectives of interventions it is crucial to collect data on clinical, microbiological and prescribing endpoints, and that this can only be done by appropriately trained and sufficiently qualified professionals. Based on the IDSA/SHEA guideline and past experience [6], the ABS team should include at least one infectious diseases physician and a clinical pharmacist, ideally with infectious disease training. The importance of an infectious diseases-trained specialist and clinical pharmacist for effective ABS programmes was shown in several randomised, controlled as well as prospective, quasi-experimental studies. This was demonstrated particularly in regard to appropriate treatment of bacteremia [36], dosage adjustment and early conversion to oral therapy [37–40].

The ABS team should issue Rules of Procedure defining the organisational structures and conditions for implementation of antibiotic stewardship programmes including their functions and objectives. The composition of the multidisciplinary ABS team should be described in detail, from mandate to staffing (qualification, status, objectives and functions, competences and cooperations) and amount of time compensated. Organisational charts can be useful to show internal and external communication structures. The Rules of Procedure should stipulate the frequency of meetings and the reporting obligations toward hospital administration. Potential conflicts of interest of members of the ABS team should be disclosed. Furthermore, it is necessary to lay down hospital-wide rules on how to deal with the pharmaceutical industry or third parties because commercial marketing strategies may possibly influence antimicrobial prescribing [41–43].

Infectious diseases physicians are especially well-suited to planning and implementing ABS programmes and to developing guidelines because of their in-depth knowledge

of the treatment of infectious diseases, their broad training in clinical internal or paediatric medicine, and not least their experience in conducting cross-departmental specialist consultations [43]. Infectious disease consultation services improved treatment quality in patients with bacteremia and in some studies also improved survival [36, 45–49]. In the case of community, nosocomial or ventilator-associated pneumonia, introduction of a consultation service in an intensive care unit (incl. training) resulted in shorter length of stay (13.8 vs. 19.2 days), a decrease of ventilation time (7.4 vs. 11.8 days), reduction in duration of therapy (9.2 vs. 14.5 days) and a decrease in mortality by 6–13 % [27, 50] due to optimised empirical and targeted therapy strategies.

Several trials, including a randomised controlled trial, investigated the efficacy of a multidisciplinary ABS team which provides feedback to prescribing physicians. Particularly the feedback from the infectious disease consultation service resulted in a significantly more appropriate antibiogram-based therapy and in discontinuation of antimicrobial therapy [51–54].

Clinical pharmacists/hospital pharmacists are involved in the activities of the Therapeutics and Drugs Committee and in developing local guidelines and formularies. They have special knowledge of pharmacology—such as the clinical relevance of adverse drug effects, dose optimisation or route of administration, and they have experience in conducting audits of antiinfective use, e.g. to ensure guideline adherence [37, 40, 55–57]. Generally, the pharmacist is responsible for design, implementation, and compliance with formulary restrictions and preauthorisation requirements. He is also responsible for processing data on antimicrobial consumption and costs for the purpose of surveillance and benchmarking (pharmacoeconomics) [8, 58–60]. Pharmacist-led parenteral-to-oral conversion programmes resulted in a significant reduction of parenteral therapy duration by 1–1.5 days without negatively impacting clinical outcomes [38, 39, 61]. This can, as shown in surgical departments of a German university hospital, lead to significant cost savings [62–64]. Computerised physician order entry systems (CPOE) could aid the pharmacist in reviewing the appropriateness of antiinfective prescriptions as these systems allow to produce a daily report on the antiinfectives prescribed without review of individual patient charts on the ward.

Ideally, the team is complemented by a medical microbiologist (in Germany: specialist in microbiology, virology and infection epidemiology; in Austria: specialist in infection control and microbiology) and the physician locally responsible for infection control [65]. The expertise of the medical microbiologist is required to establish local guidelines for laboratory diagnostics of infection including preanalytical specimen management, and to report microbiological results in accordance with national and international quality standards. ABS interventions have to be in line with current microbiological diagnostics and reporting, as well as with

easily accessible current surveillance data on pathogens. Medical microbiologists should provide support by using targeted diagnostic tests, rapid reporting and professional communication of results. Retrospective investigations indicate that introduction of point-of-care chart reviews focusing on diagnostics delivered by medical microbiologists with infectious diseases training leads to significant reduction in the use of broad-spectrum antibiotics [66, 67].

If infectious diseases specialists are not available in smaller hospitals, an experienced hospitalist can, in collaboration with an authorised pharmacist who has at least 2 years' working experience in a hospital pharmacy, assume the leadership role in lieu of an infectious diseases physician. In this case, the team members must be ABS-trained, e.g. they must have completed training courses certifying them as ABS experts with knowledge in the following areas: design and implementation of ABS tools (treatment guidelines, anti-infective formulary, treatment pathways), application and implementation of point prevalence surveys of antiinfective prescribing practices, requirements for surveillance data (consumption, pathogens, resistance), the content of current guidelines and important ABS intervention strategies. The ABS experts should be capable, as a team, of developing and implementing a programme for continuous improvement of the quality of antiinfective prescribing that is tailored to the specific needs and situation of the respective hospital. Relevant continuous training in the field of ABS is recommended.

Based on the available evidence from the literature and repeated internal consultations, the guideline development group recommends that clinical infectious diseases physicians or clinical pharmacists with ABS training should principally assume core leadership function in the ABS team. Transferability of available experience (mainly American) to the German health care system is limited. The German Society for Hygiene and Microbiology (DGHM) and the Paul Ehrlich Society for Chemotherapy (PEG) point out that the conditions in Germany (several years further training in medical microbiology, medical microbiologists working in hospital and also providing infectious disease consultation, likewise the shortage of infectious diseases physicians and specialised pharmacists) and experience in some other European countries (e.g. England and the Netherlands) should allow to consider clinically oriented and experienced medical microbiologists (German: specialist in microbiology, virology and infection epidemiology), as being suitable for core leadership function, assumed they are for the most part present and available in the hospital and released from duties in the laboratory.

The team size depends primarily on the size of hospital. In the older and the current literature, between 0.5 and 1.5 full-time equivalent posts depending on the number of beds (~200 to ~900) or level of care provided, equating to one full-time equivalent of 0.5 per 250–300 beds, is well documented as

being cost effective and associated with high net savings in the initial phase [23, 27, 29, 68–71]. Ongoing activity by the teams is essential to preserve the effects, as the quality of use and cost usually deteriorate rapidly when ABS programmes are discontinued [23, 72]. In larger hospitals, it is therefore recommended to appoint department-specific ABS representatives to support the ABS team in its activities. The ABS team must be involved in decision-making in the Therapeutics and Drugs Committee and the Hospital Infection Control Committee as these committees may influence the design of ABS strategies, and jointly coordinated programmes (involving bundles of interventions) must be discussed to be effective particularly in the area of nosocomial infections. In the event of *C. difficile* outbreaks, or if the *C. difficile* incidence increase over time, infection control strategies alone are often not sufficiently effective. As demonstrated in multiple time-series analyses, restricting use of cephalosporins, fluoroquinolones or clindamycin is necessary to reduce *C. difficile* incidence effectively (see 2.1., 3.3.) [2, 25, 73].

The recommendations of the former ABS Group Austria on the further development of ABS programmes in Austrian Hospitals (“Antibiotika-Kultur in Krankenanstalten”) [74], the IDSA/SHEA Guideline on “Hospital Antibiotic Stewardship” [6] and the Australian recommendations [43] refer to the need for hospital administration to direct the ABS team to plan ABS activities, to support the implementation of these interventions and to provide necessary resources. Several quasi-experimental before-and-after studies emphasise the importance of support given by the hospital administration or departmental management, in particular in the development of guidelines, their establishment and successful implementation [75, 76].

1.2 Availability of surveillance data on pathogens, resistance, and antimicrobial consumption

1.2.1 Pathogens and resistance

The guideline development group recommends:

Antimicrobial susceptibility data on major pathogens should be available and accessible at least yearly on a hospital-wide level and separately for general and intensive care units, or department-specific, as the case may be. Data on primary isolates should be shown by pathogen and type of specimen, e.g. blood, urine, miscellaneous samples. Culture results from screening tests should be shown separately. Susceptibility rates should indicate the number of isolates tested. Infection rates should relate consistently to a single denominator (e.g. patient-days/number of cases). Participation in an established surveillance system is recommended (A).

A requirement for successful ABS programmes is the availability of current hospital-wide data on pathogens and anti-infective use. This will allow for weak-point analysis and optimisation potential [2, 8, 77]. In addition to provision of routine reporting on pathogen identification with antibiogram, the microbiology laboratory is, in coordination with the ABS team, responsible for surveillance of pathogen and resistance patterns. Expert consensus recommends that pathogen-specific susceptibility data should be updated at least annually. Data on primary isolates and subsequent isolates should be presented separately. In addition, data should include susceptibility and resistance rates according to generally recommended breakpoints as well as the number of isolates tested. Electronic data processing available in the microbiology laboratory can facilitate unit-specific (general ward vs ICU) or department-specific evaluation of resistance. This allows to recognise the distribution of individual pathogens and antibiotic susceptibility profiles in different departments in dependence on prescribing habits, which helps guide ABS interventions.

The available infrastructure and personnel resources must allow even hospitals without an on-site microbiology laboratory, to provide hospital-based or unit-based data on pathogens and antimicrobial susceptibility, if need be, at shorter intervals, whereby presentation of data on susceptibility rates on fewer than 10 tested isolates does not appear useful.

Expert consensus recommends reporting at least on *S. aureus*, *E. coli* other *Enterobacteriaceae*, *P. aeruginosa* and *Candida* spp. by specimen type (blood, urine and miscellaneous samples) as well as on *C. difficile*, whereby screening culture results should be reported separately. Standardised surveillance is a fundamental requirement for benchmarking with other institutions/departments. Interpretation of the data takes into account the size of hospital, the level of care, and the patient mix (e.g. hematologic-oncologic patients). Participation in established surveillance systems is recommended.

1.2.2 Antimicrobial consumption

The guideline development group recommends:

Data on antimicrobial consumption, expressed as use density (daily doses per 100 patient-days) should be collected at least annually or preferably quarterly and are generally reported by the pharmacist. Data are reported institution-wide, at the ward level as well as for individual (speciality) departments. On demand, data should be broken down to the agent level and should be provided to the ABS team. Participation in an established surveillance system is recommended (A).




Fig. 1 Graphical presentation of quarterly use density (RDD/100 patient-days) for different antibiotic classes

Point prevalence surveys should be conducted for systematic quantitative and qualitative assessment of antiinfective use, and, if required should be reevaluated short-term (A). Antiinfective use data are collected at the patient level, allowing to assess prescribing quality based on indication and type of infection, and to recognise the need for targeted ABS strategies. Access to patient-level data ought to be guaranteed.

Continuous reporting of surveillance data on antiinfective consumption is useful in monitoring trends and identifying areas for evaluating appropriateness of prescribing. It therefore supports systematic audit of antimicrobial use with intervention and feedback to the prescriber [78–80]. Consumption data are usually obtained from the pharmacy and are being presented as daily doses by the pharmacist. They are an essential prerequisite for medium and long-term assessment of the effectiveness of interventions [81]. Another goal of continuous surveillance is early identification of an increase in antibiotic consumption.

Expert consensus recommends that these data should be available institution-wide, for individual departments and at the ward level (e.g. general ward, intensive care unit) at least annually, preferably quarterly. Data should be collected by antimicrobial agents and reported in the form of daily doses per 100 patient-days (e.g. defined daily doses, DDD, according to the ATC Index of the WHO, and/or recommended daily doses, RDD) [82]. Upon the request of the ABS team, aggregate antibiotic usage data should be available for specific classes of antibiotics as well as stratified by different clinical

units. Good examples for this form of data presentation such as so-called “antiinfective report” incl. graphical presentation are available for various German hospitals (Fig. 1).

Economic data (e.g. antibiotic costs) ought to be also documented; however, these data alone do not provide a suitable basis for analysis and intervention in terms of ABS. According to Article 23 (4) of the Infection Protection Act, usage data must be evaluated taking into account local resistance data and appropriate conclusions must be drawn regarding the use of antibiotics. Furthermore, the necessary adjustments of antibiotic consumption must be implemented and the staff must be informed. Participation in an established surveillance system provides a standardised method to calculate antimicrobial use density and is therefore recommended. Thus, depending on the patient mix, comparisons between different hospitals are also possible [81, 83]. However, IT-based patient-level consumption data, so-called prescribed daily doses (PDD) should be the ultimate goal.

Point prevalence surveys can be very helpful for temporary assessment of the quality of antimicrobial prescribing, e.g. before and after guideline amendment [84–86]. A point prevalence survey provides information on the choice of substance, dose, dosing interval and route of administration. In addition, data on the indication for prescribing (nosocomial vs community acquired or prophylactic) and the type of infection can be collected at patient level, allowing to evaluate the consumption density in relation to the prescribing quality. The ABS team ought to have access

to relevant patient data to conduct these surveys which are usually carried out as a 1-day point prevalence survey. Starting from the day of the survey, prescription data can also be collected retrospectively for a limited time interval (e.g. 6 days). On the day of the survey, patient-based data as mentioned above are documented. Additionally, it is recommended to document the number of patients per unit, to calculate the prevalence of anti-infective prescriptions per unit (e.g. ICU, department). This analysis allows to evaluate the relation of defined daily doses recommended by the WHO (DDD) to prescribed daily doses (PDD) derived from chart review. Additionally, other patient-relevant information can be investigated, e.g. on immunosuppression, organ insufficiencies or on presence of devices. European 1-day point prevalence surveys (<http://www.esac.be>, http://www.ecdc.europa.eu/en/healthtopics/Healthcare-associated_infections/database/Pages/database.aspx) have shown that approximately one-third of all hospitalised patients received anti-infective treatment and that even on regular wards >50 % of total consumption was given intravenously. Furthermore, within hospitals fluoroquinolones and cephalosporins were prescribed frequently, more than 30 % of the patients received combination therapy, and >50 % of perioperative prophylaxis was administered longer than 1 day. Only 62 % of patients were treated in adherence with guidelines [85–87]. Point prevalence surveys can also be used to verify the feasibility of quality indicators (see Sect. 2.2.4).

2 ABS core strategies

Most previously published experience with ABS programmes in hospital shows that sustained efficacy can be achieved under the requirements mentioned above and on the basis of generally accepted strategies or bundles of strategies. Certain components of ABS programmes are considered and prioritised as core ABS strategies, while others are considered optional or supplemental [2, 6, 22, 25]. The following core strategies are recommended by the guideline development group.

2.1 Application of local treatment guidelines/pathways, hospital anti-infective formulary, formulary restriction and approval requirements

The guideline development group recommends:

Developing and updating local treatment guidelines, clinical pathways, and an anti-infective formulary is one of the ABS team's chief responsibilities. The anti-infective formulary should be based on national and international guidelines as well as on the local/regional

pathogen and resistance patterns, and possibly drug costs. Drugs on the anti-infective formulary should be categorised according to recommended versus reserve or special compounds. In addition, these should be tagged with special prescription status and be subject to approval and preauthorisation requirements. The anti-infective formulary is updated at least yearly based on therapy guidelines and whenever necessary and approved by the Therapeutics and Drugs Committee (A).

Adherence to guidelines regarding substance selection, dosing, route and duration of treatment may improve clinical outcome in terms of mortality, as well as treatment duration and length of hospital stay. To ensure adherence, users should be involved in developing the guidelines and be educated through audits of anti-infective use or anti-infective point-of-care chart reviews (A).

Individualising anti-infective prescriptions with or without special approval requirements improves targeted therapy and reduces inappropriate treatment. Various possibilities for implementation have been described and should be used, from simple antimicrobial order forms to highly differentiated anti-infective request forms that may be subject to specific time limits or limited to certain hospital areas (A). Guideline-based anti-infective drug use or use of individual defined substances can be controlled by this means, thus minimising consumption, costs and adverse drug events.

Restricting whole substance classes can—by shifting to an alternative substance—prove to be an effective strategy for controlling nosocomial infections and the development of critical resistance levels; accordingly, anti-infective restriction ought to be targeted (B). At the same time, routine surveillance of antibiotic consumption and locally prevalent pathogens and their susceptibility patterns should be performed to detect possible adverse effects of the strategy in time (A).

Local treatment guidelines and clinical pathways are established and regularly updated by the ABS team with the involvement of the ABS representatives delegated from other clinical departments. National and international guidelines, the patient mix and local microbiology and resistance patterns should be taken into account. The established or revised local guidelines should have institution-wide validity for which consensus must be obtained. The treatment guidelines are presented to the Therapeutics and Drugs Committee and the Hospital Infection Control Committee. It is recommended to provide local treatment

Table 1 Examples for use of treatment guidelines and clinical pathways

References	Study-type/evidence	Patients	Intervention	Endpoints	Results
Soo Hoo et al. [103]	Observational study (II)	Patients with community-acquired pneumonia (58 patients before intervention, 58 patients after intervention)	Establishment of guidelines for the diagnosis and management of nosocomial pneumonia	Mortality Proportion of patients with guideline-conforming treatment	Lower mortality rate at 14 days (23 vs 8 %, $p = 0.03$) Increase in the number of patients treated in conformity with guidelines (46 vs. 81 %, $p < 0.01$)
Botelho-Nevers et al. [104]	Observational study (II)	Patients with infectious endocarditis (173 patients before intervention, 160 patients after intervention)	Establishment of treatment guidelines for management of infectious endocarditis	Mortality Guideline adherence (compound selection, duration of treatment)	Lower 1 year mortality (18.5–8.2 %, HR 0.41; 95 % CI, 0.21–0.79, $p = 0.008$) Lower hospital mortality (12.7–4.4 %, $p = 0.007$) Increase in guideline adherence: compound selection (31.6 % auf 95 %, $p < 0.001$) Compound selection and duration of treatment (22.7 % auf 61.8 %, $p < 0.001$)
Marrie et al. [93]	Randomised, controlled study (I)	Patients with community-acquired pneumonia in the emergency room of a hospital (nine hospitals with clinical pathway, 10 hospitals without clinical pathway)	Establishment of a clinical pathway for treatment of community-acquired pneumonia in the emergency room of nine hospitals	Mortality Length of hospital stay Duration of treatment Proportion of patients with monotherapy	No difference in mortality Shorter length of hospital stay by 1.7 days (6.1–4.4 days, $p = 0.04$) Shorter duration of treatment by 1.7 days (6.3–4.6 days, $p = 0.01$) Increase in the proportion of patients with monotherapy (27–64 %, $p < 0.001$)
Singh et al. [102]	Randomised, controlled study (I)	Patients with ventilator-associated pneumonia (39 patients treated in accordance with a risk score-based clinical pathway, 42 patients received standard therapy)	Establishment of risk score-based clinical pathway	Mortality Length of hospital stay (ICU) Detection of MDR pathogens Duration of treatment, costs	No difference in mortality Shorter length of hospital stay (ICU) by 5.3 days (14.7–9.4 days; $p = 0.04$) Reduced detection of MDR pathogens (38–14 %, $p = 0.017$) Shorter duration of treatment (9.8–3 days, $p = 0.0001$) Lower treatment costs (640\$–259\$, $p = 0.0001$)

Table 1 continued

References	Study-type/evidence	Patients	Intervention	Endpoints	Results
Ibrahim et al. [97]	Observational study (II)	Patients with ventilator-associated pneumonia (50 patients before intervention, 52 patients after intervention)	Establishment of a treatment guideline for management of ventilator-associated pneumonia	Mortality Length of hospital stay, antibiotic therapy complying with guidelines, Duration of treatment	No difference in mortality Increase in the proportion of antimicrobial therapy conforming to guidelines from 48 to 94.2 % ($p < 0.001$) Shorter duration of treatment from 14.8 days \pm 8.1 days to 8.6 \pm 5.1 ($p < 0.001$)

guidelines in electronic or pocketbook format and to ensure acceptance among users through training and education [88]. Without these measures guideline adherence is rather poor, and effects in terms of improving clinical outcomes or other endpoints remain small [89].

Treatment guidelines or clinical pathways can improve outcomes related to mortality, length of hospital stay and duration of treatment [90, 91]. High adherence to guidelines or clinical pathways, e.g. for management of community-acquired or nosocomial pneumonia, can be achieved with training and education. Thus, mortality can be decreased and the medium duration of therapy and hospital stay can be shortened by 1.7–6.8 days, while anti-infective usage is reduced by up to 77 % [92–98]. Various strategies of treatment optimisation have been studied for community-acquired or nosocomial pneumonia [99–102] and have partly been addressed in international and national guidelines. Their implementation in local guidelines, guideline adherence assumed, can help to avoid that therapy is either too broad or too long. An American and a French observational study have shown that involving physicians in the development of local guidelines can improve acceptance. When local consensus guidelines were posted on the intranet and regularly distributed to physicians and presented in departmental staff meetings, guideline-conform management of nosocomial pneumonia increased from 46 to 81 %, and 14-day mortality dropped from 23 to 8 % [103]. In a study of endocarditis, compliance with antimicrobial therapy improved from 23 to 62 % and 1-year mortality significantly decreased from 19 to 8 % [104] (Table 1). Numerous new investigations on improving guideline compliance have shown that institutionalising guidelines can optimise the quality of therapy in different categories (e.g. dose adjustment to renal function, parenteral-to-oral conversion, timely administration) by about 10 or more percent [105–110].

Clinical pathways complement local treatment guidelines, often taking into account diagnostic algorithms and risk scores. They are designed as a flowchart to simplify and improve the management of patients with infectious diseases. In a controlled, multi-centre Canadian study a risk score (PSI, pneumonia severity index)-based clinical pathway was instituted, addressing criteria for inpatient admission, sequential therapy and discharge of patients with community-acquired pneumonia. Although patients in the “experimental” arm had more severe disease, hospital stay and duration of parenteral antibiotic therapy was significantly shortened in this patient group, and the patients received monotherapy significantly more often without negative impact on mortality. Within this framework, an Australian study showed an approximately 10 % reduction in the use of broad-spectrum antibiotics [93, 111, 112]. Similar results were achieved by a more recent

observational study in the UK, where introduction of a risk score (CURB-65)-based clinical pathway for treatment of community-acquired pneumonia influenced prescribing behaviour. As expected, CURB65-guided therapy resulted in an overall reduction in the prescription of cephalosporins and macrolides by 19 and 14 %, respectively, without negatively affecting outcome (30-day mortality, clinical response, treatment outcome). There was a corresponding increase in use of aminopenicillin monotherapy, and guideline compliance increased from 25 % to over 60 % [113].

Acceptance and implementation of treatment guidelines not only improves by involving users in guideline development. Other supplemental ABS strategies such as repetitive education, training and audits of antibiotic prescribing with feedback to the prescriber improve acceptance and adherence [114]. This is shown by a controlled before-and-after study in which adherence was consistently improved by a combination of interventions involving distribution of information packs to staff, repeated compilation of prescription data and educational sessions followed by reminders in the form of posters [98].

Implementation of a uniform guideline for perioperative prophylaxis including recommendations for choice of agent, dosage and timing resulted in annual antimicrobial cost savings of approximately USD 112,000 in a 1400-bed hospital [115].

The institutional anti-infective formulary is established by the pharmacist in the ABS team based on therapeutic efficacy, toxicity and cost. Drugs of the formulary should be categorised into recommended versus reserve or special compounds depending on local treatment guidelines. Graphical overview with alerts (traffic light system), information on daily therapeutic costs or restrictions on use is advisable. Adding information on special prescription or approval requirements is desirable. Besides information on agent and trade names, these lists contain information on the recommended daily dose, including dose adjustments in regard to organ impairment (Table 2). The anti-infective formulary must be passed by the Therapeutics and Drugs Committee. The formulary has an immediate influence on prescribing behaviour [116].

Caution should be exercised in controlling antibiotic use via the formulary alone without an indication-based

Table 2 Example of a formulary

Antibiotic (AB)- Group	Appl.	Trade Name	Active agent	Recommended daily dose RDD		DTC
				Normal renal function CrCl > 80 ml/min	Impaired renal function CrCl 80-50 ml/min	
Penicillins	i.v.	Infectocillin	Benzylpenicillin	3 x 10 million IU or 4 x 5 million IU	2 x 10 million IU	€€
	oral	Penicillin V 1 Mega	Phenoxymethyl penicillin	3 x 1 million IE	3 x 1 million IU	€
Aminopenicillins	i.v.	Ampicillin	Ampicillin	3 x 2 g	2 x 2 g	€€
	oral	AmoxiHexal	Amoxicillin	3 x 1 g	3 x 1 g	€
Aminopenicillins + beta-lactamase inhibitors	i.v.	Ampicillin+ Sulbactam	Ampicillin/ Sulbactam	3 x 2000/1000 mg	2 x 2000/1000mg	€€
	oral	Amoclav 500 plus	Amoxicillin/ Clavulanic acid	3 x 500/125 mg	3 x 500/125 mg	€
Acylaminopenicillins	i.v.	Piperacillin	Piperacillin	3 x 4 g	2 x 4 g	€€
Acylaminopenicillins + beta-lactamase inhibitors	i.v.	Piperacillin+ Tazobactam	Piperacillin/ Tazobactam	3 x 4g/0,5 g	2 x 4g/0,5 g	€€
Carbapenems	i.v.	Meropenem	Meropenem	3 x 1 g for meningitis: 3 x 2 g	4 x 500 mg	€€€€
Tetracycline	i.v. oral	DoxyHexal SF DoxyHexal Tabs	Doxycycline Doxycycline	1 x 200 mg, then 100-200 mg/day	no dose adjustment necessary	€ €
Aminoglycosides	i.v.	TobraCell	Tobramycin	1 x 5-6 mg/kg KG	Confer with Senior physician	€€
	i.v.	Gentamicin	Gentamicin	1 x 4,5 mg/kg KG		€€
Nitroimidazoles	i.v.	Metronidazol	Metronidazole	3 x 500 mg	3 x 500 mg	€
	oral	Metronidazol	Metronidazole	3 x 400 mg	3 x 400 mg	€
Oxazolidinons	i.v.	Zyvoxid	Linezolid	2 x 600 mg	2 x 600 mg	€€€€
	oral	Zyvoxid	Linezolid	2 x 600 mg	2 x 600 mg	€€€€
Green: Recommended Antibiotic	As a matter of principle preference should be given to oral drugs, provided that the patient's condition allows					
Yellow: Reserve Antibiotic	The recommended daily dose refers to an adult patient (~ 70 kg)					
Red: Special Antibiotic, Confer with senior physician	DTC: Daily Therapeutic Cost DTC: €: 0 to €2; €€: 2 to €10; €€€: 10 to €25; €€€€: 25 to €50; €€€€€: more than 50 € to €150					
Bold	Available oral antibiotics					

treatment concept and concomitant surveillance of antibiotic consumption and resistance. It was for instance observed that by adding levofloxacin to the anti-infective formulary fluoroquinolone use subsequently increased substantially, resulting in a higher rate of MRSA infection. When an alert was inserted next to the fluoroquinolone selections on the electronic order entry screen, indicating alternative antibiotic agents in accordance with local guidelines, levofloxacin use decreased again by 50 % from 12 to 6 DDD/100 patient-days and the MRSA infection rate decreased again from 1.37 to 0.63 cases per 1000 patient-days [117]. Similar effects have been observed for other substances and classes and pathogens [118, 119].

Individualised anti-infective orders with or without approval requirements extend from simple to highly differentiated, computer-assisted order forms with an automatic prescription stop after a defined time (so-called “automatic stop order”). These can be agent, patient or indication based, temporary or limited to certain hospital areas. Individualised anti-infective orders present an effective tool to quickly and effectively influence prescribing behaviour. Special order forms or approval requirements are usually implemented for broad-spectrum antibiotics, new/expensive substances or substances requiring extensive consultation. They require justification for prescription, which must be evaluated prior to approval, and can effectively control use and costs. These substances are separately marked in the anti-infective formulary.

Many older prospective before-and-after trials dating from the 1980s and 1990s documented that restricting use of new and expensive cephalosporins generated cost savings of between 19 and 46 %, and reduced consumption by up to 50 % [6, 120–124]. Significant cost reductions being achieved through an antimicrobial-restriction policy are less commonly observed in recent years, because numerous antibiotics have lost patent protection. Nevertheless, more recent studies showed continuing effectiveness regarding reduction in antibiotic consumption of as much as 54 % [23, 125–127]. Newer research on restricting use of broad-spectrum antibiotics yielded a monthly reduction from 137 to 72 DDD/100 cases or from 181 to 102 DDD/1000 patient-days, respectively. Overall, after implementation, the ABS programme delivered effective cost savings of USD 300,000 p.a. (corresponding to net savings of USD 2350/100 cases or 2182/1000 patient-days, respectively). [59].

Use of special order forms limiting antibiotic duration has proved to be particularly effective within the field of perioperative antibiotic prophylaxis. In several prospective, quasi-experimental before-and-after studies the effect of automatic stop order forms on antibiotic consumption, costs and guideline adherence to avoid extended prophylaxis was evaluated. By educational

training, an overall 20–30 % improvement in guideline adherence was observed with respect to choice of drug and duration of antimicrobial use, with one study also showing improvement in appropriate timing of perioperative antibiotic prophylaxis before incision. This resulted in a reduction of surgical site infections from 3.2 to 1.9 %, a reduction in cost of USD 3000/100 patient-days and a reduction in consumption of approximately 20 DDD/100 patient-days [128–132]. Other equally effective automated stop orders limiting total duration of treatment (e.g. 14 days) or restricting duration of reserve drugs such as vancomycin or carbapenems (72 h for empiric therapy, 7 days for therapeutic indication) have been described. Treatment beyond was only possible following consultation with the infectious diseases specialist or pharmacist. As a result, consumption of these substances was reduced by 10–25 % [125, 133, 134].

Specific programmes to restrict antimicrobial use can minimise nosocomial infections (e.g. *C. difficile*) and the increase of resistant pathogens (ESBL, MRSA) by a rapid and marked alteration in consumption. However, such programmes are usually only temporary and lack sustainable efficacy [22]. Restriction strategies are adopted in coordination with the Therapeutics and Drugs Committee, Hospital Infection Control Committee, the pharmacy, and hospital management. Timely and continuous surveillance of consumption, infectious diseases and resistance data are to be assured, to monitor compliance, but also to be able to rapidly identify possible negative impacts. The importance of instituting a programme for the surveillance of antimicrobial use including unrestricted antibiotics, cost and the development of resistance demonstrated by a prospective quasi-experimental observational study at a 450-bed hospital in Greece. In the study, use of carbapenems, third-generation cephalosporins, and fluoroquinolones was restricted based on a national recommendation in context of growing resistance among Gram-negative microorganisms. As a result, ciprofloxacin and ceftazidime consumption decreased as desired by 28 and 42 %, respectively. Subsequently, susceptibility of *P. aeruginosa* (32–45 %) and *E. coli* (77–84 %) to ciprofloxacin increased. On the other hand, susceptibility of *K. pneumoniae* to ciprofloxacin (80–60 %) and ceftazidime (61–46 %) continued to decrease. Of note, piperacillin/tazobactam use increased by 271 % and overall costs and consumption were 12–13 % higher than before intervention [135, 136].

Programmes restricting use of cephalosporins and fluoroquinolones have been repeatedly examined for their “ecological” effects [137–140]. Multicenter controlled investigations in France show a 90 % reduction in fluoroquinolone use after introduction of a time-limited restriction, resulting in a significant reduction in MRSA. Reintroduction of fluoroquinolones was associated with a significant increase in

MRSA compared to the previous period [141, 142]. A new study from France shows that even less restrictive fluoroquinolone use (20 % reduction) combined with improved hand hygiene also reduces the rate of MRSA (moderate) and at the same time impacts positively on resistance of *P. aeruginosa* to fluoroquinolones [143]. Other new studies demonstrate effects of changes in fluoroquinolone prescribing practice on *C. difficile*-associated diarrhoea [144–148]. The effects, however, are not always due to the fluoroquinolone reduction alone.

2.2 Design and implementation of education, training and information

The guideline development group recommends:

Targeted education, training and information are essential elements of any ABS programme. They provide the foundation of knowledge needed to promote more rational use of antibiotics and reasonable microbiological diagnostic, and to improve acceptance of ABS programmes. They have the objective of optimising the therapeutic and diagnostic management of patients with infection through greater adherence to recommendations. They should preferably take place as an active training measure rather than in the form of passive communication of information (A).

Education, training and information in different formats and on various topics should be offered repeatedly as they are not sustainable as a one-off measure. They should be organised in agreement and integration with local ABS programmes (A).

Education, training and information should be independent of commercial interests, whereby the hospital administration is responsible for implementing and financing the measures (A).

Education, training and information are essential elements of every ABS programme. Overall, in a systematic review active clinician education in the form of lectures, seminars, “bedside teaching” demonstrated greater effectiveness than passive education techniques like posters, pocket cards or written prescription recommendations [149]. Two multicenter, randomised, controlled, and some before-and-after studies demonstrated that an educational intervention improved compliance with guideline-recommended diagnostic, therapeutic and prophylactic measures and resulted in a reduction in the number of non-indicated treatments [150–152]. By educational training of nurses and medical staff inappropriate submission of urine cultures decreased from 2.6 to 0.9 per 1000 patient-days; treatment of asymptomatic bacteriuria was reduced from

1.7 to 0.6 per 1000 patient-days, while in another study a significant reduction from 74 to 17 % was seen [153, 154]. In Canadian long-term health care facilities, a 1-year long educational intervention involving repeated mailing of antibiotic guidelines with feedback on individual antibiotic prescribing behaviour of urinary tract infection, pneumonia, skin and soft tissue infection and sepsis resulted in a significant 64 % reduction of nonadherent treatment compared to control facilities [155]. Nonadherent antibiotic prescriptions remained lower during follow-up, although after termination of the educational intervention, the effect was no longer significant compared to control facilities. A similar effect was achieved in a study on an educational programme for guideline-based treatment of respiratory tract infections in emergency departments, in which 1 year post-intervention a 10 %, albeit non-significant reduction in antibiotic consumption was still documented compared to sites without intervention [156].

With the aim of reducing extended use of perioperative antibiotic prophylaxis by means of information disseminated by e-mail, poster and lectures, 12 Australian hospitals succeeded in rapidly and effectively limiting the duration of antibiotic prophylaxis to maximally 48 h, thus achieving considerably lower costs, which more than outweighed the costs of the 1-year intervention [157]. However, the effect of the intervention rapidly declined with time, as seen in other studies [158]. Repeated guideline-based educational interventions are necessary. They were shown to be particularly effective in optimising perioperative antibiotic prophylaxis [6, 159]. In an Argentine multi-step ABS programme involving training and formulary restriction, antimicrobial consumption could be reduced from 43 to 28 DDD/100 patient-days, resulting in substantial savings (>900.000 USD) over 18 months. During the training period a significant increase in the rate of prescriptions based upon microbiology results (27–63 %) was found, and use of ceftriaxone and carbapenems subsequently more than halved [30]. The combination of one-on-one education (academic detailing) and special review of orders for either levofloxacin or ceftazidime was also seen as a highly effective method for reducing inadequate antibiotic use. Unnecessary antibiotic prescription was significantly reduced by 41 % with no change in clinical outcome [28, 160]. However, academic detailing is time-consuming and personnel-intensive [28, 160]. This can partly be compensated by less time-consuming feedback activities, e.g. in the form of written recommendations placed in the patient chart; however, these are not quite as effective and less sustainable [157].

Education, training and information should be independent and should not be guided by the commercial interests of the manufacturers of medical and diagnostics products, since this is the only way to ensure that prescribing and professional behaviour are not subject to direct or indirect

Table 3 Examples of the influence of commercial interests on prescribing and formulary design [41, 42]

Meetings with pharmaceutical representatives	66 % less likelihood of prescribing generic products
Travel sponsoring (congresses, etc.)	Requests to add the sponsor's drugs to the hospital formulary are associated with an odds ratio of 7.9 % (95 % CI, 1.1–55.6) 4.5- to 10-fold increase in hospital prescribing rate (sponsor's products) as compared to before travel
Continuing medical education (CME funding)	Prescribing rate, (sponsor's products) increases by 5.5–18.7 %
Research funding	Requests to add the sponsor's drugs to the hospital formulary is associated with an odds ratio of 9.5 (95 % CI, 2.6–35.7)

influence (Table 3). A systematic review examined the impact of various strategies undertaken by the pharmaceutical industry such as visits, funding for travel or lodging, sponsoring educational events, free samples, etc., on prescribing practices. According to the study, industry-sponsored continuing medical education (CME) had the biggest impact on physician prescribing practices compared to other activities, leading to a 6–19 % increase in prescription rates of the sponsor's medication [41, 42]. The responsibility of organising, holding and financing educational events should be assumed by hospital management.

2.3 Conducting proactive audits of antiinfective use

The guideline development group recommends:

Proactive on-site audits of antiinfective use in the context of antiinfective point-of-care chart reviews are important elements of ABS programmes and should be performed routinely by the ABS team (A). They enhance compliance with guidelines or clinical pathways, improve outcome in patients with infection and improve the quality of prescribing with regard to indication, choice of agent, dosing, dosing interval, administration route and treatment duration.

Depending on the problem and treatment target, besides point prevalence studies, agent-, indication- and/or diagnosis-related audits of antiinfective use should be conducted within the scope of regular antiinfective point-of-care chart reviews either hospital-wide or at the unit level, whereby quality indicators should preferably be applied (A).

Results should be fed back in direct interaction with prescribing physicians and discussed with them (A).

Proactive audit of antiinfective use with review and feedback include the collection and analysis of data on diagnosis, indication, choice of agent, dosing, administration route and treatment duration at patient level. The results are fed back to and discussed with the prescribing physicians (point-of-care interventions). In personal consultation with the prescribing

physicians reasons for choice of drug could be asked for and therapy should be optimised based on clinical, laboratory, radiological and microbiological examination results. Concomitant disease, comedication, expected pathogens when microbiology is not yet known and local antimicrobial susceptibility patterns must be taken into account. The guideline of two North American medical societies has described this type of audit as a highly effective interventional tool that provides a core strategy for an antimicrobial stewardship programme—called “prospective audit with intervention and feedback” [6].

Proactive audit of antiinfective use with review and feedback by an ABS team has been described as effectively increasing the rate of adequate antiinfective use by 20 %; the strategy can reduce the rate of inadequate use by half [34, 53, 161–164]. Methods of feedback can be modified, especially when computer-based assistance is available [165]. The quality of information is important; however, personal feedback is often more effective [165, 166]. In addition to a direct improvement in the quality of prescribing, audits of antiinfective use allow to recognise the need for education and training.

Audits of antiinfective use can be agent-, diagnosis- or indication-based and can be performed at the patient level, in individual departments, wards, or hospital-wide. Targeted (e.g. in relation to agent, speciality department or ward) as well as time-restricted antiinfective audits can be highly effective (examples are shown in Table 4). A programme in which an infectious diseases specialist or pharmacist conducted targeted point-of-care chart reviews (3×/week) of patients receiving multiple antibiotics, prolonged or high-cost therapy (120-bed hospital), achieved good acceptance: 69 % of the recommendations were accepted and implemented, of these 38 % were to discontinue

Table 4 Examples for performing targeted proactive audits of antiinfective use

- Perioperative antibiotic prophylaxis in selected surgical fields
- Targeted therapy of bacteremic patients hospital-wide
- Community-acquired pneumonia in the emergency department
- Sequential therapy on general wards with antibiotics of high bioavailability

therapy due to excessive duration, duplicate coverage or inappropriate use, and 33 % were to switch to oral application. Compared with the previous year, a cost reduction of 19 %, estimated savings of USD177,000 were achieved [167].

Agent-related proactive audit of antiinfective use can address dose adjustment to organ dysfunction, switch to oral application, discontinuation of therapy or targeted therapy based on microbiology. In a multicenter, randomised, controlled study parenteral antibiotics could be significantly reduced by 1 day when patients who had received parenteral antibiotics for longer than 3 days were reviewed by an infectious diseases physician for possible sequential therapy based on defined clinical and laboratory criteria and a recommendation was made for switch to oral drug application [38]. The intervention showed lack of effect on length of hospital stay, but reduced mean antibiotic costs per patient significantly from USD 36 to USD 20. Following updated recommendations on aminoglycoside treatment, antiinfective visitations by infectious diseases physicians achieved a significant 11 % reduction in nephrotoxicity by shortening the treatment duration from 6 to 4 days and optimise dosing by monitoring drug levels [161]. In a study assessing the effects of intervention and feedback by the infectious diseases physician, empiric treatment with levofloxacin, vancomycin and carbapenems was switched to targeted antibiotic treatment in line with guidelines. Consumption subsequently decreased by 20 % and median duration of therapy was reduced from 6 to 4 days in comparison to a control group [168, 169]. In another intervention, a prospective audit and feedback programme was instituted in a teaching hospital by pharmacists and infectious diseases physicians to counteract a trend towards increasing use of expanded-spectrum antimicrobials. This resulted in a significant reduction in consumption of third-generation cephalosporins and aztreonam within a period of 6 years from 28

to 6 DDD/1000 patient-days. Furthermore, there was a significant decrease over time in infections caused by *C. difficile* from 2.2 to 1.4 cases/1000 patient-days [29]. According to another recent time-series analysis, a significant decrease in fluoroquinolone consumption from 118 to 78 DDD/1000 patient-days over 4 years was achieved by the ABS team following implementation of daily hospital-wide audits of fluoroquinolone use based on individual patient data. At the same time, the rate of fluoroquinolone-resistant *P. aeruginosa* continuously decreased from 42 to 26 % [143]. A similar intervention in intensive care units resulted in a sustained 22 % decrease in the number of days of therapy with extended spectrum antibiotics compared with the control group—without negative impact on mortality [170] (Table 5).

With proactive audit of antimicrobial use focussing on diagnosis and indication for antibiotic treatment by an infectious diseases physician-led ABS team with direct interaction and feedback as well as written documentation of recommendations, length of stay was shortened by 3.3 days and a 6 % decrease in mortality was achieved [27]. As a result of the intervention, median hospital costs were reduced by USD 2642/intervention. By optimising the process of perioperative antibiotic prophylaxis, appropriate dosing and timely administration significantly increased from 72 to 90 % and 36 to 79 %, respectively [171]. Within the frame of quality assurance, and for benchmarking purposes with other hospitals, targeted audits of selected process of care indicators for the management of important and frequent infections can also in small acute-care hospitals lead to a significant improvement in adherence to established guidelines. In a quasi-experimental before-and-after study of a total of 36 hospitals (<200 beds) the effect of proactive audit and feedback, by using quality indicators, on the management of pneumonia in the emergency department was investigated. The hospitals demonstrated a

Table 5 Suggested evaluation categories in local audits of antimicrobial use

1.	Antimicrobial <u>therapy</u> adheres to established institutional guidelines with respect to: Choice of agent Dose Route of administration Duration of infusion Duration of treatment
2.	Antimicrobial <u>prophylaxis</u> adheres to established institutional guidelines with respect to: Choice of agent Dosing Route of administration Timing of preoperative dose Dosing interval Duration of administration

30 % improvement in the performance of microbiological diagnostics (blood/sputum cultures) prior to therapy and antibiotic administration within 4 h of hospital admission. As a consequence, mortality was reduced significantly by 12–6 % [172]. Proactive audits of anti-infective use based on selected quality indicators should regularly take place (see Sect. 2.2.4).

The ABS team should determine the objective, type, contents and frequency of point-of-care chart reviews in agreement with the wards or departments involved and should give report on its effects. The ABS team should get project-specific to hospital-wide access to the laboratory, radiological and microbiological data needed. Computer-based information technology can facilitate audits of anti-infective use (see Sect. 3.3.4)

2.4 Quality indicators

The guideline development group recommends:

ABS programmes should be integrated within the hospital's quality management. Content overlaps with the Therapeutics and Drugs Committee (drug safety) and Hospital Infection Control Committee (prevention of nosocomial infection) is useful and desired. Appropriate quality indicators to measure prescription practice (process measure), emergence of resistance or trend in consumption (outcome measure) and structure ought to be set and applied in every ABS programme (**B**). At least three indicators measuring structural quality and at least three indicators measuring process quality should be set regularly (**A**).

ABS programmes are to be regarded as a strategy to ensure quality and should preferably reside as a standard component within the hospitals' existing quality management [25]. It is recommendable to utilise data captured pursuant to the new Infection Protection Act for surveillance of resistant microorganism or anti-infective drug use (IfSG §23 Abs. 4) as well as selected data on infection management provided by external quality assurance sources. Additional quality indicators for local use should be selected and applied regularly. This allows to evaluate and document whether ABS aims can be met [171]. Owing to the different structures and organisation of hospitals, ABS measures must be evaluated locally and if need be adjusted accordingly [2, 22].

Ideally, indicators ought to be evidence-based, i.e. guideline-derived, and ought to be supported by a formal consensus process in regard of their relevance and practicability; last but not least, they ought to be also put to the practical test. Indicators have been developed for

community-acquired pneumonia and urinary tract infections. However, numerous suggestions have been put forward for indicators whose evidence base is rather small and whose relevance and practicability rests on consensus alone. In Germany, there are catalogues of quality indicators for instance for the Helios Hospital Group ("Initiative of Quality Medicine") or for the Rhön, Sana und Asklepios Hospital Group ("Quality Hospitals"). They also exist for mandatory external health care quality assurance concepts, for whose development and implementation the German National Institute for Quality Measurement in Health Care (Bundesgeschäftsstelle Qualitätssicherung gGmbH; BQS) till 2009, and since then the AQUA Insitut (the Institute for Applied Quality Improvement and Research in Health Care GmbH) was commissioned by the Federal Joint Committee (Gemeinsamer Bundesausschuss; G-BA). However, only few quality indicators have been set for measurement of antibiotic prescribing of which some are already at goal (e.g. for community-acquired pneumonia, antibiotic prophylaxis for obstetric and gynaecological indications, femur fracture, as well as hip and knee endoprosthesis). Individual more or less plausible and consented catalogues of structural indicators are available outside Germany [65, 173, 174]. A lot of experience was especially gained in France. Process quality indicators, respective pneumonia and surgical prophylaxis, are available in multiple countries (e.g. <http://www.qualitymeasures.ahrq.gov> or <http://www.jointcommission.org> or <http://www.ic.nhs.uk>).

The guideline committee in collaboration with the ABS Expert Network (<http://www.antibiotic-stewardship.de>) and the University Hospital of Freiburg established a catalogue of consensus structural and process ABS quality indicators in a multistage procedure including Delphi survey. The catalogue should facilitate external and internal quality assurance. Clinical, ecological (resistance) and economical (cost, cost-effectiveness) relevance as well as the presumed practicability were assessed separately in several categories. In analogy with the so-called QUALIFY process [175], a provisional list of potentially suitable structural and process indicators was drafted. It was based on the draft of the Guideline itself, the current literature [1, 6, 25, 86, 105, 171, 176–189], including documents and experience with the former ESAC Group (<http://www.esac.ua.ac.be>) [190] and the former ABS International Group, an initiative of 9 EU member states for the improved use of anti-infectives (<http://www.abs-international.eu>) [191]. Based on the results of a workshop (15 participants) held at the ABS Expert Network meeting in November 2011 in Freiburg, a later questionnaire survey (Delphi methods, $n = 75$ ABS experts, i.e. advanced members of the ABS training programme of varying professional background, incl. pharmacy and microbiology) and a further workshop, of the initial 99 potential indicators 67 were put forward for

discussion and 21 structure and 21 process indicators subsequently selected as presumably most suitable (see Tables 7, 8 in the Appendix) [434]. Suitable indicators on the quality of antimicrobial prescribing (process indicator) and structure (structure indicator) taken from this list (Tables 7, 8 in the Appendix) ought to be set and used in every ABS programme. At least three indicators on structure and process quality each should be determined regularly.

3 Supplemental ABS strategies

There are various strategies or measures that can supplement and complement the core ABS activities described here. They can play a pivotal role in further improvement of outcomes of antibiotic stewardship programmes. Supplemental ABS strategies include special programmes and recommendations for therapy optimisation, special rules in reporting microbiology results, rules on the management of patients with multidrug-resistant pathogens (MDR) or *C. difficile* as well as computerised support systems. Evidence for their effectiveness varies. Their implementation partly depends on the hospital's infrastructure, e.g. with computerised expert systems and information technology or the possibility for rapid measurement of antibiotic levels in serum.

3.1 Special programmes for treatment optimisation

As a rule, programmes for therapy optimisation such as de-escalation (streamlining) strategies, interventions to control duration of treatment, switch to oral administration and optimisation of antimicrobial dosing are carried out at the ward or patient level (also called "point-of-care interventions"). These are relatively focussed interventions that can be highly effective in improving the quality of antimicrobial prescribing. They are usually elements of proactive audit of anti-infective use or chart review, implementation can, however, also be computerised. [2, 22, 25].

3.1.1 De-escalation

The guideline development group recommends:

A key aspect of supplemental measures is to streamline treatment after initial empirical broad-spectrum therapy and conversion from empirical to targeted therapy. This ought to be done based on clinical criteria as well as microbiology results or other diagnostic findings. De-escalation measures ought to be preferably performed at the patient level in the context of anti-infective point-of-care chart reviews and proactive audits of anti-infective drug use (B). Programmes promoting anti-infective

de-escalation are expected to, by reducing antibiotic load, impact beneficially on the emergence of resistance, the prevention of secondary infections, cost levels and adverse drug reactions (B).

De-escalation proposes to simplify treatment, i.e. monotherapy rather than combination therapy, targeted (narrow spectrum) rather than untargeted broad-spectrum therapy, discontinuation of empiric treatment if diagnosis is uncertain [192, 193]. There are insufficient data to favour combination therapy over monotherapy in the routine management of ventilator-associated pneumonia. In addition, combination therapy did not show a benefit with regard to decreasing superinfection rates or the emergence of resistant pathogens [6, 194–197]. In a meta-analysis of eight randomised, controlled studies on patients with different infections β -lactam/aminoglycoside combination therapy did not impact favourably on the emergence of resistance. Fewer superinfections were observed with monotherapy (OR 0.62; 95 % CI, 0.42–0.93) than with combination therapy [198]. Furthermore, combination with aminoglycosides is associated with a higher incidence of nephro- and ototoxicity [199–201]. Thus, de-escalation to monotherapy is recommended based on type of infection and microbial culture results [202]. Combination therapy is only recommended for selected indications.

Observational studies on general wards and intensive care units show that 20–60 % antibiotic treatments could be adjusted based on microbial findings alone [193, 203–205]. Pharmacists and infectious diseases physicians assessed combination therapy as being unnecessary in 50 % of cases, measurable effects of de-escalation were reduced length of hospital stay and high-cost savings [206–208]. In an intervention, a computer programme identified combination antibiotic therapy across the hospital, which was then evaluated by a pharmacist or infectious diseases physician for adequacy. 98 % of combination therapy was found to be redundant. The implementation led to considerable net savings [209].

The effect of de-escalation, or treatment adjustment based on microbial culture results and/or clinical criteria was well demonstrated in at least one multicenter clinical study of patients in intensive care. Patients suspected of having developed ventilator-associated pneumonia receiving treatment in 31 French intensive care units were switched to targeted treatment based on culture and sensitivity results of pathogens obtained by bronchoalveolar lavage or endotracheal aspiration. Patients who received treatment based on bronchoalveolar lavage culture results had significantly more antibiotic-free days (5 vs 2), significant 10 % lower mortality at day 14 and decreased

sepsis-related organ failure at day 3 and 7 [100, 103]. The authors related this to the fact that invasive bronchoscopy allows to differentiate better between pulmonary infection and colonisation, and that antibiotic treatment can be discontinued earlier given negative cultures from bronchoalveolar lavage. In a randomised controlled trial conducted in an intensive care unit in North America, the course of antibiotic therapy of pneumonia was shortened by 2 days, based on clinical criteria, without negative impact on mortality [210]. Numerous other investigations confirm these observations and show that adjusting therapy is usually possible after 48–72 h [211–214].

3.1.2 Duration of treatment

The guideline development group recommends:

It is possible to shorten the duration of antiinfective treatment for many indications (e.g. perioperative antibiotic prophylaxis) and this is recommended wherever backed by good studies and evidence. The ABS team should utilise local guidelines and antiinfective point-of-care chart reviews to draw attention to the excessive duration of treatment frequently encountered in practice. The ABS team should define the duration of treatment recommended as a rule, since this is expected to impact substantially on antiinfective drug use, side effects and costs (A). Use of biomarkers such as Procalcitonin may be useful for controlling the duration of treatment in cases where there is clinical uncertainty. As a result, the number of days of antibiotic therapy can be reduced and under certain circumstances costs can be cut (C).

A frequently encountered problem in regard to antibiotic therapy is the duration of antimicrobial treatment often being too long. Large-scale studies in the USA, in European countries and elsewhere have repeatedly demonstrated prolonged duration of perioperative antibiotic prophylaxis—in 50 % or more cases perioperative antibiotic prophylaxis was administered for longer than 24 h [85, 86, 215]. This unnecessarily increases selective pressure for resistance to emerge [102, 216–219].

German recommendations with S3 Guideline level, e.g. on community-acquired and hospital-acquired pneumonia or uncomplicated community-acquired urinary tract infections, give explicit, evidence-based recommendations on duration of treatment (<http://www.awmf.org>). The results of the studies on which the recommendations on pneumonia are based demonstrate convincingly that the mean duration of treatment can be reduced without negative impact on clinical outcome and mortality [102, 220, 221]. An important trial is a prospective randomised

double-blind study of patients with ventilator-associated pneumonia undertaken in 51 French intensive care units. It was demonstrated that 8-day treatment had no disadvantage for these patients as compared to 15 days. Shorter treatment duration was associated with emergence of fewer multidrug-resistant pathogens (–20 %) [101, 102]. These findings and the results of other similar studies have had a decisive influence on the assessment and conclusions reached in recent meta-analyses [222, 223]. Other good scientific studies on urinary tract infection show similar results [224]. When implementing ABS programmes, treatment orders for patients with community-acquired pneumonia should for instance be linked to a note “no longer than 5–7 days” to remind users to undertake an individual clinical reassessment of further treatment beyond this point in time. This question can also be addressed in proactive audits of antiinfective drug use [225, 226].

Biomarkers can also be useful to guide duration of therapy. Corresponding studies are available on use of Procalcitonin particularly in the management of patients with respiratory tract infections, whereby treatment duration in the control arm does not correspond in some cases to today’s standards. Various systematic reviews and meta-analyses are available on Procalcitonin [227, 228]. Determination of Procalcitonin levels can influence the density of antibiotic treatment in intensive care units: in a prospective study antibiotic treatment was reduced by 23 %, in other studies this effect remains, whereby the cost-effectiveness is unclear and there seems to be no impact on mortality [229–235].

Numerous studies have aimed to improve adherence to guidelines on perioperative antibiotic prophylaxis, especially with regard to duration. Training programmes, local guidelines and checklists in the operating room with and without use of computer-based information technology were most often applied. For various reasons the results are not always satisfactory and comparable, depending on intervention and speciality field [128, 129, 158, 188, 236–242]. Some examples of successful outcome are the significant reduction of treatment duration from 2.4 to 1.6 days (Japan), the 15 % reduction in the amount of antibiotics prescribed for perioperative antibiotic prophylaxis (Germany), the increase in the proportion of guideline-adherent prophylaxis of no longer than 24 h duration from 3 to 66 % (Taiwan) and the reduction of prolonged prophylaxis >24 h from 21 to 8 % (Netherlands). A time-series analysis of 13 hospitals in the Netherlands demonstrated convincingly that targeted training programmes result in a decrease of perioperative antimicrobial drug use from 121 to 99 DDD (defined daily doses)/100 procedures, and in a cost reduction of 25 % per procedure [188]. If available, electronic prescribing systems can be used for automatic stop orders to reduce the proportion of patients with prolonged prophylaxis. In a US study, by computer-based order intervention,

the proportion of patients who had prophylaxis discontinued in the appropriate time frame increased by 17 %, compared to no change without intervention [243].

3.1.3 Parenteral-to-oral conversion

The guideline development group recommends:

If sufficient bioavailability is assured, and if the patient's condition allows, therapy should be switched from parenteral to oral antibiotic application (A). This measure reduces the length of hospital stay and the risk of line-related adverse events. Furthermore, it leads to a reduction in the total cost of treatment. Implementation of programmes allowing parenteral-to-oral conversion of antimicrobial agents at the institutional level ought to be facilitated by developing clinical criteria and through explicit designation in institutional guidelines or clinical pathways (B).

Critically ill patients suffering from an infection, initially receive parenteral antibiotics. Stabilised patients as well as patients with a less serious illness can be given oral agents with good bioavailability as long as there are no contraindications (e.g. disorders of gastrointestinal resorption or dysphagia) (Table 6). Conversion to oral administration has numerous advantages. Mobility is improved, patients can be discharged earlier, the risk of adverse line-related events is smaller, and the amount of nursing time required is usually reduced. Switch to oral antibiotics has been well investigated for certain indications, and recommendations are made in many guidelines, e.g. the German guideline for treatment of community-acquired pneumonia [6, 244–246]. Safety of switch to oral administration was evaluated in at least one meta-analysis and several partly multi-centre randomised controlled clinical trials. It was demonstrated, that duration of parenteral treatment and length of stay can be reduced by approximately 2–3 days without increasing mortality [61, 247–255]. In a prospective quasi-experimental observational study involving around 200 pneumonia patients, almost 70 % of the

Table 6 Substances with good-to-excellent bioavailability

- Fluoroquinolones (without norfloxacin)
- Cotrimoxazole
- Doxycycline
- Metronidazole
- Linezolid
- Rifampicin
- Fluconazole

patients could be switched to oral antibiotics at day 3, and a further 20 % between day 4 and 7. Similar experience was made in a series of other observational studies [39, 76, 111, 256, 257]. Safety was also investigated with respect to study endpoint hospital readmission [258, 259].

With the exception of endocarditis and meningitis, timely switch to oral antibiotic administration can also be reasonable for pyelonephritis, for skin and soft tissue infections, febrile neutropenia, infantile osteomyelitis/purulent arthritis [252, 260–267]. Systematic review of good clinical studies partially performed in Europe shows that switch to oral antibiotic administration for another 7–11 days is already possible at day 3 of parenteral therapy for treatment of infantile pyelonephritis without a higher incidence of renal damage or other complications [268–271]. Other studies have documented substantial cost savings from early shift to oral antibiotics and as a consequence earlier discharge from hospital [64, 272–274]. Some of these investigations were conducted by hospital pharmacists themselves [39, 275]. Prospective observational studies investigating early switch to oral antibiotics have demonstrated that sustainability can be achieved by checklists, clinical pathways defining criteria for early conversion to oral therapy and its implementation supported by hospital pharmacists [258, 276–280].

3.1.4 Dose optimisation

The guideline development group recommends:

Adequate adjustment and optimisation of the dose and dosing interval is essential for effective, safe and responsible administration of anti-infective therapy, and an important part of ABS programmes. Besides individual patient factors, optimal dosing of anti-infectives should take into account, the nature and severity of illness, the causative microorganism, concomitant medications, as well as the pharmacokinetics and pharmacodynamics of the agents prescribed. Strategies to optimise dosing in ABS programmes should include assessment of organ function for drug dose adjustment in order to avoid adverse drug events and unwanted drug interactions (A).

Furthermore, optimising the dosing interval and duration of infusion is recommended in particular in critically ill patients, best by employing a therapeutic drug monitoring (TDM) scheme; appropriate consented local institutional guidelines should be available and up to date (B).

Evaluation of ABS programmes showed that one-third of all interventions was in regard to dose optimisation of

antimicrobial treatment. This was demonstrated in many retrospective studies which provided evidence of inappropriate choice of agent and inadequate dosing [281–287]. As with all medication, anti-infective dosing requires individual review and adjustment. If need be, dose and dosing interval must be adjusted, whereby age, weight, gender, hepatic and renal function, underlying and concomitant disease as well as co-medication must be considered. Dosing is largely determined by pathogen susceptibility, the location and severity of infection [288]. Dose optimisation programmes have been implemented by pharmacists and infectious diseases physicians with similar success and can also be cost effective [37, 289–297].

Pharmacokinetic and pharmacodynamic (PK/PD) properties are important to achieve optimal anti-infective dose levels [298, 299]. Emergence of resistance can be promoted by using incorrect, low dosages of antibiotics with low-resistance barrier [216]. Therefore, strategies to avoid incorrect drug dosage or suboptimal dispensing appear useful, at least in critical areas such as intensive care units, despite uncertain evidence for a clinical benefit [101, 300–305]. Important strategies are optimisation of dosing intervals (e.g. higher concentrations of aminoglycoside with an extended dosing interval) [306] and prolonged infusions of beta-lactams especially in presence of critical illness or multidrug-resistant microorganisms [307]. In this setting, therapeutic drug monitoring (TDM) can improve antibiotic dosing [308–310].

By using TDM, the proportion of patients with serum piperacillin concentrations within therapeutic range increased from 50 to 75 % in a 30-bed intensive care unit in a French teaching hospital [311]. A much cited, multi-centre study from the Netherlands conducted in medical and surgical wards of four hospitals was able to show that active TDM-guided dosing of aminoglycosides and dosing recommendations by clinical pharmacists can significantly shorten length of stay by approximately 6 days and reduce incidence of nephrotoxicity from 13 to 3 %. A highly detailed cost-effectiveness analysis showed overall cost savings of 30 % [312]. Similar results were reported from France [313, 314]. The benefits of single-dose aminoglycoside administration compared to multiple-dose and extended-interval aminoglycoside dosage regimens can be utilised to minimise nephrotoxicity in children [38, 315, 316].

PK/PD analyses show that with beta-lactam antibiotics the duration of time that drug levels exceed the MIC of the pathogen at the site of infection is important to achieve better treatment outcomes (time-dependent killing). Beta-lactams with short half lives (<2 h) should actually be given as extended or continuous infusion, which requires drug stability at room temperature [317, 318]. An older

meta-analysis [319, 320] suggests that clinical outcome in continuous intravenous infusion of suitable beta-lactams seems to be superior to intermittent infusion of the same daily dose. More recent systematic reviews investigating continuous infusion have not confirmed superiority [310, 321], whereby different daily doses were compared, though in certain studies very good effects were observed. McKinnon et al. [322] for instance showed in a prospective randomised investigation in critically ill patients with bacteremia that continuous infusion ceftazidime or cefepime is superior to intermittent short-term regimen: clinical improvement and mortality differed significantly. In a randomised study of bacterial meningitis, where cefotaxime was administered in the first 24 h by continuous infusion versus intermittent bolus, a benefit was seen in favour of continuous infusion in terms of lower mortality [323]. Treatment success can be achieved by the drug concentration being 40–60 % of the time in the 2- to 4-fold range of the MIC. Drug concentrations remaining above the MIC 100 % of the time is not necessary. An intermittent dosing strategy with longer duration of infusion can thus suffice to guarantee optimal outcome [324]. A retrospective multicenter study showed that increasing length of infusion (4 h) gives better clinical results for intermittent dosing of piperacillin/tazobactam. Mortality was reduced from 18 to 10 % ($p = 0.02$) [325]. A similar (before and after) observational study (larger number of cases) with cefepime, piperacillin/tazobactam and meropenem could not reproduce these positive results [326]. In yet a further prospective investigation conducted across Australia and Hongkong with 2×30 patients (in addition to piperacillin/tazobactam, ticarcillin/clavulanate and meropenem were permitted), PK parameters were defined as primary endpoint. The clinical results are of interest nevertheless: clinical cure was observed in 70 vs 43 % (continuous vs. bolus) ($p < 0.01$), and survival in the two arms was 90 vs 80 % [327]. In a Czech study, 2×120 patients (intensive care, medium APACHE-II-Score >20, high incidence of *Klebsiella* infection) were randomised in continuous infusion group and bolus group. A high loading dose was given in both arms. Clinical cure (83 vs. 75 %, $p = 0.18$) and microbiological success rate (91 vs. 78 %, $p = 0.02$) were better with continuous infusion. However, a very high loading dose of meropenem was given in both arms (4×1 g over 6 h vs. 3×2 g over 30 min) [328]. Additional findings in the continuous infusion group were shorter ICU stay (10 vs. 12 days), shorter duration of therapy (7 vs. 8 days) and (as to be expected from the study design) lower total dose of meropenem. Concerning mortality, no significant statistical difference (hospital, ITT population) was detected (17 vs. 23 %).

3.1.5 Scheduled switch of antimicrobials

The guideline development group recommends:

So-called “Cycling” programmes, which involve periodically removing a specific antimicrobial drug or an antimicrobial drug class as the standard recommended therapy and later reintroducing it (periodic scheduled rotation), are not suitable as a strategy to reverse critical emergence of resistance or to control nosocomial outbreaks with multiple resistant pathogens and, as such, should not be used as a strategy to do so (A).

Strategic rotation of specific antimicrobial drugs or antimicrobial drug classes ought to be undertaken to limit the selective pressure and to achieve a reduction of infectious microorganisms or microorganisms displaying specific resistance properties for a certain time (B). There is evidence to suggest that a balanced use of different antimicrobial drugs or antimicrobial drug classes (so-called “mixing”) can minimise the emergence of resistance. In both cases, routine surveillance of antimicrobial drug use and resistance should be performed (A).

Repeated rotation of different antimicrobials or antimicrobial classes (e.g. cephalosporins, fluoroquinolones, penicillins, carbapenems) for empiric therapy of acute infection within an institution or specific unit—so-called “Cycling”—was designed to limit selective pressure and thus prevent development of resistance toward frequently prescribed antimicrobials/antimicrobial classes. Published experience with cycling strategies, mainly on aminoglycosides, is a few decades old, and, in view of the minor share of aminoglycosides used, of little interest in clinical routine today. Neither are the studies consistently successful in showing a detectable effect in minimising resistance [6, 329, 330]. In many cases, implementation was problematic, with up to 50 % of the patients in cycling programmes receiving “off cycle” antimicrobials, i.e. not receiving per protocol antimicrobial treatment [6].

More recent studies on cycling of broad-spectrum beta-lactams show little improvement in methodology or results [331–337]. Neither do mathematical models of antimicrobial cycling demonstrate benefit in respect of avoiding resistance. Mathematical modelling suggests that antibiotic cycling strategies, prompting simultaneous diversity of antimicrobials/antimicrobial classes, perform better than temporary dominance of a single antimicrobial agent/antimicrobial class [338–340]. Several clinical trials confirm this concept [341–344]. Within the scope of a Spanish prospective intervention study on ventilator-associated pneumonia in an interdisciplinary intensive care unit, it could indeed be demonstrated that, compared with

two strategies with heterogenous use of cephalosporins, penicillins, carbapenems and fluoroquinolones, cycling led to a significant increase in resistant nosocomial pneumonia pathogens [345]. Thus, with respect to antimicrobial classes, attention should be paid to use of balanced, guideline-adherent therapy. Above all, excessive use of cephalosporins and fluoroquinolones should be avoided. If surveillance data of cephalosporins and fluoroquinolones point to excessive consumption, a strategic class switch in preference of penicillins should be undertaken. There are several new publications on this topic. Following an educational campaign and subsequent introduction of restrictions, the policy “Reduction of routine use of ceftriaxone and ciprofloxacin in favour of aminopenicillins” was successfully implemented in a Scottish hospital. The endpoints observed were change in the incidence of hospital-acquired MRSA and ESBL-positive infections (without special screening) as well as *C. difficile* rates. As result of the new policy, consumption of ceftriaxone reduced by 95 % and that of ciprofloxacin by 73 % (comparison of the first and final 6 months of the study). At the same time, hospital-acquisition rates for *C. difficile* reduced by 77 %, MRSA by 25 % and ESBL cases by 17 %. The intervention had a sustained effect (up to 3 years later) [346]. Other observational studies on strategic antimicrobial substitution of cephalosporins in favour of penicillins conducted in China, Greece and India seem to confirm a decline in ESBL cases, however, cannot prove it [347–350].

3.2 Special rules for communication of microbiology results

The guideline development group recommends:

The quality of microbiology diagnostics depends crucially on compliance with guidelines on procedures in the preanalytical phase. Expert consensus recommends that any deviations from protocol ought to be reported and the reasons for rejecting the samples stated (B).

Technical progress and up-to-date molecular diagnostic methods for rapid pathogen detection should be used if they improve the quality of care and/or substantially improve identification and epidemiologic investigation of local outbreaks (A).

Positive blood culture findings, interim microscopic findings, results of rapid testing and rapid susceptibility testing should be delivered promptly to the attending physician (A).

Antibiograms ought to adhere to local guidelines with respect to antimicrobial use and diagnostic findings, be presented selectively in agreement with the

ABS team, and, if need be, include relevant interpretative comments. This procedure aids selection of a targeted, guideline-based antibiotic therapy (**B**).

The microbiology laboratory is responsible for the timely identification of trends in antimicrobial resistance and prompt communication of observations to the ABS team and the physicians responsible for infection control (**A**). This way, the clinical and epidemiological significance of the observations can be defined at an early stage.

The microbiology laboratory plays a crucial role in achieving the objectives of an antimicrobial stewardship programme by providing timely identification of relevant pathogens, selective antibiograms and active communication of diagnostic results and their interpretation, including interim reports. Microbiology diagnostics and susceptibility testing and reporting should be based on latest national [e.g. quality standards of microbiology and infectious diseases (MiQ) for Germany] and international quality standards (<http://www.eucast.org>), should address the specific requirements of the requesting physician and live up to the hospital's obligation to provide medical care. A meaningful microbiological diagnostic requires optimal sample quality, storage, and timely transport of samples to the laboratory. The transport time of urine samples stored at room temperature should not exceed 2 h, since delays in transport of samples to the laboratory may increase pathogen growth and produce false-positive test results [351, 352]. Samples that deviate from guideline-adherent pre-analytics ought to be reported or ought to lead to the implementation of rejection criteria. Criteria ought to be defined for all common samples—e.g. sputum, urine, stool and swabs—to avoid unnecessary antimicrobial therapy. It is for instance recommended that purulent sputum with more than 25 squamous epithelial cells per field ought not to be further screened; rather, findings ought to be reported and the sputum sample discarded [353–355]. Microbiological diagnostic of good-quality sputum samples can provide valuable information on the pathogen involved. Older studies investigating patients with pneumonia were able to show that high-quality sputum samples resulted in targeted antimicrobial monotherapy more often [356, 357] than inadequate sputum or no sputum culture. Reporting is also of importance on samples from non-implanted foreign bodies (drains, urinary catheters, venous catheters, tracheal cannula, wound sponge, etc.) or where low sample volume impairs sensitivity.

Automated MIC-based antibiograms and integration of molecular diagnostic assays such as PCR, PNA-FISH or MALDI-TOF into microbiology diagnostic can shorten time to pathogen identification and reporting of results [358]. Several prospective, randomised clinical studies on diagnostic of blood cultures and respiratory samples in pneumonia have shown that more rapid detection of pathogens by a few days resulted in earlier targeted antibiotic therapy. Thus, duration of empirical therapy, duration of ventilation and length of hospital stay were reduced by a few days and mortality decreased variably [36, 359–366]. More recent prospective investigations on use of rapid *Legionella* urinary antigen test in pneumonia patients have shown that it is a useful tool with which targeted antimicrobial treatment can be provided more frequently. This was less conclusively demonstrated for pneumococcal antigen in urine [367, 368]. However, carefully developed and implemented algorithms are necessary to maintain the potential benefit. At least two controlled before-and-after studies have shown that antibiotic therapy is only modified and adjusted to microbiological findings, i.e. blood culture results, if these are communicated personally to the treating physician or the culture results are documented in the patient's medical chart [369–371].

The guideline development group recommends the use of selective reporting of susceptibility testing results with respect to choice and number of antimicrobial agents depending on pathogen, local susceptibility data and existing therapy guidelines, with the objective of supporting guideline-adherent antibiotic therapy [1, 6, 372]. Two methodologically different interrupted time-series analyses indicate that selective antibiotic susceptibility reporting can influence prescribing behaviour [373, 374]. Additional reporting, providing information on major resistance mechanisms, on contamination or colonisation according to pathogen and pathogen quantity, or information on diagnostic and therapeutic guidelines can support ABS measures. However, the effect of the mode of reporting microbiology results on prescribing behaviour is not well studied.

In case of unprecedented or critical levels of bacterial resistance, the microbiology laboratory should identify the cause by molecular biological methods as well as characterisation of clonal variants by typing, in particular during outbreaks and in this case especially with the assistance of reference laboratories. Depending on test results, targeted ABS strategies should be seized by the ABS team in accordance with appropriate hygiene interventions, implemented by the infection control team.

3.3 Special rules for management of patients with multidrug-resistant microorganisms and *C. difficile*

The guideline development group recommends:

ABS strategies should be used to prevent infection with *C. difficile* (A). Restricting use of certain antimicrobial drugs or substitution of antimicrobial drug classes (e.g. penicillin for cephalosporins or fluoroquinolones) can considerably reduce the incidence of *C. difficile* infection. Infection prevention and control strategies are frequently also applied at the same time; however, they have less impact on the *C. difficile* incidence than in the epidemiology of MRSA or VRE.

Targeted ABS strategies are to varying degrees also effective in reducing multidrug resistant Gram-negative bacteria, particularly ESBL-producing microorganisms, MRSA and VRE, and ought to be specifically applied here too (B). In case of high prevalence of multidrug resistant microorganisms, recommendations on diagnostic tests, evaluation of findings and treatment, as well as infection control management should be coordinated immediately and disseminated locally (A).

Routine surveillance of antimicrobial consumption and antimicrobial susceptibility data should be performed (A) to avoid indiscriminate compensatory use of other antimicrobial drug classes, since this can promote the unintentional and uncontrolled emergence of resistance.

The importance of appropriate ABS strategies for the management of patients with multidrug-resistant microorganisms and *C. difficile* is well documented in several systematic reviews and corresponding studies especially for *C. difficile* [2, 8, 22, 25, 375]. Pretreatment especially with third-generation cephalosporins and fluoroquinolones presents a risk factor for *C. difficile* infection, as well as for the increase in ESBL-producing Gram-negative microorganisms, MRSA and VRE [376, 377].

In before-and-after studies restriction of some types of antimicrobials, particularly third-generation cephalosporin and fluoroquinolones, but also macrolides and clindamycin, resulted in a 50 % or higher reduction in the incidence of *C. difficile*-associated disease. Frequently, interventions were accompanied by general infection control strategies. However, even in controlling outbreaks, infection control practices do not always appear to be sufficiently successful, as shown by the data collected retrospectively in a methodologically robust time-series analysis. It was not

until restriction of cephalosporins, macrolides and clindamycin was imposed 6 months later that the incidence of *C. difficile*-associated disease decreased by 60 %. Utilisation of broad-spectrum penicillin subsequently increased compensatorily without repeated emergence of the epidemic *C. difficile* strain [73]. An investigation carried out over several years in a geriatric unit showed that the incidence of *C. difficile* diarrhoea was strongly associated with the density of cefotaxime use [378]. More recent time-series analyses over a period of 12–24 months confirm that substituting cephalosporins and fluoroquinolones for penicillins can lead to a decrease in the incidence of *C. difficile*-associated disease. Cephalosporin and fluoroquinolone use decreased considerably by more than 22–50 % [144, 146].

It is possible to influence the incidence of ESBL-positive isolates by implementing strategies to control antibiotic consumption. Various methodologically different but demanding studies on restriction of cephalosporin use showed a decrease in the rate of infection and colonisation with ESBL-producing microorganisms [349, 350, 379–381]. However, in respect to sustained minimisation of resistance, the effects of a policy for targeted restriction of antimicrobials are less conclusive [124, 382] and sometimes even contradictory [383–387]. Particularly, unplanned increased consumption of alternative agents, in setting of restriction, can rapidly impact negatively on the resistance situation [135, 388, 389]. The effect of restriction of third-generation cephalosporins, vancomycin and/or fluoroquinolones varied in regard to VRE and MRSA [117, 383–385, 390, 391]. For instance, a short-term effect of restriction of vancomycin and cephalosporins on gastrointestinal colonisation with VRE (decrease from 47 to 15 %) was observed [392]. According to long-term observations, VRE eventually increased again [393]. Infection control practices seem to have a stronger sustained effect in this regard, and ABS strategies alone may not suffice.

In case of high incidence of multidrug-resistant microorganisms and cumulative outbreaks, appropriate recommendations on diagnostic tests, evaluation of findings and treatment, as well as infection control management must be coordinated immediately and disseminated locally. There is generally great uncertainty about optimal treatment [394]. In certain circumstances, use of unconventional antimicrobials or of conventional antimicrobials in unusual dose and combination may become necessary. In this situation, it is indispensable for the ABS team to draft appropriate guidance and recommendations in collaboration with the microbiology laboratory, to allow optimal treatment outcome and not to promote further spread of multidrug-resistant microorganisms through inadequate antibiotic use.

3.4 Computerised information technology

The guideline development group recommends:

The ABS team should be supported by novel information and communication technology in the implementation of ABS programmes. Local treatment guidelines, the anti-infective formulary, and other ABS documents should be available electronically (A).

Electronic prescribing tools with and without linkage to electronic preauthorisation solutions to ABS documents or to active communication of information using computerised reminders to the prescriber should be used to improve the use of anti-infectives in the interests of patient safety (A). They ought to be used to reduce consumption and/or costs (B).

Computerised decision support systems that are integrated into the hospital's internal information system can, by utilising electronic medical records, help evaluate and optimise the indication for anti-infective therapy, drug selection and dosing (C).

To implement computerised ABS measures, the ABS team must have hospital-wide access rights to electronic medical records (with due respect to data protection).

The ABS team should be supported by novel computer-based information and communication technology through the provision of hospital-wide availability of ABS documents (anti-infective formularies, guidelines, treatment pathways). Development and application of electronic computerised decision support systems (CDSS) is to be encouraged. To utilise these systems optimally, it is useful to link them to an electronic patient record/chart or/and a patient-based computer physician order entry system (CPOE). In spite of the tremendous advances that have been made in the development of these systems in the hospital sector, availability varies in German and Austrian hospitals. Software designed specifically for ABS purposes hardly exists at all. Systematic reviews evaluating the impact of CDSSs specifically in the field of ABS (studies to 2007) found them to be of limited benefit [395, 396].

Electronic hospital information systems are used to varying extent in most hospitals in Germany. The system gives the treating physician access to patient-related and treatment-relevant data. In the interests of patient safety, and taking account of data protection, the ABS team should also have access to these data (anti-infectives, and microbiological laboratory results). Furthermore, electronic hospital-wide surveillance data on pathogens and anti-infective consumption should be available to the ABS team at all times. The ABS team should receive support on use and layout of computerised information systems from experts [397–401].

Besides automated electronic alerts/short consultations and computerised decision support systems, in future, electronic prescribing systems, i.e. patient-based computer physician order entry systems (CPOE) with and without approval and reminder/alert functions will be particularly important for interventional ABS activities. As far as prescribing quality is concerned, these systems offer many advantages over paper-based medication orders with regard to legibility, completeness, fast delivery of information and possibly to approval or reminder/alert functions [402]; however, they are not as yet standard practice in German-speaking countries. By using CPOE systems, the rate of medication ordering errors can be reduced considerably (dosing, interactions, allergies) [403–407]. On the other hand, the extent to which these systems influence resistance or clinical outcomes and mortality is inconclusive [408–413]. In addition, CPOE systems could facilitate audits of antimicrobial prescribing through timely provision of patient-related, cross-unit and cross-departmental antimicrobial prescribing data [414, 415]. In a randomised controlled trial conducted in the USA, an ABS team [infectious diseases physician (50 % FTE), clinical pharmacist (80 % FTE)] reviewed antibiotic prescribing based on a list of alerts generated by an electronic decision support system. Among others, the following selection criteria were used: intravenous antimicrobial application in spite of good oral bioavailability, unnecessary combination therapy, and antibiogram discordant therapy. Compared with the control arm, USD 38 were saved per day per patient (around 16 % of total antibiotic costs) and 1 h of work a day with automated system alerts [416, 417]. A reduction in rates of antimicrobial use can be achieved by integrating an antimicrobial approval system into electronic prescribing [75, 243, 408, 409]. Web-based reviews of guideline-adherent prescribing of third-generation cephalosporins resulted in a significant 50 % reduction that was sustained over 15 months [75]. In another study, vancomycin use required an indication (by drop-down menu or free text) at initial electronic ordering and after 72 h. Treatment was stopped automatically if no indication was entered both times. As a result, initial vancomycin orders per physician were reduced significantly by 29 %, and 36 % fewer renewal orders were written after 72 h. The amount of days of vancomycin therapy decreased by 36 %. However, no information was provided on clinical outcome [418]. Electronic prescribing systems can contribute to reduce antibiotic expenses, if information on antibiotic cost/hospital day is provided while the order is placed [419]. This seems to be more effective than automated feedback to prescribers on antibiotic expenditure in comparison to others [420].

Electronic documentation of the timing of perioperative antibiotic prophylaxis with provider-specific feedback (confidentially to the anaesthetist) on the rate of prophylaxis given too early or too late appeared to be effective. At

the time the intervention was initiated 69 % of the patients received antibiotics within 60 min of incision, and 92 % a year later [421]. Similar good-to-very good results were reported for the use of so-called electronic “Real-time Alerts” in improving timing of perioperative prophylaxis (>99 % of perioperative prophylaxis in one study). An electronic alert system was implemented after 4 h operating time to remind surgical teams to redose perioperative prophylactic antibiotics. The intervention was effective: 68 % of patients with cardiac surgery in the reminder group received intraoperative redosing versus only 40 % in the control group. The rate of surgical site infection was similar in both groups (4 and 6 %), but lower than in the pre-study period (10 %) [422, 423].

Several studies on electronic expert systems were conducted in a hospital in Salt Lake City (1986–2001). Implementation in many German hospitals, however, is difficult on account of inadequate technical prerequisites. These systems provide clinical decision support in the form of detailed therapy recommendations and alerts based on interlinked data such as allergies, laboratory results, microbiological

findings, etc. Studies on this programme showed a significant reduction in the number of antibiotics prescribed, duration of treatment, costs, and adverse drug events [237, 424–431]. A comprehensive computerised system consisting of an antimicrobial guideline and approval system in regard to reserve antibiotics also proved highly effective in an Australian hospital. It facilitated turning around a trend towards greater use of reserve antibiotics and resulted in increasing conformity with guideline-recommended therapies [432]. Effects were less strong in other studies. In a European multi-centre study (incl. Denmark, Italy, Germany) a computerised decision support system that looked at local susceptibility data, showed a rate of “appropriate” empirical antibiotic treatment of 73 %, which was only negligibly better than that of the control group of 64 % [433]. A reduction of just under 11 % in antibiotic consumption was achieved in an Australian intensive care unit, while the proportion of inappropriate antimicrobial use declined by only 10 % [412].

Appendix

See Tables 7, 8 (Sect. 2.2.4).

Table 7 ABS structure indicators

to 1. Requirements
Personnel/team/mandate/infrastructure
<ul style="list-style-type: none"> • Multidisciplinary ABS team is appointed and authorized by the hospital management and is headed by an infectious diseases physician (or physician trained in ABS) plus pharmacist • ABS team is represented in the Therapeutics and Drugs committee • At least 2 (recorded) ABS team meetings per year • ABS strategic report includes quantitative objectives with selected quality indicators • In-house preanalytical requirements for microbiologic samples, including rejection criteria, have been defined
Antimicrobial drug use surveillance/data
<ul style="list-style-type: none"> • Antimicrobial consumption data (in the form of DDD/RDD or PDD per 100 patient days or per patient) available at least once per year for several clinical divisions (departmental and/or medical vs surgical divisions and/or general ward vs intensive care unit) and for the most important antiinfective drug classes and total consumption • Rate of oral vs. parenteral dispensed or prescribed daily doses (% DDD/RDD or PDD) of the most important and relevant drugs available at least once per year for several clinical divisions (departmental and/or medical vs surgical divisions and/or general ward vs intensive care unit)
Infection and resistance surveillance/data
<ul style="list-style-type: none"> • Selected resistance rates and corresponding incidence figures (for clinical isolates) available at least once per year hospital-wide or for at least one clinical division • Incidence figures for <i>Clostridium difficile</i>-associated diarrhea available at least once per year for several clinical division (departmental and/or general ward vs intensive care unit) • Hospital-wide incidence figures for nosocomial sepsis/bacteremia available at least once per year
to 2. ABS core strategies
Antiinfective formulary and local consensus treatment guidelines
<ul style="list-style-type: none"> • In-house list of antiinfectives (formulary) is available and up to date (not older than 2 years) • Prescription of restricted/alert antiinfectives from a defined list is individualized (specific patients) and must be approved • Written, locally consented practice guidelines for empiric therapy, detailing the most important indications and infectious diseases are available and up to date (not older than 2 years) • Written, locally consented practice guidelines for surgical prophylaxis are available and up to date (not older than 2 years) • Written recommendation for parenteral-to-oral switch antimicrobial therapy (criteria & agents) are available and up to date (not older than 2 years)
Information, training and education
<ul style="list-style-type: none"> • Educational sessions about local consented practice guidelines (tailored to clinical divisions needs and/or ward type) organized by ABS team members or ABS representatives from clinical divisions at least every other year • Internal or external ABS-relevant continuing professional education offered for at least 10 % of medical staff who are not ABS representatives with at least 4 ABS relevant CME credits per year • ABS-relevant continuing professional education offered for ABS team members and ABS representatives from clinical divisions with at least 8 ABS-relevant CME credits per year
Audits and use of indicators
<ul style="list-style-type: none"> • Regular ward rounds by ABS team members with attending physicians in at least three clinical services/departments, at least three times each per year
to 3. Other ABS strategies
<ul style="list-style-type: none"> • Use of selective reporting of antibiograms (adapted according to local guidelines) • Electronically available guidelines and/or assisted decision analysis (adapted to or representing locally consented practice guidelines) via personal computer, PDA or smartphone

Table 8 ABS process indicators

Community-acquired pneumonia
<ul style="list-style-type: none"> • Initial therapy (drugs, dosing) according to local/national guideline • Two sets of blood cultures obtained on the day of therapy initiation • Monotherapy until day 4 (patients on general wards only) • Therapy duration no longer than 7 days (patients on general wards only)
Health care-associated pneumonia
<ul style="list-style-type: none"> • Initial therapy (drugs) according to local/national guideline • Two sets of blood cultures obtained on the day of therapy initiation • Therapy duration no longer than 10 days
Bloodstream infection
<ul style="list-style-type: none"> • Transesophageal echocardiography (TEE) within 10 days after first positive blood culture (bloodstream infection due to <i>Staphylococcus aureus</i>, streptococci, [not nosocomial] enterococci, HACEK^a organisms) • Follow-up blood cultures on day 4–7 after initial blood culture positivity (bloodstream infection due to <i>Staphylococcus aureus</i> and fungi)
Urinary tract infection
<ul style="list-style-type: none"> • Documented positive urine culture (significant bacteriuria, no mixed flora) • Initial therapy (drugs; dosing) according to local/national guideline • Therapy duration no longer than 10 days (pyelonephritis, patients on general wards only) • Switch to oral administration until day 5 (pyelonephritis, patients on general wards only) • No antibiotic therapy for asymptomatic catheter-associated bacteriuria
Parenteral-to-oral switch therapy
<ul style="list-style-type: none"> • Oral administration of substances with high oral bioavailability (fluoroquinolones [without norfloxacin], clindamycin, doxycycline, linezolid, metronidazole, rifampicin, fluconazole, voriconazole) (patients without disorders of gastrointestinal resorption, short bowel syndrome, emesis, severe sepsis/septic shock)
Empiric therapy for indications other than pneumonia and urinary tract infection
<ul style="list-style-type: none"> • Initial empiric (before/without identified microorganism) therapy (agents) according to local guideline
Dosing
<ul style="list-style-type: none"> • Dose adaptation according to renal function within 2 days
Perioperative antibiotic prophylaxis
<ul style="list-style-type: none"> • Prophylaxis (drugs and dosing) according to local guideline • Timing: prophylaxis initiation within 1 h before incision • Timing: prophylaxis discontinued within 1 day
Management of multidrug-resistant microorganisms (MDR)
<ul style="list-style-type: none"> • Infection and/or colonization by MDR microorganisms explicitly listed in discharge summary

TEE transesophageal echocardiograph

^a HACEK organisms are a group of Gram-negative pathogens that share an enhanced capacity to produce endocardial infections: *Haemophilus species* (*H. parainfluenzae*, *H. aphrophilus*, *H. paraphrophilus*), *Actinobacillus actinomycetemcomitans*, *Cardiobacterium hominis*, *Eikenella corrodens*, and *Kingella species*

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

- MacDougall C, Polk RE. Antimicrobial stewardship programs in health care systems. *Clin Microbiol Rev.* 2005;18:638–56 (IV).
- Davey P, Brown E, Fenelon L, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. *Cochrane Database Syst Rev.* 2005;4:CD003543 (I).
- Paterson DL. The role of antimicrobial management programs in optimizing antibiotic prescribing within hospitals. *Clin Infect Dis.* 2006;42:S90–5 (IV).
- Fishman N. Antimicrobial stewardship. *Am J Infect Control.* 2006;34:S55–63 (IV).
- Fishman N. Antimicrobial stewardship. *Am J Med.* 2006;119:S53–61 (IV).
- Dellit TH, Owens RC, McGowan JE Jr, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. *Clin Infect Dis.* 2007;44:159–77 (I).
- Owens RC, Jr. Antimicrobial stewardship: concepts and strategies in the 21st century. *Diagn Microbiol Infect Dis.* 2008;61:110–28 (IV).
- Patel D, Lawson W, Guglielmo BJ. Antimicrobial stewardship programs: interventions and associated outcomes. *Expert Rev Anti Infect Ther.* 2008;6:209–22 (I).
- Gould IM. Antibiotic policies to control hospital-acquired infection. *J Antimicrob Chemother.* 2008;61:763–5 (IV).
- Lesprit P, Brun-Buisson C. Hospital antibiotic stewardship. *Curr Opin Infect Dis.* 2008;21:344–9 (III).
- Pagani L, Gyssens IC, Huttner B, Nathwani D, Harbarth S. Navigating the Web in search of resources on antimicrobial stewardship in health care institutions. *Clin Infect Dis.* 2009;48:626–32 (IV).
- Drew RH. Antimicrobial stewardship programs: how to start and steer a successful program. *J Manag Care Pharm.* 2009;15:S18–23 (IV).
- Owens RC Jr. Antimicrobial stewardship: application in the intensive care unit. *Infect Dis Clin North Am.* 2009;23:683–702 (IV).
- Patel SJ, Saiman L. Principles and strategies of antimicrobial stewardship in the neonatal intensive care unit. *Semin Perinatol.* 2012;36:431–6 (IV).
- Kaki R, Elligsen M, Walker S, Simor A, Palmay L, Daneman N. Impact of antimicrobial stewardship in critical care: a systematic review. *J Antimicrob Chemother.* 2011;66:1223–30 (I).
- Newland JG, Hersh AL. Purpose and design of antimicrobial stewardship programs in pediatrics. *Pediatr Infect Dis J.* 2010;29:862–3 (IV).
- Hersh AL, Beekmann SE, Polgreen PM, Zaoutis TE, Newland JG. Antimicrobial stewardship programs in pediatrics. *Infect Control Hosp Epidemiol.* 2009;30:1211–7 (IV).
- Patel SJ, Larson EL, Kubin CJ, Saiman L. A review of antimicrobial control strategies in hospitalized and ambulatory pediatric populations. *Pediatr Infect Dis J.* 2007;26:531–7 (I).
- Septimus EJ, Owens RC Jr. Need and potential of antimicrobial stewardship in community hospitals. *Clin Infect Dis.* 2011;53:S8–14 (IV).
- Ohl CA, Dodds Ashley ES. Antimicrobial stewardship programs in community hospitals: the evidence base and case studies. *Clin Infect Dis.* 2011;53:S23–8 (IIa).
- Pate PG, Storey DF, Baum DL. Implementation of an antimicrobial stewardship program at a 60-bed long-term acute care hospital. *Infect Control Hosp Epidemiol.* 2012;33:405–8 (III).
- Davey P, Brown E, Charani E, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. *Cochrane Database Syst Rev.* 2013;4:CD003543 (I).
- Standiford HC, Chan S, Tripoli M, Weekes E, Forrest GN. Antimicrobial stewardship at a large tertiary care academic medical center: cost analysis before, during, and after a 7-year program. *Infect Control Hosp Epidemiol.* 2012;33:338–45 (II).
- Goldman MP, Nair R. Antibacterial treatment strategies in hospitalized patients: what role for pharmacoeconomics? *Cleve Clin J Med.* 2007;74:S38–47 (I).
- Davey P, Brown E, Fenelon L, et al. Systematic review of antimicrobial drug prescribing in hospitals. *Emerg Infect Dis.* 2006;12:211–6 (I).
- Knox K, Lawson W, Dean B, Holmes A. Multidisciplinary antimicrobial management and the role of the infectious diseases pharmacist—a UK perspective. *J Hosp Infect.* 2003;53:85–90 (I).
- Gums JG, Yancey RW Jr, Hamilton CA, Kubilis PS. A randomized, prospective study measuring outcomes after antibiotic therapy intervention by a multidisciplinary consult team. *Pharmacotherapy.* 1999;19:1369–77 (I).
- Solomon DH, Van HL, Glynn RJ, et al. Academic detailing to improve use of broad-spectrum antibiotics at an academic medical center. *Arch Intern Med.* 2001;161:1897–902 (I).
- Carling P, Fung T, Killion A, Terrin N, Barza M. Favorable impact of a multidisciplinary antibiotic management program conducted during 7 years. *Infect Control Hosp Epidemiol.* 2003;24:699–706 (II).
- Bantar C, Franco D, Heft C, et al. Does a reduction in antibiotic consumption always represent a favorable outcome from an intervention program on prescribing practice? *Int J Infect Dis.* 2006;10:231–5 (II).
- Bevilacqua S, Demore B, Erpelding ML, et al. Effects of an operational multidisciplinary team on hospital antibiotic use and cost in France: a cluster controlled trial. *Int J Clin Pharm.* 2011;33:521–8 (II).
- Danaher PJ, Milazzo NA, Kerr KJ, Lagasse CA, Lane JW. The antibiotic support team—a successful educational approach to antibiotic stewardship. *Mil Med.* 2009;174:201–5 (II).
- Diamantis S, Rioux C, Bonnal C, et al. Evaluation of initial antibiotic therapy for bacteremia and role of an antibiotic management team for antibiotic stewardship. *Med Mal Infect.* 2010;40:637–43 (II).
- Gendrin V, Letranchant L, Henard S, et al. Impact of corrective measures on fluoroquinolones prescriptions for urinary tract infections during a 2-round relevance study. *Presse Med.* 2012;41:e10–4 (III).
- Bauer S, Bouldouyre MA, Oufella A, et al. Impact of a multidisciplinary staff meeting on the quality of antibiotherapy prescription for bone and joint infections in orthopedic surgery. *Med Mal Infect.* 2012;42:603–7 (III).
- Byl B, Clevenbergh P, Jacobs F, et al. Impact of infectious diseases specialists and microbiological data on the appropriateness of antimicrobial therapy for bacteremia. *Clin Infect Dis.* 1999;29:60–6 (I).
- Dranitsaris G, Spizzirri D, Pitre M, McGeer A. A randomized trial to measure the optimal role of the pharmacist in promoting evidence-based antibiotic use in acute care hospitals. *Int J Technol Assess Health Care.* 2001;17:171–80 (I).
- Bailey TC, Ritchie DJ, McMullin ST, et al. A randomized, prospective evaluation of an interventional program to discontinue

- intravenous antibiotics at two tertiary care teaching institutions. *Pharmacotherapy*. 1997;17:277–81 (I).
39. Dunn K, O'Reilly A, Silke B, Rogers T, Bergin C. Implementing a pharmacist-led sequential antimicrobial therapy strategy: a controlled before-and-after study. *Int J Clin Pharm*. 2011;33:208–14 (II).
 40. Walker SE. Physicians' acceptance of a preformatted pharmacy intervention chart note in a community hospital antibiotic step-down program. *J Pharm Technol*. 1998;14:141–5 (I).
 41. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? *JAMA*. 2000;283:373–80 (I).
 42. Zipkin DA, Steinman MA. Interactions between pharmaceutical representatives and doctors in training. A thematic review. *J Gen Intern Med*. 2005;20:777–86 (I).
 43. Cruickshank M, Duguid M. Antimicrobial stewardship in Australian hospitals 2011. Sydney: Australian Commission on Safety & Quality in Health Care; 2011(IV).
 44. Petrak RM, Sexton DJ, Butera ML, et al. The value of an infectious diseases specialist. *Clin Infect Dis*. 2003;36:1013–7 (IV).
 45. Fluckiger U, Zimmerli W, Sax H, Frei R, Widmer AF. Clinical impact of an infectious disease service on the management of bloodstream infection. *Eur J Clin Microbiol Infect Dis*. 2000;19:493–500 (II).
 46. Kern WV. Management of *Staphylococcus aureus* bacteremia and endocarditis: progress and challenges. *Curr Opin Infect Dis*. 2010;23:346–58 (II).
 47. Honda H, Krauss MJ, Jones JC, Olsen MA, Warren DK. The value of infectious diseases consultation in *Staphylococcus aureus* bacteremia. *Am J Med*. 2010;123:631–7 (II).
 48. Gros H, Aslangul E, Lesprit P, Mainardi JL. Positive blood culture in hospital: notification methods and impact of recommendations by an infectious disease specialist. *Med Mal Infect*. 2012;42:76–9 (III).
 49. Schmitt S, McQuillen DP, Nahass R, et al. Infectious diseases specialty intervention is associated with decreased mortality and lower healthcare costs. *Clin Infect Dis*. 2014;58:22–28 (III).
 50. Raineri E, Pan A, Mondello P, Acquarolo A, Candiani A, Crema L. Role of the infectious diseases specialist consultant on the appropriateness of antimicrobial therapy prescription in an intensive care unit. *Am J Infect Control*. 2008;36:283–90 (II).
 51. Borer A, Gilad J, Meydan N, Schlaeffer P, Riesenber K, Schlaeffer F. Impact of regular attendance by infectious disease specialists on the management of hospitalised adults with community-acquired febrile syndromes. *Clin Microbiol Infect*. 2004;10:911–6 (II).
 52. Della LP, Gherardi V, Pellegrino F, Cocchi I, Esposito R, Kiren V. Improving the appropriateness of antibiotic prescription in hospitals: a pilot study assessing the effectiveness of an infectious diseases specialist's consultation programme. *Int J Antimicrob Agents*. 2008;31:488–9 (II).
 53. Camins BC, King MD, Wells JB, et al. Impact of an antimicrobial utilization program on antimicrobial use at a large teaching hospital: a randomized controlled trial. *Infect Control Hosp Epidemiol*. 2009;30:931–8 (I).
 54. Kawanami GH, Fortaleza CM. Factors predictive of inappropriateness in requests for parenteral antimicrobials for therapeutic purposes: a study in a small teaching hospital in Brazil. *Scand J Infect Dis*. 2011;43:528–35 (III).
 55. Pastel DA, Chang S, Nessim S, Shane R, Morgan MA. Department of pharmacy-initiated program for streamlining empirical antibiotic therapy. *Hosp Pharm* 1992;27:596–603, 614 (I).
 56. von Gunten V, Reymond JP, Beney J. Clinical and economic outcomes of pharmaceutical services related to antibiotic use: a literature review. *Pharm World Sci*. 2007;29:146–63 (I).
 57. Toth NR, Chambers RM, Davis SL. Implementation of a care bundle for antimicrobial stewardship. *Am J Health Syst Pharm*. 2010;67:746–9 (II).
 58. De RT, Willems L, Simoens S. Economic effects of clinical pharmacy interventions: a literature review. *Am J Health Syst Pharm*. 2008;65:1161–72 (I).
 59. Ng CK, Wu TC, Chan WM, et al. Clinical and economic impact of an antibiotics stewardship programme in a regional hospital in Hong Kong. *Qual Saf Health Care*. 2008;17:387–92 (II).
 60. Tonna AP, Stewart D, West B, Gould I, McCaig D. Antimicrobial optimisation in secondary care: the pharmacist as part of a multidisciplinary antimicrobial programme—a literature review. *Int J Antimicrob Agents*. 2008;31:511–7 (I).
 61. McLaughlin CM, Bodasing N, Boyter AC, Fenelon C, Fox JG, Seaton RA. Pharmacy-implemented guidelines on switching from intravenous to oral antibiotics: an intervention study. *QJM*. 2005;98:745–52 (II).
 62. Weber A, Schneider C, Grill E, Strobl R, Vetter-Kerkhoff C, Jauch KW. Interventions by clinical pharmacists on surgical wards—impact on antibiotic therapy. *Zentralbl Chir*. 2011;136:66–73 (II).
 63. Grill E, Weber A, Lohmann S, Vetter-Kerkhoff C, Strobl R, Jauch KW. Effects of pharmaceutical counselling on antimicrobial use in surgical wards: intervention study with historical control group. *Pharmacoepidemiol Drug Saf*. 2011;20:739–46 (III).
 64. Yen YH, Chen HY, Wuan-Jin L, Lin YM, Shen WC, Cheng KJ. Clinical and economic impact of a pharmacist-managed i.v.-to-p.o. conversion service for levofloxacin in Taiwan. *Int J Clin Pharmacol Ther*. 2012;50:136–41 (III).
 65. Van GE, Costers M, Peetermans WE, Struelens MJ. Nationwide implementation of antibiotic management teams in Belgian hospitals: a self-reporting survey. *J Antimicrob Chemother*. 2010;65:576–80 (IV).
 66. O'Neill E, Humphreys H, Smyth E. Impact of recommendations by clinical microbiologists on antimicrobial treatment in the intensive care units of a Dublin teaching hospital. *Clin Infect Dis*. 2005;40:636–7 (III).
 67. Kothari A, Sagar V, Panigrahi B, Selot N. Controlling costs in the intensive-care unit: role of daily microbiologist rounds in an Indian hospital. *Clin Microbiol Infect*. 2008;14:1187–8 (IV).
 68. Fraser GL, Stogsdill P, Dickens JD Jr, Wennberg DE, Smith RP Jr, Prato BS. Antibiotic optimization. An evaluation of patient safety and economic outcomes. *Arch Intern Med*. 1997;157:1689–94 (I).
 69. Philmon C, Smith T, Williamson S, Goodman E. Controlling use of antimicrobials in a community teaching hospital. *Infect Control Hosp Epidemiol*. 2006;27:239–44 (II).
 70. Uckay I, Vernaz-Hegi N, Harbarth S, et al. Activity and impact on antibiotic use and costs of a dedicated infectious diseases consultant on a septic orthopaedic unit. *J Infect*. 2009;58:205–12 (III).
 71. Beovic B, Kreft S, Seme K, Cizman M. The impact of total control of antibiotic prescribing by infectious disease specialist on antibiotic consumption and cost. *J Chemother*. 2009;21:46–51 (II).
 72. Larosa LA, Fishman NO, Lautenbach E, Koppel RJ, Morales KH, Linkin DR. Evaluation of antimicrobial therapy orders circumventing an antimicrobial stewardship program: investigating the strategy of “stealth dosing”. *Infect Control Hosp Epidemiol*. 2007;28:551–6 (III).
 73. Valiquette L, Cossette B, Garant MP, Diab H, Pepin J. Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of *Clostridium difficile*-associated disease caused by the hypervirulent NAP1/027 strain. *Clin Infect Dis*. 2007;45:S112–21 (II).

74. Allerberger F, Frank A, Gareis R. Antibiotic stewardship through the EU project “ABS International”. *Wien Klin Wochenschr.* 2008;120:256–63 (IV).
75. Richards MJ, Robertson MB, Dartnell JG, et al. Impact of a web-based antimicrobial approval system on broad-spectrum cephalosporin use at a teaching hospital. *Med J Aust.* 2003;178:386–90 (II).
76. Schwartzberg E, Rubinovich S, Hassin D, et al. Developing and implementing a model for changing physicians’ prescribing habits—the role of clinical pharmacy in leading the change. *J Clin Pharm Ther.* 2006;31:179–85 (II).
77. Wickens HJ, Jacklin A. Impact of the Hospital Pharmacy Initiative for promoting prudent use of antibiotics in hospitals in England. *J Antimicrob Chemother.* 2006;58:1230–7 (IV).
78. Biswal S, Mishra P, Malhotra S, Puri GD, Pandhi P. Drug utilization pattern in the intensive care unit of a tertiary care hospital. *J Clin Pharmacol.* 2006;46:945–51 (IV).
79. Burgmann H, Janata O, Allerberger F, Frank A. Hospital antibiotic management in Austria—results of the ABS maturity survey of the ABS International group. *Wien Klin Wochenschr.* 2008;120:280–3 (IV).
80. Dumpis U, Gulbinovic J, Struwe J, Lagergren A, Griskevicius L, Bergman U. Differences in antibiotic prescribing in three university hospitals in the Baltic region revealed by a simple protocol for quality assessment of therapeutic indications. *Int J Clin Pharmacol Ther.* 2007;45:568–76 (IV).
81. McNeil V, Cruickshank M, Duguid M. Safer use of antimicrobials in hospitals: the value of antimicrobial usage data. *Med J Aust.* 2010;193:S114–7 (IV).
82. Schweickert B, Kern WV, de WK, et al. Surveillance of antibiotic consumption: clarification of the “definition of data on the nature and extent of antibiotic consumption in hospitals according to section sign 23 paragraph 4 sentence 2 of the IfSG”. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz.* 2013;56:903–12 (IV).
83. de WK, Maier L, Steib-Bauert M, Kern P, Kern WV. Trends in antibiotic use at a university hospital: defined or prescribed daily doses? Patient days or admissions as denominator? *Infection.* 2006;34:91–4 (IV).
84. Cusini A, Rampini SK, Bansal V, et al. Different patterns of inappropriate antimicrobial use in surgical and medical units at a tertiary care hospital in Switzerland: a prevalence survey. *PLoS One.* 2010;5:e14011 (IV).
85. Zarb P, Goossens H. European Surveillance of Antimicrobial Consumption (ESAC): value of a point-prevalence survey of antimicrobial use across Europe. *Drugs.* 2011;71:745–55 (IV).
86. Zarb P, Amadeo B, Muller A, et al. Identification of targets for quality improvement in antimicrobial prescribing: the web-based ESAC Point Prevalence Survey 2009. *J Antimicrob Chemother.* 2011;66:443–9 (IV).
87. Ansari F, Erntell M, Goossens H, Davey P. The European surveillance of antimicrobial consumption (ESAC) point-prevalence survey of antibacterial use in 20 European hospitals in 2006. *Clin Infect Dis.* 2009;49:1496–504 (IV).
88. Pulver LK, Tett SE, Coombes J. The Queensland experience of participation in a national drug use evaluation project, community-acquired pneumonia towards improving outcomes nationally (CAPTION). *BMC Pulm Med.* 2009;9:38 (III).
89. Lomas J, Anderson GM, Domnick-Pierre K, Vayda E, Enkin MW, Hannah WJ. Do practice guidelines guide practice? The effect of a consensus statement on the practice of physicians. *N Engl J Med.* 1989;321:1306–11 (II).
90. Martinez R, Reyes S, Lorenzo MJ, Menendez R. Impact of guidelines on outcome: the evidence. *Semin Respir Crit Care Med.* 2009;30:172–8 (I).
91. Bassi GL, Ferrer M, Saucedo LM, Torres A. Do guidelines change outcomes in ventilator-associated pneumonia? *Curr Opin Infect Dis.* 2010;23:171–7 (IV).
92. Dempsey CL. Nursing home-acquired pneumonia: outcomes from a clinical process improvement program. *Pharmacotherapy.* 1995;15:33S–8S (III).
93. Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Vandervoort MK, Feagan BG, CAPITAL Study Investigators. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. Community-acquired pneumonia intervention trial assessing levofloxacin. *JAMA.* 2000;283:749–55 (I).
94. Dean NC, Silver MP, Bateman KA, James B, Hadlock CJ, Hale D. Decreased mortality after implementation of a treatment guideline for community-acquired pneumonia. *Am J Med.* 2001;110:451–7 (II).
95. Dean NC, Bateman KA, Donnelly SM, Silver MP, Snow GL, Hale D. Improved clinical outcomes with utilization of a community-acquired pneumonia guideline. *Chest.* 2006;130:794–9 (II).
96. Price J, Ekleberry A, Grover A, et al. Evaluation of clinical practice guidelines on outcome of infection in patients in the surgical intensive care unit. *Crit Care Med.* 1999;27:2118–24 (II).
97. Ibrahim EH, Ward S, Sherman G, Schaiff R, Fraser VJ, Kollef MH. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. *Crit Care Med.* 2001;29:1109–15 (II).
98. Barlow G, Nathwani D, Williams F, et al. Reducing door-to-antibiotic time in community-acquired pneumonia: controlled before-and-after evaluation and cost-effectiveness analysis. *Thorax.* 2007;62:67–74 (II).
99. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. *Chest.* 1999;115:462–74 (IV).
100. Fagon JY, Chastre J, Wolff M, et al. Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia. A randomized trial. *Ann Intern Med.* 2000;132:621–30 (I).
101. Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. *JAMA.* 2003;290:2588–98 (I).
102. Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. *Am J Respir Crit Care Med.* 2000;162:505–11 (I).
103. Soo Hoo GW, Wen YE, Nguyen TV, Goetz MB. Impact of clinical guidelines in the management of severe hospital-acquired pneumonia. *Chest.* 2005;128:2778–87 (II).
104. Botelho-Nevers E, Thuny F, Casalta JP, et al. Dramatic reduction in infective endocarditis-related mortality with a management-based approach. *Arch Intern Med.* 2009;169:1290–8 (II).
105. Schouten JA, Hulscher ME, Trap-Liefers J, et al. Tailored interventions to improve antibiotic use for lower respiratory tract infections in hospitals: a cluster-randomized, controlled trial. *Clin Infect Dis.* 2007;44:931–41 (I).
106. Jenkins TC, Knepper BC, Sabel AL, et al. Decreased antibiotic utilization after implementation of a guideline for inpatient cellulitis and cutaneous abscess. *Arch Intern Med.* 2011;171:1072–9 (III).
107. Grenier C, Pepin J, Nault V, et al. Impact of guideline-consistent therapy on outcome of patients with healthcare-associated and community-acquired pneumonia. *J Antimicrob Chemother.* 2011;66:1617–24 (III).

108. Thornhill MH, Dayer MJ, Forde JM, et al. Impact of the NICE guideline recommending cessation of antibiotic prophylaxis for prevention of infective endocarditis: before and after study. *BMJ*. 2011;342:d2392 (II).
109. Westphal JF, Jehl F, Javelot H, Nonnenmacher C. Enhanced physician adherence to antibiotic use guidelines through increased availability of guidelines at the time of drug ordering in hospital setting. *Pharmacoepidemiol Drug Saf*. 2011;20:162–8 (III).
110. Schnoor M, Meyer T, Suttorp N, Raspe H, Welte T, Schafer T. Development and evaluation of an implementation strategy for the German guideline on community-acquired pneumonia. *Qual Saf Health Care*. 2010;19:498–502 (II).
111. Lancaster JW, Lawrence KR, Fong JJ, et al. Impact of an institution-specific hospital-acquired pneumonia protocol on the appropriateness of antibiotic therapy and patient outcomes. *Pharmacotherapy*. 2008;28:852–62 (II).
112. McIntosh KA, Maxwell DJ, Pulver LK, et al. A quality improvement initiative to improve adherence to national guidelines for empiric management of community-acquired pneumonia in emergency departments. *Int J Qual Health Care*. 2011;23:142–50 (III).
113. Chalmers JD, Singanayagam A, Akram AR, Choudhury G, Mandal P, Hill AT. Safety and efficacy of CURB65-guided antibiotic therapy in community-acquired pneumonia. *J Antimicrob Chemother*. 2011;66:416–23 (II).
114. Mol PG, Wieringa JE, Nannanpanday PV, et al. Improving compliance with hospital antibiotic guidelines: a time-series intervention analysis. *J Antimicrob Chemother*. 2005;55:550–7 (II).
115. Willemsen I, van den BR, Bijsterveldt T, et al. A standardized protocol for perioperative antibiotic prophylaxis is associated with improvement of timing and reduction of costs. *J Hosp Infect*. 2007;67:156–60 (II).
116. Winters BD, Thiemann DR, Brotman DJ. Impact of a restrictive antimicrobial policy on the process and timing of antimicrobial administration. *J Hosp Med*. 2010;5:E41–5 (III).
117. Madaras-Kelly KJ, Remington RE, Lewis PG, Stevens DL. Evaluation of an intervention designed to decrease the rate of nosocomial methicillin-resistant *Staphylococcus aureus* infection by encouraging decreased fluoroquinolone use. *Infect Control Hosp Epidemiol*. 2006;27:155–69 (II).
118. Church EC, Mauldin PD, Bosso JA. Antibiotic resistance in *Pseudomonas aeruginosa* related to quinolone formulary changes: an interrupted time series analysis. *Infect Control Hosp Epidemiol*. 2011;32:400–2 (II).
119. Bassetti M, Righi E, Ansaldi F, et al. Impact of limited cephalosporin use on prevalence of methicillin-resistant *Staphylococcus aureus* in the intensive care unit. *J Chemother*. 2009;21:633–8 (II).
120. Britton HL, Schwinghammer TL, Romano MJ. Cost containment through restriction of cephalosporins. *Am J Hosp Pharm*. 1981;38:1897–900 (II).
121. Hayman JN, Sbravati EC. Controlling cephalosporin and aminoglycoside costs through pharmacy and therapeutics committee restrictions. *Am J Hosp Pharm*. 1985;42:1343–7 (II).
122. Woodward RS, Medoff G, Smith MD, Gray JL III. Antibiotic cost savings from formulary restrictions and physician monitoring in a medical-school-affiliated hospital. *Am J Med*. 1987;83:817–23 (III).
123. Maswoswe JJ, Okpara AU. Enforcing a policy for restricting antimicrobial drug use. *Am J Health Syst Pharm*. 1995;52:1433–5 (III).
124. White AC, Atmar RL, Wilson J, Cate TR, Stager CE, Greenberg SB. Effects of requiring prior authorization for selected antimicrobials: expenditures, susceptibilities, and clinical outcomes. *Clin Infect Dis*. 1997;25:230–9 (II).
125. Siddiqui S, Hussein K, Manasia R, et al. Impact of antibiotic restriction on broad spectrum antibiotic usage in the ICU of a developing country. *J Pak Med Assoc*. 2007;57:484–7 (III).
126. Tunger O, Karakaya Y, Cetin CB, Dinc G, Borand H. Rational antibiotic use. *J Infect Dev Ctries*. 2009;3:88–93 (III).
127. Altunsoy A, Aypak C, Azap A, Ergonul O, Balik I. The impact of a nationwide antibiotic restriction program on antibiotic usage and resistance against nosocomial pathogens in Turkey. *Int J Med Sci*. 2011;8:339–44 (III).
128. Gomez MI, Acosta-Gnass SI, Mosqueda-Barboza L, Basualdo JA. Reduction in surgical antibiotic prophylaxis expenditure and the rate of surgical site infection by means of a protocol that controls the use of prophylaxis. *Infect Control Hosp Epidemiol*. 2006;27:1358–65 (II).
129. Hermesen ED, Smith SS, Puumala SE, Rupp ME. Improvement in prescribing habits and economic outcomes associated with the introduction of a standardized approach for surgical antimicrobial prophylaxis. *Infect Control Hosp Epidemiol*. 2008;29:457–61 (II).
130. Parker BM, Henderson JM, Vitagliano S, et al. Six sigma methodology can be used to improve adherence for antibiotic prophylaxis in patients undergoing noncardiac surgery. *Anesth Analg*. 2007;104:140–6 (II).
131. Perez A, Dennis RJ, Rodriguez B, et al. An interrupted time series analysis of parenteral antibiotic use in Colombia. *J Clin Epidemiol*. 2003;56:1013–20 (II).
132. Salama S, Rotstein C, Mandell L. A multidisciplinary hospital-based antimicrobial use program: impact on hospital pharmacy expenditures and drug use. *Can J Infect Dis*. 1996;7:104–9 (II).
133. Belliveau PP, Rothman AL, Maday CE. Limiting vancomycin use to combat vancomycin-resistant *Enterococcus faecium*. *Am J Health Syst Pharm*. 1996;53:1570–5 (II).
134. Marra AR, de Almeida SM, Correa L, et al. The effect of limiting antimicrobial therapy duration on antimicrobial resistance in the critical care setting. *Am J Infect Control*. 2009;37:204–9 (II).
135. Falagas ME, Bliziotis IA, Michalopoulos A, et al. Effect of a policy for restriction of selected classes of antibiotics on antimicrobial drug cost and resistance. *J Chemother*. 2007;19:178–84 (II).
136. Lewis GJ, Fang X, Gooch M, Cook PP. Decreased resistance of *Pseudomonas aeruginosa* with restriction of ciprofloxacin in a large teaching hospital's intensive care and intermediate care units. *Infect Control Hosp Epidemiol*. 2012;33:368–73 (II).
137. Pepin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for *Clostridium difficile*-associated diarrhea: a cohort study during an epidemic in Quebec. *Clin Infect Dis*. 2005;41:1254–60 (III).
138. LeBlanc L, Pepin J, Toulouse K, et al. Fluoroquinolones and risk for methicillin-resistant *Staphylococcus aureus*, Canada. *Emerg Infect Dis*. 2006;12:1398–405 (III).
139. Weber SG, Gold HS, Hooper DC, Karchmer AW, Carmeli Y. Fluoroquinolones and the risk for methicillin-resistant *Staphylococcus aureus* in hospitalized patients. *Emerg Infect Dis*. 2003;9:1415–22 (III).
140. MacDougall C, Powell JP, Johnson CK, Edmond MB, Polk RE. Hospital and community fluoroquinolone use and resistance in *Staphylococcus aureus* and *Escherichia coli* in 17 US hospitals. *Clin Infect Dis*. 2005;41:435–40 (III).
141. Charbonneau P, Parienti JJ, Thibon P, et al. Fluoroquinolone use and methicillin-resistant *Staphylococcus aureus* isolation rates in hospitalized patients: a quasi experimental study. *Clin Infect Dis*. 2006;42:778–84 (II).
142. Parienti JJ, Cattoir V, Thibon P, et al. Hospital-wide modification of fluoroquinolone policy and methicillin-resistant *Staphylococcus aureus* rates: a 10-year interrupted time-series analysis. *J Hosp Infect*. 2011;78:118–22 (II).

143. Lafaurie M, Porcher R, Donay JL, Touratier S, Molina JM. Reduction of fluoroquinolone use is associated with a decrease in methicillin-resistant *Staphylococcus aureus* and fluoroquinolone-resistant *Pseudomonas aeruginosa* isolation rates: a 10 year study. *J Antimicrob Chemother.* 2012;67:1010–5 (II).
144. Talpaert MJ, Gopal RG, Cooper BS, Wade P. Impact of guidelines and enhanced antibiotic stewardship on reducing broad-spectrum antibiotic usage and its effect on incidence of *Clostridium difficile* infection. *J Antimicrob Chemother.* 2011;66:2168–74 (III).
145. Kallen AJ, Thompson A, Ristaino P, et al. Complete restriction of fluoroquinolone use to control an outbreak of *Clostridium difficile* infection at a community hospital. *Infect Control Hosp Epidemiol.* 2009;30:264–72 (III).
146. Price J, Cheek E, Lippett S, et al. Impact of an intervention to control *Clostridium difficile* infection on hospital- and community-onset disease; an interrupted time series analysis. *Clin Microbiol Infect.* 2010;16:1297–302 (III).
147. Willemsen I, Cooper B, van BC, Winters M, Andriess G, Kluytmans J. Improving quinolone use in hospitals by using a bundle of interventions in an interrupted time series analysis. *Antimicrob Agents Chemother.* 2010;54:3763–9 (II).
148. Aldeyab MA, Devine MJ, Flanagan P, et al. Multihospital outbreak of *Clostridium difficile* ribotype 027 infection: epidemiology and analysis of control measures. *Infect Control Hosp Epidemiol.* 2011;32:210–9 (III).
149. Ranji SR, Steinman MA, Shojania KG, Gonzales R. Interventions to reduce unnecessary antibiotic prescribing: a systematic review and quantitative analysis. *Med Care.* 2008;46:847–62 (I).
150. Serisier DJ, Bowler SD. Effect of a simple educational intervention on the hospital management of community-acquired pneumonia. *Respirology.* 2007;12:389–93 (III).
151. Akter SF, Heller RD, Smith AJ, Milly AF. Impact of a training intervention on use of antimicrobials in teaching hospitals. *J Infect Dev Ctries.* 2009;3:447–51 (II).
152. Kao LS, Lew DF, Doyle PD, et al. A tale of 2 hospitals: a staggered cohort study of targeted interventions to improve compliance with antibiotic prophylaxis guidelines. *Surgery.* 2010;148:255–62 (II).
153. Zabarsky TF, Sethi AK, Donskey CJ. Sustained reduction in inappropriate treatment of asymptomatic bacteriuria in a long-term care facility through an educational intervention. *Am J Infect Control.* 2008;36:476–80 (III).
154. Pavese P, Saurel N, Labarere J, et al. Does an educational session with an infectious diseases physician reduce the use of inappropriate antibiotic therapy for inpatients with positive urine culture results? A controlled before-and-after study. *Infect Control Hosp Epidemiol.* 2009;30:596–9 (II).
155. Monette J, Miller MA, Monette M, et al. Effect of an educational intervention on optimizing antibiotic prescribing in long-term care facilities. *J Am Geriatr Soc.* 2007;55:1231–5 (I).
156. Metlay JP, Camargo CA Jr, MacKenzie T, et al. Cluster-randomized trial to improve antibiotic use for adults with acute respiratory infections treated in emergency departments. *Ann Emerg Med.* 2007;50:221–30 (I).
157. Landgren FT, Harvey KJ, Mashford ML, Moulds RF, Guthrie B, Hemming M. Changing antibiotic prescribing by educational marketing. *Med J Aust.* 1988;149:595–9 (II).
158. Ozgun H, Ertugrul BM, Soyder A, Ozturk B, Aydemir M. Perioperative antibiotic prophylaxis: adherence to guidelines and effects of educational intervention. *Int J Surg.* 2010;8:159–63 (II).
159. Kanter G, Connelly NR, Fitzgerald J. A system and process redesign to improve perioperative antibiotic administration. *Anesth Analg.* 2006;103:1517–21 (II).
160. Pettersson E, Vernby A, Molstad S, Lundborg CS. Can a multifaceted educational intervention targeting both nurses and physicians change the prescribing of antibiotics to nursing home residents? A cluster randomized controlled trial. *J Antimicrob Chemother.* 2011;66:2659–66 (I).
161. Zahar JR, Rioux C, Girou E, et al. Inappropriate prescribing of aminoglycosides: risk factors and impact of an antibiotic control team. *J Antimicrob Chemother.* 2006;58:651–6 (II).
162. Kisuule F, Wright S, Barreto J, Zenilman J. Improving antibiotic utilization among hospitalists: a pilot academic detailing project with a public health approach. *J Hosp Med.* 2008;3:64–70 (II).
163. Kiyatkin DE, Wright S, Zenilman J, Kisuule F. Improving utilization of antimicrobial drugs among physician assistants in the ED. *JAAPA* 2011;24:44, 47-1 (II).
164. Linnebur SA, Fish DN, Ruscin JM, et al. Impact of a multidisciplinary intervention on antibiotic use for nursing home-acquired pneumonia. *Am J Geriatr Pharmacother.* 2011;9:442–50 (II).
165. Cosgrove SE, Patel A, Song X, et al. Impact of different methods of feedback to clinicians after postprescription antimicrobial review based on the Centers for Disease Control and Prevention's 12 steps to prevent antimicrobial resistance among hospitalized adults. *Infect Control Hosp Epidemiol.* 2007;28:641–6 (II).
166. Ivers N, Jamtvedt G, Flottorp S, et al. Audit and feedback: effects on professional practice and healthcare outcomes. *Cochrane Database Syst Rev.* 2012;6:CD000259 (I).
167. LaRocco A Jr. Concurrent antibiotic review programs—a role for infectious diseases specialists at small community hospitals. *Clin Infect Dis.* 2003;37:742–3 (II).
168. Masia M, Matoses C, Padilla S, et al. Limited efficacy of a nonrestricted intervention on antimicrobial prescription of commonly used antibiotics in the hospital setting: results of a randomized controlled trial. *Eur J Clin Microbiol Infect Dis.* 2008;27:597–605 (I).
169. Rattanaumpawan P, Sutha P, Thamlikitkul V. Effectiveness of drug use evaluation and antibiotic authorization on patients' clinical outcomes, antibiotic consumption, and antibiotic expenditures. *Am J Infect Control.* 2010;38:38–43 (II).
170. Elligsen M, Walker SA, Pinto R, et al. Audit and feedback to reduce broad-spectrum antibiotic use among intensive care unit patients: a controlled interrupted time series analysis. *Infect Control Hosp Epidemiol.* 2012;33:354–61 (II).
171. Zvonar RK, Bush P, Roth V. Practice changes to improve delivery of surgical antibiotic prophylaxis. *Healthc Q.* 2008;11:141–4 (II).
172. Chu LA, Bratzler DW, Lewis RJ, et al. Improving the quality of care for patients with pneumonia in very small hospitals. *Arch Intern Med.* 2003;163:326–32 (II).
173. Cooke J, Alexander K, Charani E, et al. Antimicrobial stewardship: an evidence-based, antimicrobial self-assessment toolkit (ASAT) for acute hospitals. *J Antimicrob Chemother.* 2010;65:2669–73 (IV).
174. Amadeo B, Dumartin C, Parneix P, Fourier-Reglat A, Rogues AM. Relationship between antibiotic consumption and antibiotic policy: an adjusted analysis in the French healthcare system. *J Antimicrob Chemother.* 2011;66:434–42 (III).
175. Nothacker M, Reiter A. Qualitätsindikatoren für Nationale VersorgungsLeitlinien. In: *ÄZQ (Hrsg.) Programm für Nationale VersorgungsLeitlinien von BÄK, KBV und AWMF—Qualitätsindikatoren, Manual für Autoren.* 18–31. 2009.
176. Afshar N, Tabas J, Afshar K, Silbergleit R. Blood cultures for community-acquired pneumonia: are they worthy of two quality measures? A systematic review. *J Hosp Med.* 2009;4:112–23.
177. Dumartin C, Rogues AM, Amadeo B, et al. Antibiotic stewardship programmes: legal framework and structure and process

- indicator in Southwestern French hospitals, 2005–2008. *J Hosp Infect.* 2011;77:123–8 (III).
178. Hermanides HS, Hulscher ME, Schouten JA, Prins JM, Geerlings SE. Development of quality indicators for the antibiotic treatment of complicated urinary tract infections: a first step to measure and improve care. *Clin Infect Dis.* 2008;46:703–11 (IV).
 179. Kanwar M, Brar N, Khatib R, Fakhri MG. Misdiagnosis of community-acquired pneumonia and inappropriate utilization of antibiotics: side effects of the 4-h antibiotic administration rule. *Chest.* 2007;131:1865–9 (III).
 180. Morris AM, Brener S, Dresser L, et al. Use of a structured panel process to define quality metrics for antimicrobial stewardship programs. *Infect Control Hosp Epidemiol.* 2012;33:500–6 (IV).
 181. Nathwani D, Sneddon J, Patton A, Malcolm W. Antimicrobial stewardship in Scotland: impact of a national programme. *Antimicrob Resist Infect Control.* 2012;1:7 (III).
 182. Nguyen HB, Corbett SW, Steele R, et al. Implementation of a bundle of quality indicators for the early management of severe sepsis and septic shock is associated with decreased mortality. *Crit Care Med.* 2007;35:1105–12 (II).
 183. Pines JM, Isserman JA, Hinfey PB. The measurement of time to first antibiotic dose for pneumonia in the emergency department: a white paper and position statement prepared for the American Academy of Emergency Medicine. *J Emerg Med.* 2009;37:335–40 (IV).
 184. Pulcini C, Defres S, Aggarwal I, Nathwani D, Davey P. Design of a ‘day 3 bundle’ to improve the reassessment of inpatient empirical antibiotic prescriptions. *J Antimicrob Chemother.* 2008;61:1384–8 (III).
 185. Quattromani E, Powell ES, Khare RK, et al. Hospital-reported data on the pneumonia quality measure “Time to First Antibiotic Dose” are not associated with inpatient mortality: results of a nationwide cross-sectional analysis. *Acad Emerg Med.* 2011;18:496–503 (III).
 186. Saizy-Callaert S, Causse R, Fuhman C, Le Paih MF, Thebault A, Chouaid C. Impact of a multidisciplinary approach to the control of antibiotic prescription in a general hospital. *J Hosp Infect.* 2003;53:177–82 (III).
 187. Shorr AF, Owens RC Jr. Guidelines and quality for community-acquired pneumonia: measures from the Joint Commission and the Centers for Medicare and Medicaid Services. *Am J Health Syst Pharm.* 2009;66:S2–7 (IV).
 188. Van Kasteren ME, Mannien J, Kullberg BJ, et al. Quality improvement of surgical prophylaxis in Dutch hospitals: evaluation of a multi-site intervention by time series analysis. *J Antimicrob Chemother.* 2005;56:1094–102 (II).
 189. von Gunten V, Troillet N, Beney J, et al. Impact of an interdisciplinary strategy on antibiotic use: a prospective controlled study in three hospitals. *J Antimicrob Chemother.* 2005;55:362–6 (II).
 190. Buyle FM, Metz-Gercek S, Mechtler R, et al. Prospective multicentre feasibility study of a quality of care indicator for intravenous to oral switch therapy with highly bioavailable antibiotics. *J Antimicrob Chemother.* 2012;67:2043–6 (II).
 191. Kern WV, Metz-Gercek S, Mechtler R, et al. *Staphylococcus aureus* blood-stream infection management indicators as quality indicators for hospital antibiotic stewardship: feasibility study by the ABS International Quality Indicators (ABS QI) team. *Clin Microbiol Infect* 2009;15 Suppl 4:S188 (IV).
 192. Drew RH, White R, MacDougall C, Hermsen ED, Owens RC Jr. Insights from the Society of Infectious Diseases Pharmacists on antimicrobial stewardship guidelines from the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. *Pharmacotherapy.* 2009;29:593–607 (IV).
 193. Huttner B, Jones M, Rubin MA, et al. Double trouble: how big a problem is redundant anaerobic antibiotic coverage in Veterans Affairs medical centres? *J Antimicrob Chemother.* 2012;67:1537–9 (III).
 194. Aarts MA, Hancock JN, Heyland D, McLeod RS, Marshall JC. Empiric antibiotic therapy for suspected ventilator-associated pneumonia: a systematic review and meta-analysis of randomized trials. *Crit Care Med.* 2008;36:108–17 (I).
 195. De Waele JJ, Ravyts M, Depuydt P, Blot SI, Decruyenaere J, Vogelaers D. De-escalation after empirical meropenem treatment in the intensive care unit: fiction or reality? *J Crit Care.* 2010;25:641–6.
 196. Johnson SJ, Ernst EJ, Moores KG. Is double coverage of gram-negative organisms necessary? *Am J Health Syst Pharm.* 2011;68:119–24 (IV).
 197. Niederman MS, Souloountsi V. De-escalation therapy: is it valuable for the management of ventilator-associated pneumonia? *Clin Chest Med.* 2011;32:517–34 (I).
 198. Bliziotis IA, Samonis G, Vardakas KZ, Chrysanthopoulou S, Falagas ME. Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials. *Clin Infect Dis.* 2005;41:149–58 (I).
 199. Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. *BMJ.* 2004;328:668 (I).
 200. Marcus R, Paul M, Elphick H, Leibovici L. Clinical implications of beta-lactam-aminoglycoside synergism: systematic review of randomised trials. *Int J Antimicrob Agents.* 2011;37:491–503 (I).
 201. Abad CL, Kumar A, Safdar N. Antimicrobial therapy of sepsis and septic shock—when are two drugs better than one? *Crit Care Clin.* 2011;27:e1–27 (I).
 202. Boyd N, Nailor MD. Combination antibiotic therapy for empiric and definitive treatment of gram-negative infections: insights from the Society of Infectious Diseases Pharmacists. *Pharmacotherapy.* 2011;31:1073–84 (IV).
 203. Alvarez-Lerma F, Alvarez B, Luque P, et al. Empiric broad-spectrum antibiotic therapy of nosocomial pneumonia in the intensive care unit: a prospective observational study. *Crit Care.* 2006;10:R78 (II).
 204. Mettler J, Simcock M, Sendi P, et al. Empirical use of antibiotics and adjustment of empirical antibiotic therapies in a university hospital: a prospective observational study. *BMC Infect Dis.* 2007;7:21 (III).
 205. Montravers P, Dupont H, Gauzit R, Veber B, Bedos JP, Lepape A. Strategies of initiation and streamlining of antibiotic therapy in 41 French intensive care units. *Crit Care.* 2011;15:R17 (II).
 206. Briceland LL, Nightingale CH, Quintiliani R, Cooper BW, Smith KS. Antibiotic streamlining from combination therapy to monotherapy utilizing an interdisciplinary approach. *Arch Intern Med.* 1988;148:2019–22 (III).
 207. Schlueter M, James C, Dominguez A, Tsu L, Seymann G. Practice patterns for antibiotic de-escalation in culture-negative healthcare-associated pneumonia. *Infection.* 2010;38:357–62 (IV).
 208. Shime N, Satake S, Fujita N. De-escalation of antimicrobials in the treatment of bacteraemia due to antibiotic-sensitive pathogens in immunocompetent patients. *Infection.* 2011;39:319–25 (IV).
 209. Glowacki RC, Schwartz DN, Itokazu GS, Wisniewski MF, Kieszkowski P, Weinstein RA. Antibiotic combinations with redundant antimicrobial spectra: clinical epidemiology and pilot

- intervention of computer-assisted surveillance. *Clin Infect Dis*. 2003;37:59–64 (II).
210. Micek ST, Ward S, Fraser VJ, Kollef MH. A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. *Chest*. 2004;125:1791–9 (I).
 211. Kollef MH, Kollef KE. Antibiotic utilization and outcomes for patients with clinically suspected ventilator-associated pneumonia and negative quantitative BAL culture results. *Chest*. 2005;128:2706–13 (II).
 212. Giantsou E, Liratzopoulos N, Efraimidou E, et al. De-escalation therapy rates are significantly higher by bronchoalveolar lavage than by tracheal aspirate. *Intensive Care Med*. 2007;33:1533–40 (II).
 213. Heyland DK, Dodek P, Muscedere J, Day A, Cook D. Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia. *Crit Care Med*. 2008;36:737–44 (II).
 214. Eachempati SR, Hydo LJ, Shou J, Barie PS. Does de-escalation of antibiotic therapy for ventilator-associated pneumonia affect the likelihood of recurrent pneumonia or mortality in critically ill surgical patients? *J Trauma*. 2009;66:1343–8 (III).
 215. Amadeo B, Zarb P, Muller A, et al. European surveillance of antibiotic consumption (ESAC) point prevalence survey 2008: paediatric antimicrobial prescribing in 32 hospitals of 21 European countries. *J Antimicrob Chemother*. 2010;65:2247–52 (III).
 216. Guillemot D, Carbon C, Balkau B, et al. Low dosage and long treatment duration of beta-lactam: risk factors for carriage of penicillin-resistant *Streptococcus pneumoniae*. *JAMA*. 1998;279:365–70 (II).
 217. Harbarth S, Harris AD, Carmeli Y, Samore MH. Parallel analysis of individual and aggregated data on antibiotic exposure and resistance in gram-negative bacilli. *Clin Infect Dis*. 2001;33:1462–8 (II).
 218. Albrich WC, Monnet DL, Harbarth S. Antibiotic selection pressure and resistance in *Streptococcus pneumoniae* and *Streptococcus pyogenes*. *Emerg Infect Dis*. 2004;10:514–7 (III).
 219. Zillich AJ, Sutherland JM, Wilson SJ, et al. Antimicrobial use control measures to prevent and control antimicrobial resistance in US hospitals. *Infect Control Hosp Epidemiol*. 2006;27:1088–95 (III).
 220. Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. *Clin Infect Dis*. 2003;37:752–60 (I).
 221. van NC, van't Wout JW, Assendelft WJ, et al. Treatment duration of febrile urinary tract infection (FUTIRST trial): a randomized placebo-controlled multicenter trial comparing short (7 days) antibiotic treatment with conventional treatment (14 days). *BMC Infect Dis*. 2009;9:131 (I).
 222. Pugh R, Grant C, Cooke RP, Dempsey G. Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults. *Cochrane Database Syst Rev*. 2011;10:CD007577 (I).
 223. Havey TC, Fowler RA, Daneman N. Duration of antibiotic therapy for bacteremia: a systematic review and meta-analysis. *Crit Care*. 2011;15:R267 (I).
 224. Eliakim-Raz N, Yahav D, Paul M, Leibovici L. Duration of antibiotic treatment for acute pyelonephritis and septic urinary tract infection—7 days or less versus longer treatment: systematic review and meta-analysis of randomized controlled trials. *J Antimicrob Chemother*. 2013;68:2183–91 (I).
 225. Hayashi Y, Paterson DL. Strategies for reduction in duration of antibiotic use in hospitalized patients. *Clin Infect Dis*. 2011;52:1232–40 (III).
 226. Liew YX, Chlebicki MP, Lee W, Hsu LY, Kwa AL. Use of procalcitonin (PCT) to guide discontinuation of antibiotic use in an unspecified sepsis is an antimicrobial stewardship program (ASP). *Eur J Clin Microbiol Infect Dis*. 2011;30:853–5 (III).
 227. Schuetz P, Muller B, Christ-Crain M, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. *Cochrane Database Syst Rev*. 2012;9:CD007498 (I).
 228. Agarwal R, Schwartz DN. Procalcitonin to guide duration of antimicrobial therapy in intensive care units: a systematic review. *Clin Infect Dis*. 2011;53:379–87 (I).
 229. Bouadma L, Luyt CE, Tubach F, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. *Lancet*. 2010;375:463–74 (I).
 230. Schroeder S, Hochreiter M, Koehler T, et al. Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study. *Langenbecks Arch Surg*. 2009;394:221–6 (I).
 231. Kopterides P, Siempos II, Tsangaris I, Tsantes A, Armaganidis A. Procalcitonin-guided algorithms of antibiotic therapy in the intensive care unit: a systematic review and meta-analysis of randomized controlled trials. *Crit Care Med*. 2010;38:2229–41 (I).
 232. Heyland DK, Johnson AP, Reynolds SC, Muscedere J. Procalcitonin for reduced antibiotic exposure in the critical care setting: a systematic review and an economic evaluation. *Crit Care Med*. 2011;39:1792–9 (I).
 233. Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. *Am J Respir Crit Care Med*. 2008;177:498–505 (I).
 234. Tang H, Huang T, Jing J, Shen H, Cui W. Effect of procalcitonin-guided treatment in patients with infections: a systematic review and meta-analysis. *Infection*. 2009;37:497–507 (I).
 235. Hohn A, Schroeder S, Gehrt A, et al. Procalcitonin-guided algorithm to reduce length of antibiotic therapy in patients with severe sepsis and septic shock. *BMC Infect Dis*. 2013;13:158 (III).
 236. Gyssens IC, Geerligs IE, Dony JM, et al. Optimising antimicrobial drug use in surgery: an intervention study in a Dutch university hospital. *J Antimicrob Chemother*. 1996;38:1001–12 (II).
 237. Burke JP. Maximizing appropriate antibiotic prophylaxis for surgical patients: an update from LDS Hospital, Salt Lake City. *Clin Infect Dis*. 2001;33:S78–83 (II).
 238. Hosoglu S, Aslan S, Akalin S, Bosnak V. Audit of quality of perioperative antimicrobial prophylaxis. *Pharm World Sci*. 2009;31:14–7 (II).
 239. Burkitt KH, Mor MK, Jain R, et al. Toyota production system quality improvement initiative improves perioperative antibiotic therapy. *Am J Manag Care*. 2009;15:633–42 (III).
 240. Takahashi Y, Takesue Y, Nakajima K, et al. Implementation of a hospital-wide project for appropriate antimicrobial prophylaxis. *J Infect Chemother*. 2010;16:418–23 (II).
 241. Meyer E, Schwab F, Pollitt A, Bettolo W, Schroeren-Boersch B, Trautmann M. Impact of a change in antibiotic prophylaxis on total antibiotic use in a surgical intensive care unit. *Infection*. 2010;38:19–24 (III).
 242. Sun TB, Chao SF, Chang BS, Chen TY, Gao PY, Shyr MH. Quality improvements of antimicrobial prophylaxis in coronary artery bypass grafting. *J Surg Res*. 2011;167:329–35 (III).
 243. Haynes K, Linkin DR, Fishman NO, et al. Effectiveness of an information technology intervention to improve prophylactic antibacterial use in the postoperative period. *J Am Med Inform Assoc*. 2011;18:164–8 (II).

244. Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. *Thorax*. 2009;64:iii1–55 (I).
245. Wiersinga WJ, Bonten MJ, Boersma WG, et al. SWAB/NVALT (Dutch Working Party on Antibiotic Policy and Dutch Association of Chest Physicians) guidelines on the management of community-acquired pneumonia in adults. *Neth J Med*. 2012;70:90–101 (I).
246. Hoffken G, Lorenz J, Kern W, et al. S3-guideline on ambulant acquired pneumonia and deep airway infections. *Pneumologie*. 2005;59:612–64 (I).
247. Siegel RE, Halpern NA, Almenoff PL, Lee A, Cashin R, Greene JG. A prospective randomized study of inpatient IV antibiotics for community-acquired pneumonia—the optimal duration of therapy. *Chest*. 1996;110:965–71 (I).
248. Athanassa Z, Makris G, Dimopoulos G, Falagas ME. Early switch to oral treatment in patients with moderate to severe community-acquired pneumonia: a meta-analysis. *Drugs*. 2008;68:2469–81 (I).
249. Oosterheert JJ, Bonten MJ, Schneider MM, et al. Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial. *BMJ*. 2006;333:1193 (I).
250. Rhew DC, Tu GS, Ofman J, Henning JM, Richards MS, Weingarten SR. Early switch and early discharge strategies in patients with community-acquired pneumonia: a meta-analysis. *Arch Intern Med*. 2001;161:722–7 (I).
251. Castro-Guardiola A, Viejo-Rodriguez AL, Soler-Simon S, et al. Efficacy and safety of oral and early-switch therapy for community-acquired pneumonia: a randomized controlled trial. *Am J Med*. 2001;111:367–74 (I).
252. Li JZ, Willke RJ, Rittenhouse BE, Rybak MJ. Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant Staphylococci: results from a randomized clinical trial. *Surg Infect (Larchmt)*. 2003;4:57–70 (I).
253. Chan R, Hemeryck L, O'Regan M, Clancy L, Feely J. Oral versus intravenous antibiotics for community acquired lower respiratory tract infection in a general hospital: open, randomised controlled trial. *BMJ*. 1995;310:1360–2 (I).
254. Omidvari K, de Boisblanc BP, Karam G, Nelson S, Haponik E, Summer W. Early transition to oral antibiotic therapy for community-acquired pneumonia: duration of therapy, clinical outcomes, and cost analysis. *Respir Med*. 1998;92:1032–9 (I).
255. Manuel O, Burnand B, Bady P, et al. Impact of standardised review of intravenous antibiotic therapy 72 hours after prescription in two internal medicine wards. *J Hosp Infect*. 2010;74:326–31 (II).
256. Ramirez JA, Vargas S, Ritter GW, et al. Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia. *Arch Intern Med*. 1999;159:2449–54 (II).
257. Lee RW, Lindstrom ST. Early switch to oral antibiotics and early discharge guidelines in the management of community-acquired pneumonia. *Respirology*. 2007;12:111–6 (II).
258. Mertz D, Koller M, Haller P, et al. Outcomes of early switching from intravenous to oral antibiotics on medical wards. *J Antimicrob Chemother*. 2009;64:188–99 (II).
259. Nathan RV, Rhew DC, Murray C, Bratzler DW, Houck PM, Weingarten SR. In-hospital observation after antibiotic switch in pneumonia: a national evaluation. *Am J Med*. 2006;119:512–7 (IV).
260. Bocquet N, Sergent AA, Jais JP, et al. Randomized trial of oral versus sequential IV/oral antibiotic for acute pyelonephritis in children. *Pediatrics*. 2012;129:e269–75 (I).
261. Klasterksy J, Paesmans M. Risk-adapted strategy for the management of febrile neutropenia in cancer patients. *Support Care Cancer*. 2007;15:477–82 (IV).
262. Bachur R, Pagon Z. Success of short-course parenteral antibiotic therapy for acute osteomyelitis of childhood. *Clin Pediatr (Phila)*. 2007;46:30–5 (II).
263. Kern WV. Risk assessment and treatment of low-risk patients with febrile neutropenia. *Clin Infect Dis*. 2006;42:533–40 (I).
264. van NC, van't Wout JW, Spelt IC, et al. Prospective cohort study of acute pyelonephritis in adults: safety of triage towards home based oral antimicrobial treatment. *J Infect*. 2010;60:114–21 (II).
265. Jagodzinski NA, Kanwar R, Graham K, Bache CE. Prospective evaluation of a shortened regimen of treatment for acute osteomyelitis and septic arthritis in children. *J Pediatr Orthop*. 2009;29:518–25 (III).
266. Stengel D, Bauwens K, Sehoul J, Ekkernkamp A, Porzolt F. Systematic review and meta-analysis of antibiotic therapy for bone and joint infections. *Lancet Infect Dis*. 2001;1:175–88 (I).
267. Cenizal MJ, Skiest D, Luber S, et al. Prospective randomized trial of empiric therapy with trimethoprim-sulfamethoxazole or doxycycline for outpatient skin and soft tissue infections in an area of high prevalence of methicillin-resistant *Staphylococcus aureus*. *Antimicrob Agents Chemother*. 2007;51:2628–30 (I).
268. Hodson EM, Willis NS, Craig JC. Antibiotics for acute pyelonephritis in children. *Cochrane Database Syst Rev*. 2007;4:CD003772 (I).
269. Neuhaus TJ, Berger C, Buechner K, et al. Randomised trial of oral versus sequential intravenous/oral cephalosporins in children with pyelonephritis. *Eur J Pediatr*. 2008;167:1037–47 (I).
270. Vouloumanou EK, Rafailidis PI, Kazantzi MS, Athanasiou S, Falagas ME. Early switch to oral versus intravenous antimicrobial treatment for hospitalized patients with acute pyelonephritis: a systematic review of randomized controlled trials. *Curr Med Res Opin*. 2008;24:3423–34 (I).
271. Hom J. Are oral antibiotics equivalent to intravenous antibiotics for the initial management of pyelonephritis in children? *Paediatr Child Health*. 2010;15:150–2 (I).
272. Kuti JL, Le TN, Nightingale CH, Nicolau DP, Quintiliani R. Pharmacoeconomics of a pharmacist-managed program for automatically converting levofloxacin route from i.v. to oral. *Am J Health Syst Pharm*. 2002;59:2209–15 (II).
273. Rigaud B, Malbranche C, Pioud V, et al. Good clinical practices and inpatient antibiotics: optimization of fluoroquinolone switch therapy. *Presse Med*. 2007;36:1159–66 (II).
274. Lorgelly PK, Atkinson M, Lakhanpaul M, et al. Oral versus i.v. antibiotics for community-acquired pneumonia in children: a cost-minimisation analysis. *Eur Respir J*. 2010;35:858–64 (I).
275. Przybylski KG, Rybak MJ, Martin PR, et al. A pharmacist-initiated program of intravenous to oral antibiotic conversion. *Pharmacotherapy*. 1997;17:271–6 (II).
276. Vogtlander NP, Van Kasteren ME, Natsch S, Kullberg BJ, Hekster YA, Van Der Meer JW. Improving the process of antibiotic therapy in daily practice: interventions to optimize timing, dosage adjustment to renal function, and switch therapy. *Arch Intern Med*. 2004;164:1206–12 (II).
277. Waagsbo B, Sundoy A, Paulsen EQ. Reduction of unnecessary i.v. antibiotic days using general criteria for antibiotic switch. *Scand J Infect Dis*. 2008;40:468–73 (II).
278. Shindo Y, Sato S, Maruyama E, et al. Implication of clinical pathway care for community-acquired pneumonia in a

- community hospital: early switch from an intravenous beta-lactam plus a macrolide to an oral respiratory fluoroquinolone. *Intern Med*. 2008;47:1865–74 (IV).
279. Buyle F, Vogelaers D, Peleman R, Van MG, Robays H. Implementation of guidelines for sequential therapy with fluoroquinolones in a Belgian hospital. *Pharm World Sci*. 2010;32:404–10 (II).
 280. Dryden M, Saeed K, Townsend R, et al. Antibiotic stewardship and early discharge from hospital: impact of a structured approach to antimicrobial management. *J Antimicrob Chemother*. 2012;67:2289–96 (II).
 281. Metjian TA, Prasad PA, Kogon A, Coffin SE, Zaoutis TE. Evaluation of an antimicrobial stewardship program at a pediatric teaching hospital. *Pediatr Infect Dis J*. 2008;27:106–11 (II).
 282. Hoefel HH, Lautert L, Schmitt C, Soares T, Jordan S. Vancomycin administration: mistakes made by nursing staff. *Nurs Stand*. 2008;22:35–42 (IV).
 283. Magnotti LJ, Schroepfel TJ, Fabian TC, et al. Reduction in inadequate empiric antibiotic therapy for ventilator-associated pneumonia: impact of a unit-specific treatment pathway. *Am Surg*. 2008;74:516–22 (III).
 284. Dalley AJ, Lipman J, Venkatesh B, Rudd M, Roberts MS, Cross SE. Inadequate antimicrobial prophylaxis during surgery: a study of beta-lactam levels during burn debridement. *J Antimicrob Chemother*. 2007;60:166–9 (III).
 285. Luna CM, Aruj P, Niederman MS, et al. Appropriateness and delay to initiate therapy in ventilator-associated pneumonia. *Eur Respir J*. 2006;27:158–64 (III).
 286. Ramsay C, Brown E, Hartman G, Davey P. Room for improvement: a systematic review of the quality of evaluations of interventions to improve hospital antibiotic prescribing. *J Antimicrob Chemother*. 2003;52:764–71 (I).
 287. Zaragoza R, Artero A, Camarena JJ, Sancho S, Gonzalez R, Nogueira JM. The influence of inadequate empirical antimicrobial treatment on patients with bloodstream infections in an intensive care unit. *Clin Microbiol Infect*. 2003;9:412–8 (III).
 288. McKenzie C. Antibiotic dosing in critical illness. *J Antimicrob Chemother*. 2011;66:ii25–31 (IV).
 289. Cordova MA, Generali JA, White SJ, Godwin HN. The effects of two pharmacy intervention methods on cefazolin dosing interval for surgical prophylaxis. *Hospital pharmacy*. 1986;21:405–14 (II).
 290. Avorn J, Soumerai SB, Taylor W, Wessels MR, Janousek J, Weiner M. Reduction of incorrect antibiotic dosing through a structured educational order form. *Arch Intern Med*. 1988;148:1720–4 (II).
 291. Burton ME, Ash CL, Hill DP Jr, Handy T, Shepherd MD, Vasko MR. A controlled trial of the cost benefit of computerized bayesian aminoglycoside administration. *Clin Pharmacol Ther*. 1991;49:685–94 (I).
 292. Destache CJ, Meyer SK, Bittner MJ, Hermann KG. Impact of a clinical pharmacokinetic service on patients treated with aminoglycosides: a cost-benefit analysis. *Ther Drug Monit*. 1990;12:419–26 (I).
 293. McNabb JJ, Nightingale CH, Quintiliani R, Nicolau DP. Cost-effectiveness of ceftazidime by continuous infusion versus intermittent infusion for nosocomial pneumonia. *Pharmacotherapy*. 2001;21:549–55 (II).
 294. Grant EM, Kuti JL, Nicolau DP, Nightingale C, Quintiliani R. Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital. *Pharmacotherapy*. 2002;22:471–83 (II).
 295. Scaglione F. Can PK/PD be used in everyday clinical practice. *Int J Antimicrob Agents*. 2002;19:349–53 (III).
 296. Kaufman SE, Donnell RW, Hickey WS. Rationale and evidence for extended infusion of piperacillin-tazobactam. *Am J Health Syst Pharm*. 2011;68:1521–6 (I).
 297. Duszynska W, Taccone FS, Switala M, Hurkacz M, Kowalska-Krochmal B, Kubler A. Continuous infusion of piperacillin/tazobactam in ventilator-associated pneumonia: a pilot study on efficacy and costs. *Int J Antimicrob Agents*. 2012;39:153–8 (III).
 298. DeRyke CA, Lee SY, Kuti JL, Nicolau DP. Optimising dosing strategies of antibacterials utilising pharmacodynamic principles: impact on the development of resistance. *Drugs*. 2006;66:1–14 (IV).
 299. Owens RC Jr, Shorr AF. Rational dosing of antimicrobial agents: pharmacokinetic and pharmacodynamic strategies. *Am J Health Syst Pharm*. 2009;66:S23–30 (IV).
 300. Markou N, Markantonis SL, Dimitrakis E, et al. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study. *Clin Ther*. 2008;30:143–51 (II).
 301. Daikos GL, Lolans VT, Jackson GG. First-exposure adaptive resistance to aminoglycoside antibiotics in vivo with meaning for optimal clinical use. *Antimicrob Agents Chemother*. 1991;35:117–23 (III).
 302. Gumbo T, Louie A, Deziel MR, Parsons LM, Salfinger M, Drusano GL. Selection of a moxifloxacin dose that suppresses drug resistance in *Mycobacterium tuberculosis*, by use of an in vitro pharmacodynamic infection model and mathematical modeling. *J Infect Dis*. 2004;190:1642–51 (III).
 303. Henderson-Begg SK, Livermore DM, Hall LM. Effect of sub-inhibitory concentrations of antibiotics on mutation frequency in *Streptococcus pneumoniae*. *J Antimicrob Chemother*. 2006;57:849–54 (III).
 304. Olofsson SK, Geli P, Andersson DI, Cars O. Pharmacodynamic model to describe the concentration-dependent selection of cefotaxime-resistant *Escherichia coli*. *Antimicrob Agents Chemother*. 2005;49:5081–91 (III).
 305. Tam VH, Schilling AN, Neshat S, Poole K, Melnick DA, Coyle EA. Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother*. 2005;49:4920–7 (III).
 306. Smyth AR, Bhatt J. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. *Cochrane Database Syst Rev*. 2012;2:CD002009 (I).
 307. Sime FB, Roberts MS, Peake SL, Lipman J, Roberts JA. Does beta-lactam pharmacokinetic variability in critically ill patients justify therapeutic drug monitoring? A systematic review. *Ann Intensive Care*. 2012;2:35 (I).
 308. Roberts JA, Joynt GM, Choi GY, Gomersall CD, Lipman J. How to optimise antimicrobial prescriptions in the intensive care unit: principles of individualised dosing using pharmacokinetics and pharmacodynamics. *Int J Antimicrob Agents*. 2012;39:187–92 (IV).
 309. Roberts JA, Norris R, Paterson DL, Martin JH. Therapeutic drug monitoring of antimicrobials. *Br J Clin Pharmacol*. 2012;73:27–36 (IV).
 310. Roberts JA, Webb S, Paterson D, Ho KM, Lipman J. A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics. *Crit Care Med*. 2009;37:2071–8 (I).
 311. Blondiaux N, Wallet F, Favory R, et al. Daily serum piperacillin monitoring is advisable in critically ill patients. *Int J Antimicrob Agents*. 2010;35:500–3 (II).
 312. van Lent-Evers NA, Mathot RA, Geus WP, van Hout BA, Vinks AA. Impact of goal-oriented and model-based

- clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis. *Ther Drug Monit.* 1999;21:63–73 (I).
313. Leon-Djian CB, Bourguignon L, Spath HM, Maire P. Cost-effectiveness analysis of active TDM in elderly patients treated with aminoglycosides. *Therapie.* 2011;66:445–52 (IV).
314. Duszynska W. Pharmacokinetic-pharmacodynamic modelling of antibiotic therapy in severe sepsis. *Anaesthesiol Intensive Ther.* 2012;44:158–64 (IV).
315. Hennessy S, Leonard CE, Localio AR, et al. Prescriber adherence to pharmacokinetic monitoring service recommendations for aminoglycoside dosing and the risk of acute kidney injury. *Int J Clin Pharmacol Ther.* 2011;49:536–44 (III).
316. Mueller EW, Boucher BA. The use of extended-interval aminoglycoside dosing strategies for the treatment of moderate-to-severe infections encountered in critically ill surgical patients. *Surg Infect (Larchmt).* 2009;10:563–70 (I).
317. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. *Clin Infect Dis.* 1998;26:1–10 (IV).
318. Drusano GL. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. *Nat Rev Microbiol.* 2004;2:289–300 (IV).
319. Kasiakou SK, Lawrence KR, Choulis N, Falagas ME. Continuous versus intermittent intravenous administration of antibacterials with time-dependent action: a systematic review of pharmacokinetic and pharmacodynamic parameters. *Drugs.* 2005;65:2499–511 (I).
320. Kasiakou SK, Sermaides GJ, Michalopoulos A, Soteriades ES, Falagas ME. Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials. *Lancet Infect Dis.* 2005;5:581–9 (I).
321. Tamma PD, Putcha N, Suh YD, Van Arendonk KJ, Rinke ML. Does prolonged beta-lactam infusions improve clinical outcomes compared to intermittent infusions? A meta-analysis and systematic review of randomized, controlled trials. *BMC Infect Dis.* 2011;11:181 (I).
322. McKinnon PS, Paladino JA, Schentag JJ. Evaluation of area under the inhibitory curve (AUC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. *Int J Antimicrob Agents.* 2008;31:345–51 (III).
323. Pelkonen T, Roine I, Cruzeiro ML, Pitkaranta A, Kataja M, Peltonen H. Slow initial beta-lactam infusion and oral paracetamol to treat childhood bacterial meningitis: a randomised, controlled trial. *Lancet Infect Dis.* 2011;11:613–21 (I).
324. Dandekar PK, Maglio D, Sutherland CA, Nightingale CH, Nicolau DP. Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion. *Pharmacotherapy.* 2003;23:988–91 (III).
325. Yost RJ, Cappelletty DM. The retrospective cohort of extended-infusion piperacillin-tazobactam (RECEIPT) study: a multicenter study. *Pharmacotherapy.* 2011;31:767–75 (III).
326. Arnold HM, Hollands JM, Skrupky LP, et al. Prolonged infusion antibiotics for suspected gram-negative infections in the ICU: a before-after study. *Ann Pharmacother.* 2013;47:170–80 (II).
327. Dulhunty JM, Roberts JA, Davis JS, et al. Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. *Clin Infect Dis.* 2013;56:236–44 (I).
328. Chytra I, Stepan M, Benes J, et al. Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial. *Crit Care.* 2012;16:R113 (I).
329. Toltzis P, Dul MJ, Hoyer C, et al. The effect of antibiotic rotation on colonization with antibiotic-resistant bacilli in a neonatal intensive care unit. *Pediatrics.* 2002;110:707–11 (II).
330. de CC, Franchineau P, Gourgand JM, Lorient Y, Gaulme J, Sirot J. Clinical and bacteriological survey after change in aminoglycoside treatment to control an epidemic of *Enterobacter cloacae*. *J Hosp Infect.* 1994;28:219–29 (II).
331. Martinez JA, Nicolas JM, Marco F, et al. Comparison of antimicrobial cycling and mixing strategies in two medical intensive care units. *Critical Care Medicine.* 2006;34:329–36 (III).
332. Martinez JA, Delgado E, Marti S, et al. Influence of antipseudomonal agents on *Pseudomonas aeruginosa* colonization and acquisition of resistance in critically ill medical patients. *Intensive Care Med.* 2009;35:439–47 (III).
333. Cadena J, Taboada CA, Burgess DS, et al. Antibiotic cycling to decrease bacterial antibiotic resistance: a 5-year experience on a bone marrow transplant unit. *Bone Marrow Transpl.* 2007;40:151–5 (IV).
334. Craig M, Cumpston AD, Hobbs GR, Devetten MP, Sarwari AR, Ericson SG. The clinical impact of antibacterial prophylaxis and cycling antibiotics for febrile neutropenia in a hematological malignancy and transplantation unit. *Bone Marrow Transpl.* 2007;39:477–82 (III).
335. de Araujo OR, da Silva DC, Diegues AR, et al. Cefepime restriction improves gram-negative overall resistance patterns in neonatal intensive care unit. *Braz J Infect Dis.* 2007;11:277–80 (II).
336. Francetic I, Kalenic S, Huic M, et al. Impact of aminoglycoside cycling in six tertiary intensive care units: prospective longitudinal interventional study. *Croat Med J.* 2008;49:207–14 (IV).
337. Hedrick TL, Schulman AS, McElearney ST, et al. Outbreak of resistant *Pseudomonas aeruginosa* infections during a quarterly cycling antibiotic regimen. *Surg Infect (Larchmt).* 2008;9:139–52 (IV).
338. Bonhoeffer S, Lipsitch M, Levin BR. Evaluating treatment protocols to prevent antibiotic resistance. *Proc Natl Acad Sci USA.* 1997;94:12106–11 (III).
339. Bergstrom CT, Lo M, Lipsitch M. Ecological theory suggests that antimicrobial cycling will not reduce antimicrobial resistance in hospitals. *Proc Natl Acad Sci USA.* 2004;101:13285–90 (III).
340. Bal AM, Kumar A, Gould IM. Antibiotic heterogeneity: from concept to practice. *Ann N Y Acad Sci.* 2010;1213:81–91 (IV).
341. Erdeljc V, Francetic I, Bosnjak Z, et al. Distributed lags time series analysis versus linear correlation analysis (Pearson's r) in identifying the relationship between antipseudomonal antibiotic consumption and the susceptibility of *Pseudomonas aeruginosa* isolates in a single Intensive Care Unit of a tertiary hospital. *Int J Antimicrob Agents.* 2011;37:467–71 (III).
342. Miliani K, L'Heriteau F, Lacave L, Carbonne A, Astagneau P. Imipenem and ciprofloxacin consumption as factors associated with high incidence rates of resistant *Pseudomonas aeruginosa* in hospitals in northern France. *J Hosp Infect.* 2011;77:343–7 (III).
343. Takesue Y, Nakajima K, Ichiki K, et al. Impact of a hospital-wide programme of heterogeneous antibiotic use on the development of antibiotic-resistant Gram-negative bacteria. *J Hosp Infect.* 2010;75:28–32 (II).
344. Pluss-Suard C, Pannatier A, Kronenberg A, Muhlemann K, Zanetti G. Impact of antibiotic use on carbapenem resistance in *Pseudomonas aeruginosa*: is there a role for antibiotic diversity? *Antimicrob Agents Chemother.* 2013;57:1709–13 (III).
345. Sandiumenge A, Lisboa T, Gomez F, Hernandez P, Canadell L, Rello J. Effect of antibiotic diversity on ventilator-associated pneumonia caused by ESKAPE organisms. *Chest.* 2011;140:643–51 (II).

346. Dancer SJ, Kirkpatrick P, Corcoran DS, Christison F, Farmer D, Robertson C. Approaching zero: temporal effects of a restrictive antibiotic policy on hospital-acquired *Clostridium difficile*, extended-spectrum beta-lactamase-producing coliforms and methicillin-resistant *Staphylococcus aureus*. *Int J Antimicrob Agents*. 2013;41:137–42 (II).
347. Lee J, Pai H, Kim YK, et al. Control of extended-spectrum beta-lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae* in a children's hospital by changing antimicrobial agent usage policy. *J Antimicrob Chemother*. 2007;60:629–37 (II).
348. Petrikos G, Markogiannakis A, Papaparaskevas J, et al. Differences in the changes in resistance patterns to third- and fourth-generation cephalosporins and piperacillin/tazobactam among *Klebsiella pneumoniae* and *Escherichia coli* clinical isolates following a restriction policy in a Greek tertiary care hospital. *Int J Antimicrob Agents*. 2007;29:34–8 (II).
349. Wen Z, Wei X, Xiao Y, et al. Intervention study of the association of antibiotic utilization measures with control of extended-spectrum beta-lactamase (ESBL)-producing bacteria. *Microbes Infect*. 2010;12:710–5 (II).
350. Murki S, Jonnalal S, Mohammed F, Reddy A. Restriction of cephalosporins and control of extended spectrum beta-lactamase producing gram negative bacteria in a neonatal intensive care unit. *Indian Pediatr*. 2010;47:785–8 (III).
351. Wilson ML, Gaido L. Laboratory diagnosis of urinary tract infections in adult patients. *Clin Infect Dis*. 2004;38:1150–8 (II).
352. Gatermann SG, Fünfstück R, Handrick W, et al. MiQ 2 Harnwegsinfektionen. 2. Auflage. 2005. München, Urban & Fischer. Mikrobiologisch-infektiologische Qualitätsstandards (MiQ).
353. Anevlaivis S, Petroglou N, Tzavaras A, et al. A prospective study of the diagnostic utility of sputum Gram stain in pneumonia. *J Infect*. 2009;59:83–9 (II).
354. Barenfanger J, Drake C, Leon N, Mueller T, Trout T. Clinical and financial benefits of rapid detection of respiratory viruses: an outcomes study. *J Clin Microbiol*. 2000;38:2824–8 (III).
355. Podbielski A, Herrmann M, Kniehl E, Mauch H, Rüssmann H. MiQ 7 Infektionen der tiefen Atemwege—Teil I. [2. Auflage]. 2010. München, Urban & Fischer. Mikrobiologisch-infektiologische Qualitätsstandards (MiQ).
356. Roson B, Carratala J, Verdager R, Dorca J, Manresa F, Gudiol F. Prospective study of the usefulness of sputum Gram stain in the initial approach to community-acquired pneumonia requiring hospitalization. *Clin Infect Dis*. 2000;31:869–74 (II).
357. Gleckman R, DeVita J, Hibert D, Pelletier C, Martin R. Sputum gram stain assessment in community-acquired bacteremic pneumonia. *J Clin Microbiol*. 1988;26:846–9 (II).
358. Tenover FC. Potential impact of rapid diagnostic tests on improving antimicrobial use. *Ann N Y Acad Sci*. 2010;1213:70–80 (I).
359. Bauer KA, West JE, Balada-Llasat JM, Pancholi P, Stevenson KB, Goff DA. An antimicrobial stewardship program's impact with rapid polymerase chain reaction methicillin-resistant *Staphylococcus aureus*/S. aureus blood culture test in patients with S. aureus bacteremia. *Clin Infect Dis*. 2010;51:1074–80 (II).
360. Kerremans JJ, Verboom P, Stijnen T, et al. Rapid identification and antimicrobial susceptibility testing reduce antibiotic use and accelerate pathogen-directed antibiotic use. *J Antimicrob Chemother*. 2008;61:428–35 (I).
361. Bouza E, Torres MV, Radice C, et al. Direct E-test (AB Bio-disk) of respiratory samples improves antimicrobial use in ventilator-associated pneumonia. *Clin Infect Dis*. 2007;44:382–7 (I).
362. Doern GV, Vautour R, Gaudet M, Levy B. Clinical impact of rapid in vitro susceptibility testing and bacterial identification. *J Clin Microbiol*. 1994;32:1757–62 (I).
363. Forrest GN, Roghmann MC, Toombs LS, et al. Peptide nucleic acid fluorescent in situ hybridization for hospital-acquired enterococcal bacteremia: delivering earlier effective antimicrobial therapy. *Antimicrob Agents Chemother*. 2008;52:3558–63 (II).
364. Lucignano B, Ranno S, Liesenfeld O, et al. Multiplex PCR allows rapid and accurate diagnosis of bloodstream infections in newborns and children with suspected sepsis. *J Clin Microbiol*. 2011;49:2252–8 (III).
365. Frye AM, Baker CA, Rustvold DL, et al. Clinical impact of a real-time PCR assay for rapid identification of staphylococcal bacteremia. *J Clin Microbiol*. 2012;50:127–33 (III).
366. Buchan BW, Riebe KM, Ledebner NA. Comparison of the MALDI Biotyper system using Sepsityper specimen processing to routine microbiological methods for identification of bacteria from positive blood culture bottles. *J Clin Microbiol*. 2012;50:346–52 (III).
367. Falguera M, Ruiz-Gonzalez A, Schoenenberger JA, et al. Prospective, randomised study to compare empirical treatment versus targeted treatment on the basis of the urine antigen results in hospitalised patients with community-acquired pneumonia. *Thorax*. 2010;65:101–6 (I).
368. Sorde R, Falco V, Lowak M, et al. Current and potential usefulness of pneumococcal urinary antigen detection in hospitalized patients with community-acquired pneumonia to guide antimicrobial therapy. *Arch Intern Med*. 2011;171:166–72 (II).
369. Arbo MD, Snyderman DR. Influence of blood culture results on antibiotic choice in the treatment of bacteremia. *Arch Intern Med*. 1994;154:2641–5 (II).
370. Bouza E, Sousa D, Munoz P, Rodriguez-Creixems M, Fron C, Lechuz JG. Bloodstream infections: a trial of the impact of different methods of reporting positive blood culture results. *Clin Infect Dis*. 2004;39:1161–9 (I).
371. Holtzman C, Whitney D, Barlam T, Miller NS. Assessment of impact of peptide nucleic acid fluorescence in situ hybridization for rapid identification of coagulase-negative staphylococci in the absence of antimicrobial stewardship intervention. *J Clin Microbiol*. 2011;49:1581–2 (II).
372. Nathwani D. Antimicrobial prescribing policy and practice in Scotland: recommendations for good antimicrobial practice in acute hospitals. *J Antimicrob Chemother*. 2006;57:1189–96 (IV).
373. Steffee CH, Morrell RM, Wasilauskas BL. Clinical use of rifampicin during routine reporting of rifampicin susceptibilities: a lesson in selective reporting of antimicrobial susceptibility data. *J Antimicrob Chemother*. 1997;40:595–8 (III).
374. McNulty CA, Lasseter GM, Charlett A, et al. Does laboratory antibiotic susceptibility reporting influence primary care prescribing in urinary tract infection and other infections? *J Antimicrob Chemother*. 2011;66:1396–404 (II).
375. Hsu J, Abad C, Dinh M, Safdar N. Prevention of endemic healthcare-associated *Clostridium difficile* infection: reviewing the evidence. *Am J Gastroenterol*. 2010;105:2327–39 (I).
376. Wilcox MH, Planche T. *Clostridium difficile* infection. *BMJ*. 2009;338:b2528 (IV).
377. Debast SB, Vaessen N, Choudry A, Wieggers-Ligtvoet EA, van den Berg RJ, Kuijper EJ. Successful combat of an outbreak due to *Clostridium difficile* PCR ribotype 027 and recognition of specific risk factors. *Clin Microbiol Infect*. 2009;15:427–34 (III).
378. Wilcox MH, Freeman J, Fawley W, et al. Long-term surveillance of cefotaxime and piperacillin-tazobactam prescribing and incidence of *Clostridium difficile* diarrhoea. *J Antimicrob Chemother*. 2004;54:168–72 (II).
379. Brahmi N, Blel Y, Kouraichi N, et al. Impact of ceftazidime restriction on gram-negative bacterial resistance in an intensive care unit. *J Infect Chemother*. 2006;12:190–4 (II).

380. Lipworth AD, Hyle EP, Fishman NO, et al. Limiting the emergence of extended-spectrum beta-lactamase-producing enterobacteriaceae: influence of patient population characteristics on the response to antimicrobial formulary interventions. *Infect Control Hosp Epidemiol*. 2006;27:279–86 (II).
381. Tangden T, Eriksson BM, Melhus A, Svennblad B, Cars O. Radical reduction of cephalosporin use at a tertiary hospital after educational antibiotic intervention during an outbreak of extended-spectrum beta-lactamase-producing *Klebsiella pneumoniae*. *J Antimicrob Chemother*. 2011;66:1161–7 (II-III).
382. Bamberger DM, Dahl SL. Impact of voluntary vs enforced compliance of 3Rd-generation cephalosporin use in a teaching hospital. *Arch Intern Med*. 1992;152:554–7 (II).
383. Anglim AM, Klym B, Byers KE, Scheld WM, Farr BM. Effect of a vancomycin restriction policy on ordering practices during an outbreak of vancomycin-resistant *Enterococcus faecium*. *Arch Intern Med*. 1997;157:1132–6 (II).
384. May AK, Melton SM, McGwin G, Cross JM, Moser SA, Rue LW. Reduction of vancomycin-resistant enterococcal infections by limitation of broad-spectrum cephalosporin use in a trauma and burn intensive care unit. *Shock*. 2000;14:259–64 (II).
385. Stiefel U, Paterson DL, Pultz NJ, Gordon SM, Aron DC, Don-skey CJ. Effect of the increasing use of piperacillin/tazobactam on the incidence of vancomycin-resistant enterococci in four academic medical centers. *Infect Contr Hosp Epidemiol*. 2004;25:380–3 (IV).
386. de Man P, Verhoeven BAN, Verbrugh HA, Vos MC, van den Anker JN. An antibiotic policy to prevent emergence of resistant bacilli. *Lancet*. 2000;355:973–8 (II).
387. Toltzis P, Yamashita T, Vilt L, et al. Antibiotic restriction does not alter endemic colonization with resistant Gram-negative rods in a pediatric intensive care unit. *Crit Care Med*. 1998;26:1893–9 (II).
388. Rahal JJ, Urban C, Horn D, et al. Glass restriction of cephalosporin use to control total cephalosporin resistance in nosocomial *Klebsiella*. *JAMA J Am Med Assoc*. 1998;280:1233–7 (II).
389. Arda B, Sipahi OR, Yamazhan T, et al. Short-term effect of antibiotic control policy on the usage patterns and cost of antimicrobials, mortality, nosocomial infection rates and antibacterial resistance. *J Infect*. 2007;55:41–8 (III).
390. Landman D, Chockalingam M, Quale JM. Reduction in the incidence of methicillin-resistant *Staphylococcus aureus* and ceftazidime-resistant *Klebsiella pneumoniae* following changes in a hospital antibiotic formulary. *Clin Infect Dis*. 1999;28:1062–6 (II).
391. Leverstein-van Hall MA, Fluit AC, Blok HE, et al. Control of nosocomial multiresistant Enterobacteriaceae using a temporary restrictive antibiotic agent policy. *Eur J Clin Microbiol Infect Dis*. 2001;20:785–91 (III).
392. Quale J, Landman D, Saurina G, Atwood E, DiTore V, Patel K. Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycin-resistant enterococci. *Clin Infect Dis*. 1996;23:1020–5 (II).
393. Lautenbach E, Larosa LA, Marr AM, Nachamkin I, Bilker WB, Fishman NO. Changes in the prevalence of vancomycin-resistant enterococci in response to antimicrobial formulary interventions: impact of progressive restrictions on use of vancomycin and third-generation cephalosporins. *Clin Infect Dis*. 2003;36:440–6 (II).
394. Zhou JJ, Patel SJ, Jia H, et al. Clinicians' knowledge, attitudes, and practices regarding infections with multidrug-resistant gram-negative bacilli in intensive care units. *Infect Control Hosp Epidemiol*. 2013;34:274–83 (III).
395. Pearson SA, Moxey A, Robertson J, et al. Do computerised clinical decision support systems for prescribing change practice? A systematic review of the literature (1990–2007). *BMC Health Serv Res*. 2009;9:154 (I).
396. Linder JA, Schnipper JL, Tsurikova R, et al. Documentation-based clinical decision support to improve antibiotic prescribing for acute respiratory infections in primary care: a cluster randomised controlled trial. *Inform Prim Care*. 2009;17:231–40 (I).
397. Haux R, Swinkels W, Ball M, Knaup P, Lun KC. Transformation of health care through innovative use of information technology: challenges for health and medical informatics education. *Int J Med Inform*. 1998;50:1–6 (IV).
398. Haux R, Knaup P, Bauer AW, et al. Information processing in healthcare at the start of the third millennium: potential and limitations. *Methods Inf Med*. 2001;40:156–62 (IV).
399. Haux R. Health care in the information society: what should be the role of medical informatics? *Methods Inf Med*. 2002;41:31–5 (IV).
400. Haux R, Ammenwerth E, Herzog W, Knaup P. Health care in the information society. A prognosis for the year 2013. *Int J Med Inform*. 2002;66:3–21 (IV).
401. Haux R. Health information systems—past, present, future. *Int J Med Inform*. 2006;75:268–81 (IV).
402. Cunningham TR, Geller ES, Clarke SW. Impact of electronic prescribing in a hospital setting: a process-focused evaluation. *Int J Med Inform*. 2008;77:546–54 (III).
403. Sturzlinger H, Hiebinger C, Pertl D, Traurig P. Computerized physician order entry—effectiveness and efficiency of electronic medication ordering with decision support systems. *GMS Health Technol Assess*. 2009;5:Doc07 (I).
404. Di Pentima MC, Chan S, Eppes SC, Klein JD. Antimicrobial prescription errors in hospitalized children: role of antimicrobial stewardship program in detection and intervention. *Clin Pediatr (Phila)*. 2009;48:505–12 (II).
405. Kazemi A, Ellenius J, Pourasghar F, et al. The effect of computerized physician order entry and decision support system on medication errors in the neonatal ward: experiences from an Iranian teaching hospital. *J Med Syst*. 2011;35:25–37 (II).
406. Cox ZL, Nelsen CL, Waitman LR, McCoy JA, Peterson JF. Effects of clinical decision support on initial dosing and monitoring of tobramycin and amikacin. *Am J Health Syst Pharm*. 2011;68:624–32 (II).
407. Traugott KA, Maxwell PR, Green K, Frei C, Lewis JS. Effects of therapeutic drug monitoring criteria in a computerized prescriber-order-entry system on the appropriateness of vancomycin level orders. *Am J Health Syst Pharm*. 2011;68:347–52 (II).
408. Kim JY, Sohn JW, Park DW, Yoon YK, Kim YM, Kim MJ. Control of extended-spectrum {beta}-lactamase-producing *Klebsiella pneumoniae* using a computer-assisted management program to restrict third-generation cephalosporin use. *J Antimicrob Chemother*. 2008;62:416–21 (II).
409. Yong MK, Buising KL, Cheng AC, Thursky KA. Improved susceptibility of Gram-negative bacteria in an intensive care unit following implementation of a computerized antibiotic decision support system. *J Antimicrob Chemother*. 2010;65:1062–9 (II).
410. Garg AX, Adhikari NK, McDonald H, et al. Effects of computerized clinical decision support systems on practitioner performance and patient outcomes: a systematic review. *JAMA*. 2005;293:1223–38 (I).
411. McKinley BA, Moore LJ, Sucher JF, et al. Computer protocol facilitates evidence-based care of sepsis in the surgical intensive care unit. *J Trauma*. 2011;70:1153–66 (III).
412. Thursky K. Use of computerized decision support systems to improve antibiotic prescribing. *Expert Rev Anti Infect Ther*. 2006;4:491–507 (I).

413. Sintchenko V, Coiera E, Gilbert GL. Decision support systems for antibiotic prescribing. *Curr Opin Infect Dis*. 2008;21:573–9 (I).
414. Di Pentima MC, Chan S. Impact of antimicrobial stewardship program on vancomycin use in a pediatric teaching hospital. *Pediatr Infect Dis J*. 2010;29:707–11 (II).
415. Lesprit P, Duong T, Girou E, Hemery F, Brun-Buisson C. Impact of a computer-generated alert system prompting review of antibiotic use in hospitals. *J Antimicrob Chemother*. 2009;63:1058–63 (II).
416. Hulan T, Rosenbloom ST, Hargrove F, et al. Oral quinolones in hospitalized patients: an evaluation of a computerized decision support intervention. *J Intern Med*. 2004;256:349–57 (II).
417. McGregor JC, Weekes E, Forrest GN, et al. Impact of a computerized clinical decision support system on reducing inappropriate antimicrobial use: a randomized controlled trial. *J Am Med Inform Assoc*. 2006;13:378–84 (I).
418. Shojania KG, Yokoe D, Platt R, Fiskio J, Ma'luf N, Bates DW. Reducing vancomycin use utilizing a computer guideline: results of a randomized controlled trial. *J Am Med Inform Assoc*. 1998;5:554–62 (I).
419. Rubinstein E, Barzilai A, Segev S, et al. Antibiotic cost reduction by providing cost information. *Eur J Clin Pharmacol*. 1988;35:269–72 (II).
420. Parrino TA. The nonvalue of retrospective peer comparison feedback in containing hospital antibiotic costs. *Am J Med*. 1989;86:442–8 (II).
421. O'Reilly M, Talsma A, VanRiper S, Khetarpal S, Burney R. An anesthesia information system designed to provide physician-specific feedback improves timely administration of prophylactic antibiotics. *Anesth Analg*. 2006;103:908–12 (II).
422. Nair BG, Newman SF, Peterson GN, Wu WY, Schwid HA. Feedback mechanisms including real-time electronic alerts to achieve near 100% timely prophylactic antibiotic administration in surgical cases. *Anesth Analg*. 2010;111:1293–300 (II).
423. Zanetti G, Flanagan HL Jr, Cohn LH, Giardina R, Platt R. Improvement of intraoperative antibiotic prophylaxis in prolonged cardiac surgery by automated alerts in the operating room. *Infect Control Hosp Epidemiol*. 2003;24:13–6 (II).
424. Burke JP, Classen DC, Pestotnik SL, Evans RS, Stevens LE. The HELP system and its application to infection control. *J Hosp Infect*. 1991;18:424–31 (IV).
425. Burke JP. Surveillance, reporting, automation, and interventional epidemiology. *Infect Control Hosp Epidemiol*. 2003;24:10–2 (IV).
426. Evans RS, Larsen RA, Burke JP, et al. Computer surveillance of hospital-acquired infections and antibiotic use. *JAMA J Am Med Assoc*. 1986;256:1007–11 (II).
427. Evans RS, Pestotnik SL, Classen DC, et al. A computer-assisted management program for antibiotics and other anti-infective agents. *N Engl J Med*. 1998;338:232–8 (II).
428. Evans RS, Pestotnik SL, Classen DC, Burke JP. Evaluation of a computer-assisted antibiotic-dose monitor. *Ann Pharmacother*. 1999;33:1026–31 (II).
429. Pestotnik SL, Classen DC, Evans RS, Burke JP. Implementing antibiotic practice guidelines through computer-assisted decision support: clinical and financial outcomes. *Ann Intern Med*. 1996;124:884 (II).
430. Mullett CJ, Evans RS, Christenson JC, Dean JM. Development and impact of a computerized pediatric anti-infective decision support program. *Pediatrics*. 2001;108:art-e75 (II).
431. Mullett CJ, Thomas JG, Smith CL, Sarwari AR, Khakoo RA. Computerized antimicrobial decision support: an offline evaluation of a database-driven empiric antimicrobial guidance program in hospitalized patients with a bloodstream infection. *Int J Med Inform*. 2004;73:455–60 (IV).
432. Buising KL, Thursky KA, Robertson MB, et al. Electronic antibiotic stewardship—reduced consumption of broad-spectrum antibiotics using a computerized antimicrobial approval system in a hospital setting. *J Antimicrob Chemother*. 2008;62:608–16 (II).
433. Paul M, Andreassen S, Tacconelli E, et al. Improving empirical antibiotic treatment using TREAT, a computerized decision support system: cluster randomized trial. *J Antimicrob Chemother*. 2006;58:1238–45 (I).
434. Thern J, de With K, Strauss R, Steib-Bauert M, Weber N, Kern WV. Selection of hospital antimicrobial prescribing quality indicators: a consensus among German antibiotic stewardship (ABS) networkers. *Infection*. 2014;42:351–62 (III).